WEED, INC. (Form: S-1/A, Received: 11/17/2017 10:28:15)

As filed with the Securities and Exchange Commission on November 16, 2017

Registration No. 333- 219922

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Amendment No. 1

Form S-1

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

WEED, Inc .

(Exact name of registrant as specified in its charter)

Nevada	8731	83-0452269
(State or other jurisdiction of incorporation or organization	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification No.)

4920 N. Post Trail Tucson, AZ 85750	(520) 818-8582
(Address, including zip code, of registrant’s principal executive offices)	(Telephone number, including area code)

Glenn E. Martin, President

WEED, Inc.

4920 N. Post Trail

Tucson, AZ 85750

(520) 818-8582 (Name, address, including zip code, and telephone

number, including area code, of agent for service)

COPIES TO:

Craig V. Butler, Esq.

Law Offices of Craig V. Butler

300 Spectrum Center Drive, Suite 300

Irvine, CA 92618

(949) 484-5667

Approximate date of commencement of proposed sale to the public:

From time to time after this registration statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☑
(Do not check if a smaller reporting company)
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

CALCULATION OF REGISTRATION FEE

Title of each class of securities to be registered	Amount to be registered (1)	Proposed maximum offering price per share (2)	Proposed maximum aggregate offering price (1)	Amount of registration fee
Common Stock, $0.001 par value	8,982,015	$1.00	$8,982,015	$1,118.27
Total Registration Fee				$1,118.27

(1)

The Registrant is registering for resale by the selling stockholders identified in the prospectus contained herein 8,982,015 shares of common stock. Pursuant to Rule 416 under the Securities Act of 1933, as amended, the shares of common stock registered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions. Pursuant to Rule 416 of the Securities Act, as amended, this registration statement shall be deemed to cover additional securities (i) to be offered or issued in connection with any provision of any securities purported to be registered hereby to be offered pursuant to terms that provide for a change in the amount of securities being offered or issued to prevent dilution resulting from stock splits, stock dividends, or similar transactions and (ii) of the same class as the securities covered by this registration statement issued or issuable prior to completion of the distribution of the securities covered by this registration statement as a result of a split of, or a stock dividend paid with respect to, the registered securities.

(2)

Estimated solely for purposes of calculating the registration fee under Rule 457 under the Securities Act, as amended. Our common stock is not traded on any national exchange. The price of $1.00 per share is a fixed price at which the selling security holders may sell their shares until our common stock is quoted on the OTCBB, or the OTCQX or OTCQB tiers of OTC Markets, at which time the shares may be sold at prevailing market prices or privately negotiated prices. The price of $1.00 per share was based on a per share price we sold our common stock to a private investor in a material transaction prior to the date we originally filed this registration statement.

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

YOU MAY RELY ON THE INFORMATION CONTAINED IN THIS PROSPECTUS. WE HAVE NOT AUTHORIZED ANYONE TO PROVIDE INFORMATION DIFFERENT FROM THAT CONTAINED IN THIS PROSPECTUS. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR SALE OF COMMON STOCK MEANS THAT INFORMATION CONTAINED IN THIS PROSPECTUS IS CORRECT AFTER THE DATE OF THIS PROSPECTUS. THIS PROSPECTUS IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY THESE SHARES OF THE COMMON STOCK IN ANY CIRCUMSTANCES UNDER WHICH THE OFFER OR SOLICITATION IS UNLAWFUL.		8,982,015 SHARES WEED, INC.
________________

TABLE OF CONTENTS

	Page

Prospectus Summary	2	----------------------- PROSPECTUS ----------------------- _____________, 2017
Corporate Information	2
Risk Factors	4
Use of Proceeds	8
Selling Security Holders	9
Plan of Distribution	13
Description of Securities	15
Interests of Experts and Counsel	15
Description of Business	16
Description of Property	26
Legal Proceedings	23
Index to Financial Statements	25
Management’s Discussion and Analysis or Plan of Operation	26
Changes in Accountants	39
Directors, Executive Officers	40
Executive Compensation	41
Security Ownership	43
Certain Transactions	39
Available Information	44
Experts	46

Until ____________, 2017, all dealers that effect transactions in these securities whether or not participating in this offering may be required to deliver a prospectus. This is in addition to the dealer’s obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

iii

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the SEC is effective. This prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

Subject to Completion, Dated November 16, 2017

PROSPECTUS

8,982,015 shares of common stock

WEED, INC.

This prospectus relates to the resale of Common Shares which were issued by WEED, Inc., a Nevada corporation (“we” or the “Company”) in previous private placement transactions by the selling security holders named herein under “Selling Shareholders.” We will not receive any proceeds from the resale of these Common Shares.

The Selling Shareholders may offer all or part of the shares for resale from time to time through public or private transactions, at $1.00 per share, which is the fixed price at which the Selling Shareholders may sell their shares until our common stock is quoted on the OTCBB, or the OTCQX or OTCQB tiers of OTC Markets, at which time the shares may be sold at prevailing market prices or privately negotiated prices. The Company is paying for all registration, listing and qualification fees, printing fees and legal fees.

Our Common Shares are quoted on OTC Market’s “OTC Pink” tier under the ticker symbol “BUDZ.”

Investing in the common stock involves risks. WEED, Inc., currently has limited operations, limited income, and limited assets, is in unsound financial condition, and you should not invest unless you can afford to lose your entire investment. See “Risk Factors” beginning on page 4. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is November __, 2017

PROSPECTUS SUMMARY

You should read the following summary together with the more detailed information and the financial statements appearing elsewhere in this Prospectus. This Prospectus contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under “Risk Factors” and elsewhere in this Prospectus. Unless the context indicates or suggests otherwise, references to “we,” “our,” “us,” the “Company,” or the “Registrant” refer to WEED, Inc., a Nevada corporation.

WEED, INC.

We are an early stage holding company currently focused on the development and application of cannabis-derived compounds for the treatment of human disease. Our wholly-owned subsidiary, Sangre AT, LLC (“Sangre”), has begun a planned five-year Cannabis Genomic Study to complete a genetic blueprint of the Cannabis plant genus, by creating a global genomic classification of the entire plant. By targeting cannabis-derived molecules that stimulate the endocannabinoid system, Sangre’s research team plans to develop scientifically-valid and evidence-based cannabis strains for the production of disease-specific medicines. The goal of the research is to identify, collect, patent, and archive a collection of highly-active medicinal strains. We plan to conduct this study only in states where cannabis has been legalized for medicinal purposes.

Using annotated genomic data and newly generated phenotypic data, Sangre plans to identify and isolate regions of the plant genome which are related to growth, synthesis of desired molecules, and drought and pest resistance. This complex data set would then be utilized in a breeding program to generate and establish new hybrid cultivars which exemplify the traits that are desired by the medical and patient community. This breeding program would produce new seed stocks and clones, which we plan on patenting. If successful this intellectual property should generate immense value for the Company. After developing a comprehensive understanding of the annotated genome of a variety of cannabis strains, and obtaining intellectual property protection over the most promising strains, we plan to move forward either independently or with strategic partners to develop medicinal products for the treatment of a multitude of human diseases.

Currently, we do not have the money or funding to achieve the above goals and we will not be able to achieve our goals unless we are successful in obtaining additional funding, likely through sales of our securities, all which may serve to dilute the ownership position of our current and future shareholders.

Corporate Information

We were originally incorporated under the name Plae, Inc., in the State of Arizona on August 20, 1999. At the time we operated under the name Plae, Inc., no business was conducted. No books or records were maintained and no meetings were held. In essence, nothing was done after incorporation until Glenn E. Martin took possession of Plae, Inc. in January 2005. On February 18, 2005, the corporate name was changed to King Mines, Inc. and then subsequently changed to its current name, United Mines, Inc., on March 30, 2005. No shares were issued until the Company became United Mines, Inc. From 2005 until 2015, we were an exploration stage mineral exploration company that owned a number of unpatented BLM mining claims and Arizona State Land Department exploration leases.

On November 26, 2014, our Board of Directors approved the redomestication of our company from Arizona to Nevada (the “Articles of Domestication”), and approved Articles of Incorporation in Nevada, which differed from then-Articles of Incorporation in Arizona, primarily by (a) changing our name from United Mines, Inc. to WEED, Inc., (b) authorizing Twenty Million (20,000,000) shares of preferred stock, with blank check rights granted to our Board of Directors, and (c) authorizing Two Hundred Million (200,000,000) shares of common stock (the “Nevada Articles of Incorporation”). On December 19, 2014, the holders of a majority of our outstanding common stock approved the Articles of Domestication and the Nevada Articles of Incorporation at a Special Meeting of Shareholders. On January 16, 2015, the Articles of Domestication and the Nevada Articles of Incorporation went effective with the Secretary of State of the State of Nevada. On February 2, 2015, our name change to WEED, Inc., and a corresponding ticker symbol change to “BUDZ” went effective with FINRA and was reflected on the quotation of our common stock on OTC Markets.

These changes were effected in order to make our corporate name and ticker symbol better align with our short-term and long-term business focus, which in the short-term is to conduct Sangre’s Cannabis Genomic Study over the next 5 years, process those results, and in the long-term to be an international cannabis research and product development company, with a globally-recognized brand focusing on building and purchasing labs, land and building commercial grade “Cultivation Centers” to consult, assist, manage & lease to universities, state governments, licensed dispensary owners and worldwide organic grow operators on a contract basis, with a concentration on the legal and medical Cannabis sector. Our long-term plan is to become a True “Seed-to-Sale” global holding company providing infrastructure, financial solutions, product development and real estate options in this new emerging market. Our long term plans may also include acquisitions of synergistic businesses, such as distilleries to make infused beverages and/or super oxygenated water with CBD and THC. We have also formed WEED Australia Ltd., registered as an unlisted public company in Australia, to address future global demand, however the entity has been dormant since its inception.

Our corporate offices are located at 4920 N. Post Trail, Tucson, AZ 85750, telephone number (520) 818-8582.

SUMMARY OF THE OFFERING

Common Shares offered by Selling Shareholders		8,982,015 Common Shares.

Common Shares outstanding before the offering		99,991,020 Common Shares as of the date hereof.

Common Shares outstanding after the offering		99,991,020 Common Shares.

Use of proceeds		We will not receive any proceeds from the sale of shares by the Selling Shareholders.

OTC Markets Trading Symbol		BUDZ

Risk Factors		The Common Shares offered hereby involves a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire investment. See “Risk Factors”.

RISK FACTORS

We have a limited operating history and historical financial information upon which you may evaluate our performance.

You should consider, among other factors, our prospects for success in light of the risks and uncertainties encountered by companies that, like us, are in their early stages of development. We may not successfully address these risks and uncertainties or successfully complete our studies and/or implement our existing and new products. If we fail to do so, it could materially harm our business and impair the value of our common stock. Even if we accomplish these objectives, we may not generate the positive cash flows or profits we anticipate in the future. We were incorporated in the State of Arizona on August 20, 1999. From 2005 until 2015, we were an exploration stage mineral exploration company that owned a number of unpatented mining claims and Arizona State Land Department claims. On November 26, 2014, our Board of Directors approved the redomestication of our company from Arizona to Nevada and we shifted our business focus to a company concentrating on the development and application of cannabis-derived compounds for the treatment of human disease. Although our subsidiary, Sangre, has begun its planned five-year Cannabis Genomic Study to complete a global genomic classification of the Cannabis plant genus the completion of the study is likely years away. Unanticipated problems, expenses and delays are frequently encountered in establishing a new business, conducting research, and developing new products. These include, but are not limited to, inadequate funding, unforeseen research issues, lack of consumer acceptance, competition, product development, and inadequate sales and marketing. The failure by us to meet any of these conditions would have a materially adverse effect upon us and may force us to reduce or curtail operations. No assurance can be given that we can or will ever operate profitably.

We may not be able to meet our future capital needs.

To date, we have not generated any revenue and we have limited cash liquidity and capital resources. Our future capital requirements will depend on many factors, including the progress and results of our Cannabis Genomic Study, our ability to develop products, cash flow from operations, and competing market developments. We anticipate the Cannabis Genomic Study will cost approximately $15,000,000 to complete. We will need additional capital in the near future. Any equity financings will result in dilution to our then-existing stockholders. Although we currently do not have any debt financing, any sources of debt financing in the future may result in a high interest expense. Any financing, if available, may be on unfavorable terms. If adequate funds are not obtained, we will be required to reduce or curtail operations.

If we cannot obtain additional funding, our research and development efforts may be reduced or discontinued and we may not be able to continue operations.

We have historically experienced negative cash flows from operations since our inception and we expect the negative cash flows from operations to continue for the foreseeable future. Unless and until we are able to generate revenues, we expect such losses to continue for the foreseeable future. As discussed in our financial statements, there exists substantial doubt regarding our ability to continue as a going concern.

Research and development efforts are highly dependent on the amount of cash and cash equivalents on hand combined with our ability to raise additional capital to support our future operations through one or more methods, including but not limited to, issuing additional equity or debt.

In addition, we may also raise additional capital through additional equity offerings, and licensing our research and/or future products in development. While we will continue to explore these potential opportunities, there can be no assurances that we will be successful in raising sufficient capital on terms acceptable to us, or at all, or that we will be successful in licensing our future products. Based on our current projections, we believe we have insufficient cash on hand to meet our obligations as they become due based on current assumptions. The uncertainties surrounding our future cash inflows have raised substantial doubt regarding our ability to continue as a going concern.

Any disruption and/or instability in economic conditions and capital markets could adversely affect our ability to access the capital markets, and thus adversely affect our business and liquidity.

Economic conditions and issues with the financial markets have had, and will continue to have, a negative impact on our ability to access the capital markets, and thus have a negative impact on our business and liquidity. The shortage of liquidity and credit combined with the substantial losses in worldwide equity markets could lead to an extended worldwide recession. We may face significant challenges if conditions in the capital markets do not improve. Our ability to access the capital markets has been and continues to be severely restricted at a time when we need to access such markets, which could have a negative impact on our business plans. Even if we are able to raise capital, it may not be at a price or on terms that are favorable to us. We cannot predict the occurrence of future disruptions or how long the current conditions may continue.

Our proposed business is dependent on laws pertaining to the cannabis industry .

Continued development of the cannabis industry is dependent upon continued legislative authorization of marijuana at the state level. Any number of factors could slow or halt progress in this area. Further, progress for the industry, while encouraging, is not assured. While there may be ample public support for legislative action, numerous factors impact the legislative process. Any one of these factors could slow or halt use of marijuana, which would negatively impact our business.

As of the end of February 2017, 28 states and the District of Columbia allow its citizens to use medical marijuana. Voters in the states of Colorado, Washington, Alaska, Oregon and the District of Columbia have approved ballot measures to legalize cannabis for adult use. The state laws are in conflict with the Federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The prior administration (President Obama) effectively stated that it is not an efficient use of resources to direct law federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical marijuana. However, the Trump administration has indicated the potential for stricter enforcement of the marijuana industry at the federal level, but to date there has been very little in terms of action. There is no guarantee that the Trump administration or future administrations will maintain the low-priority enforcement of federal laws in the marijuana industry that was adopted by the Obama administration. The Trump administration or any new administration that follows could change this policy and decide to enforce the federal laws strongly. Any such change in the federal government’s enforcement of current federal laws could cause significant financial damage to our business and our shareholders.

Further, and while we do not intend to harvest, distribute or sell cannabis, if we conduct research with the cannabis plant or lease buildings to growers of cannabis, etc., we could be deemed to be participating in marijuana cultivation, which remains illegal under federal law, and exposes us to potential criminal liability, with the additional risk that our properties could be subject to civil forfeiture proceedings.

The cannabis industry faces strong opposition .

It is believed by many that large well-funded businesses may have a strong economic opposition to the cannabis industry. We believe that the pharmaceutical industry clearly does not want to cede control of any product that could generate significant revenue. For example, medical cannabis will likely adversely impact the existing market for the current “marijuana pill” sold by mainstream pharmaceutical companies. Further, the medical cannabis industry could face a material threat from the pharmaceutical industry, should cannabis displace other drugs or encroach upon the pharmaceutical industry’s products. The pharmaceutical industry is well funded with a strong and experienced lobby that eclipses the funding of the medical cannabis movement. Any inroads the pharmaceutical industry could make in halting or impeding the cannabis industry could have a detrimental impact on our proposed business.

Cannabis remains illegal under Federal law .

Cannabis is a schedule-I controlled substance and is illegal under federal law. Even in those states in which the use of cannabis has been legalized, its production and use remains a violation of federal law. Since federal law criminalizing the use of cannabis preempts state laws that legalize its use, strict enforcement of federal law regarding marijuana would likely result in our inability to proceed with our business plan.

Laws and regulations affecting the medical cannabis industry are constantly changing, which could detrimentally affect our proposed operations.

Local, state and federal medical cannabis laws and regulations are broad in scope and subject to evolving interpretations, which could require us to incur substantial costs associated with compliance or alter our business plan. In addition, violations of these laws, or allegations of such violations, could disrupt our business and result in a material adverse effect on our operations. In addition, it is possible that regulations may be enacted in the future that will be directly applicable to our proposed business. We cannot predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business.

If we are unable to recruit and retain qualified personnel, our business could be harmed.

Our growth and success highly depend on qualified personnel. Competition in the industry could cause us difficulty in recruiting or retaining a sufficient number of qualified technical personnel, which could harm our ability to develop new products. Also, the fact cannabis remains illegal at the federal level may dissuade qualified personnel from working in the cannabis industry, thus limiting the pool of qualified individuals to run our business. If we are unable to attract and retain necessary key talents, it would harm our ability to develop competitive product and retain good customers and could adversely affect our business and operating results.

We may be unable to adequately protect our proprietary rights.

Our ability to compete partly depends on the superiority, uniqueness and value of our intellectual property. To protect our proprietary rights, we will rely on a combination of patent, copyright and trade secret laws, confidentiality agreements with our employees and third parties, and protective contractual provisions. Despite these efforts, any of the following occurrences may reduce the value of our intellectual property:

● Our applications for patents relating to our business may not be granted and, if granted, may be challenged or invalidated;

● Issued patents may not provide us with any competitive advantages;

● Our efforts to protect our intellectual property rights may not be effective in preventing misappropriation of our technology;

● Our efforts may not prevent the development and design by others of products or technologies similar to or competitive with, or superior to those we develop;

● Another party may obtain a blocking patent and we would need to either obtain a license or design around the patent in order to continue to offer the contested feature or service in our products; or

● The fact cannabis is illegal at the federal level may impact our ability to secure patents from the United States Patent and Trademark Office, and other intellectual property protections may not be available to us.

We may become involved in lawsuits to protect or enforce our patents that would be expensive and time consuming.

In order to protect or enforce our patent rights, we may initiate patent litigation against third parties. In addition, we may become subject to interference or opposition proceedings conducted in patent and trademark offices to determine the priority and patentability of inventions. The defense of intellectual property rights, including patent rights through lawsuits, interference or opposition proceedings, and other legal and administrative proceedings, would be costly and divert our technical and management personnel from their normal responsibilities. An adverse determination of any litigation or defense proceedings could put our pending patent applications at risk of not being issued.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. For example, during the course of this kind of litigation,confidential information may be inadvertently disclosed in the form of documents or testimony in connection with discovery requests, depositions or trial testimony. This disclosure could have a material adverse effect on our business and our financial results.

The Selling Shareholders may sell their shares of common stock in the open market, which may cause our stock price to decline.

The Selling Shareholders may sell the shares of common stock being registered in this offering in the public market. That means that up to 8,982,015 shares of common stock, the number of shares being registered in this offering, may be sold in the public market. Such sales will likely cause our stock price to decline.

Sale of our common stock by the Selling Shareholders could encourage short sales by third parties, which could contribute to the further decline of our stock price.

The significant downward pressure on the price of our common stock caused by the sale of material amounts of common stock could encourage short sales by third parties. Such an event could place further downward pressure on the price of our common stock.

Our common stock has been thinly traded and we cannot predict the extent to which a trading market will develop.

Our common stock is traded on the OTC Markets’ “Pink Current Information” tier. Our common stock is thinly traded compared to larger more widely known companies. Thinly traded common stock can be more volatile than common stock trading in an active public market. We cannot predict the extent to which an active public market for our common stock will develop or be sustained after this offering.

Because we are subject to the “penny stock” rules, the level of trading activity in our stock may be reduced.

Our common stock is traded on the OTC Markets’ “Pink Current Information” tier. Broker-dealer practices in connection with transactions in “penny stocks” are regulated by certain penny stock rules adopted by the Securities and Exchange Commission. Penny stocks, like shares of our common stock, generally are equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on NASDAQ. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and, if the broker-dealer is the sole market maker, the broker-dealer must disclose this fact and the broker-dealer's presumed control over the market, and monthly account statements showing the market value of each penny stock held in the customer's account. In addition, broker-dealers who sell these securities to persons other than established customers and “accredited investors” must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction. Consequently, these requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security subject to the penny stock rules, and investors in our common stock may find it difficult to sell their shares.

SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS

We have made forward-looking statements in this prospectus, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business,” that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include the information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities, the effects of future regulation and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are only predictions and involve known and unknown risks and uncertainties, including the risks outlined under “Risk Factors” and elsewhere in this prospectus.

Although we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee future results, events, levels of activity, performance or achievement. We are not under any duty to update any of the forward-looking statements after the date of this prospectus to conform these statements to actual results, unless required by law.

USE OF PROCEEDS

This prospectus relates to shares of our common stock that may be offered and sold from time to time by the Selling Shareholders. We will not receive any proceeds from the sale of shares of common stock in this offering.

SELLING SHAREHOLDERS

The Selling Shareholders may offer from time to time up to an aggregate of 8,982,015 shares of our Common Stock.

Except as otherwise provided, the following table sets forth certain information with respect to the beneficial ownership of our common stock including the names of the Selling Shareholders, the number of shares of our Common Stock owned beneficially by the Selling Shareholders as of August 11, 2017, the number of shares of Common Stock being offered by each selling stockholder hereby, and the number and percentage of shares of Common Stock that will be owned by each selling stockholder following the completion of this offering:

Name of Selling Shareholder	Shares of Common Stock Owned Prior to Offering	Shares of Common Stock to be Offered for the Selling Shareholder’s Account	Shares of Common Stock Owned by Selling Shareholder After the Offering	Percent of Common Stock to be Owned by the Selling Shareholder After the Offering

Victor and Krista Amereno	2,124	2,124	--	--
Melanie Anderson	250,000	250,000	--	--
James Burton Anderson	500,000	500,000	--	--
Kelly Berry	1,063	1,063	--	--
Jayne Breen	860,000	860,000	--	--
John Breen	22,291	22,291	--	--
Nakai Breen	5,309	5,309	--	--
Ryan Breen (9)	5,047,766 (9)	1,037,151 (9)	4,010,615	4.01 %
Mark Brewster	534	534	--	--
Richard Bridgeforth	43,186	43,186	--	--
Buena Vista Consultant LLC (1)	3,186	3,186	--	--
Candice Bullis	1,063	1,063	--	--
Mindy Bullis	2,124	2,124	--	--
Michelle Cammaran	532	532	--	--
Kiante Devaun Carroll	5,309	5,309	--	--
CFO Solutions LLC (2)	3,077	3,077	--	--
CH Capital LLC (3)	53,070	53,070	--	--
Charles Castelli	50,000	50,000	--	--
Jessica M Cox	2,124	2,124	--	--
John D’Andrea	5,309	5,309	--	--
Dale R Johnson	120,000	120,000	--	--
Philip Doyley	2,124	2,124	--	--
David A Eckert	132,970	132,970	--	--

FMTC Roth Ira FBO David A Eckert	19,696	19,696	--	--
Elliott Kwestels	128,000	128,000	--	--
Charlotte Elliott & Gary Elliott	3,186	3,186	--	--
Aimee Elliott	5,309	5,309	--	--
Fred Erickson	2,124	2,124	--	--
Experimental Schools Corporation of Arizona (4)	2,124	2,124	--	--
Joseph Feeney	2,124	2,124	--	--
Larry Fuller	2,030	2,030	--	--
Joe & Theresia Gantenhammer	1,594	1,594	--	--
GEM Management Group LLC Nicole Breen	19,947,520 (10)	305,505	19,642,015 (10)	19.58 %
Christopher Gewelke	1,063	1,063	--	--
Peter Gilboy	2,656	2,656	--	--
Lawrence Gochioco	2,000	2,000	--	--
Malcolm Gochioco	1,000	1,000	--	--
Niels Karsten Gudell	2,124	2,124	--	--
Shaddine Gum	1,063	1,063	--	--
Whitney Gum	1,063	1,063	--	--
Darren Hamans	10,000	10,000	--	--
Chris Harriman	124,601	124,601	--	--
Camille Hartmetz	532	532	--	--
JB Henrickson	12,303	12,303	--	--
Scott Hill	13,170	13,170	--	--
Sandra Hogan	3,000	3,000	--	--
Arnold Hollander	1,063	1,063	--	--
Richard Huff	1,063	1,063	--	--
Scott Douglas Hurley	1,063	1,063	--	--
Rudy Ingersoll	2,124	2,124	--	--
Jeff Miller	240,000	240,000	--	--
Dale Johnson	94	94	--	--
KGP Consulting LLC (5)	1,063	1,063	--	--
Gurutej Kaur Khalsa	1,063	1,063	--	--
RBC Capital Markets LLc Cust FBO Elliot Kwestels	8,000	8,000	--	--
Brenda L Damarin TTEE	2,000	2,000	--	--
Ashley Jason Lee	1,063	1,063	--	--
Craig Lee	532	532	--	--
Edward E Lehman	5,230	5,230	--	--
Roger Leon	1,063	1,063	--	--
Derrick Lewis	2,656	2,656	--	--

Steven Long	2,124	2,124	--	--
Charles Lull	490,063	490,063	--	--
Ashley & Robert Luna	10,615	10,615	--	--
Linda J Martin	21,229	21,229	--	--
Nodar Temuri Maskhulia	1,063	1,063	--	--
Edward Matkoff	55,000	55,000	--	--
Rodger Mattes	2,124	2,124	--	--
Edward Mccullough	1,063	1,063	--	--
Alexandra Miller	2,124	2,124	--	--
Gregory Miller	1,063	1,063	--	--
Gregory Paul Miller	1,099	1,099	--	--
Jaret Miller	6,370	6,370	--	--
Mari Miller	1,063	1,063	--	--
Melissa Miller	1,063	1,063	--	--
Jenny Miranda	532	532	--	--
Robin Mitchell	4,778	4,778	--	--
Flora Nefwani	2,124	2,124	--	--
Jaliyah Nefwani	1,063	1,063	--	--
Kingston Nefwani	1,063	1,063	--	--
Marialice Nichols	6,000	6,000	--	--
Gabriel O’Daniel	5,309	5,309	--	--
Holliegh O’Daniel	5,309	5,309	--	--
Jordan O’Daniel	5,309	5,309	--	--
Kimberly O’Daniel	21,229	21,229	--	--
Ronald Olsen	10,934	10,934	--	--
Ronald C Olsen	1,329	1,329	--	--
Steve Pagac	1,063	1,063	--	--
Patrick Brodnick	240,000	240,000	--	--
Jason & Christina Pawelczyk	2,124	2,124	--	--
Perleberg Enterprises Inc. (6)	1,063	1,063	--	--
Bryan H Perleberg	532	532	--	--
Tyler D Perleberg	532	532	--	--
Michael Peskin	922	922	--	--
Todd Peterson	12,000	12,000	--	--
Robert Pulver	1,063	1,063	--	--
Jessica Raygoza	532	532	--	--
RBC Capital Markets LLC Cust FBO Elliott Kwestels	4,000	4,000	--	--
Keith Regan	4,245	4,245	--	--
Danny Roth	1,000	1,000	--	--
Sal Rutigliano	165,000	165,000	--	--
Alec Noel Sanchez	1,063	1,063	--	--

Jordyn Kane Sanchez	1,063	1,063	--	--
Nicole Sanchez	2,124	2,124	--	--
Barbra Sasselli	1,063	1,063	--	--
Melanie Scopelitus	90,000	90,000	--	--
Kalena Larise Scott	1,063	1,063	--	--
Kimberly Scott	2,124	2,124	--	--
Carmen Seabre	1,700	1,700	--	--
Valerie Seabre	31,842	31,842	--	--
Buddy Shaw	532	532	--	--
Linda Shaw	21,229	21,229	--	--
Linda & Jerry Shaw	5,309	5,309	--	--
Patricia Shouse	1,063	1,063	--	--
Robert Shouse	1,063	1,063	--	--
Sikh Dharma of Phoenix, Inc. (7)	6,370	6,370	--	--
Carmine Simpson	1,500	1,500	--	--
Soul Singh & Meher Kaur Khalsa	5,309	5,309	--	--
Jonathan Smuda	532	532	--	--
Wendy L Starr-Turley	532	532	--	--
Stephanie & Jose Alonso Garcia	1,063	1,063	--	--
Stephen R Murphy	25,000	25,000	--	--
David Summers	1,063	1,063	--	--
Gordan Surran	532	532	--	--
Tanque Verde Baptist Church	10,615	10,615	--	--
Thomas Harrington	102,000	102,000	--	--
Diane Thomas	1,063	1,063	--	--
Diane K Wallace	162	162	--	--
John M Wallace	162	162	--	--
Water of Life Metropolation Community (8)	10,615	10,615	--	--
Benita Watford	6,370	6,370	--	--
Russell Watson	10,615	10,615	--	--
Edward Weaver	1,063	1,063	--	--
Roger Weckworth	1,275	1,275	--	--
Herbert Weiss	2,500	2,500	--	--
Beverly Weiss	5,309	5,309	--	--
Charles Welch	2,230	2,230	--	--
Antonia Whyte	20,000	20,000	--	--
Patrick E Williams	195,850	195,850	--	--
Varooge Yarganian	1,063	1,063	--	--
Jennifer Jill Zavada	1,063	1,063	--	--

Tom Zdroik	1,063	1,063	--	--
Lex Seabre	1,500,000	1,500,000	--	--
Rodger Seabre	1,300,000	1,300,000	--	--
Mary A Williams	145,850	145,850	--	--
Travis Nelson	50,000	50,000	--	--
Amanda Gross	33,000	33,000	--	--
Ted Hadfields	50,000	50,000	--	--
Yuriy Fofanov	50,000	50,000	--	--
Chad Wagner	25,000	25,000	--	--
Russ Karlen	100,000	100,000	--	--
Eric Karlen	20,000	20,000	--	--
Matthew Turner	20,000	20,000	--	--

(1)

Buena Vista Consultant LLC is controlled by Alan Blankenship.

(2)

CFO Solutions LLC is controlled by J.B. Henriksen.

(3)

CH Capital LLC is controlled by Mark Steward.

(4)

Experimental Schools Corporation of Arizona is controlled by Nicholas Sofka.

(5)

KGP Consulting LLC is controlled by Kerri G. Parsons.

(6)

Perleberg Enterprises Inc. is controlled by Dean Perlberg

(7)

Sikh Dharma of Phoenix, Inc. is controlled by Soul Singh Khalsa.

(8)

Water of Life Metropolation Community is controlled by Rev. James Burns.

(9)

Includes 37,151 shares held in the name of both Daniel J. Breen and Ryan Breen.

(10)

Includes all shares beneficially-owned by Ms. Nicole Breen, including those in her name, those in children’s names, and those held in the name of GEM Management, LLC.

None of the Selling Shareholders has, or within the past three years has had, any position, office or material relationship with us or any of our predecessors or affiliates, except as follows:

●

Nicole Breen is our Secretary and Treasurer and serves on our Board of Directors. She is the daughter of Glenn E. Martin, our Chief Executive Officer.

●

Ryan Breen is the husband of Nicole Breen.

●

Jayne Breen is the mother of Ryan Breen. She was a consultant to the company for a number of years. Neither Nicole Breen nor Ryan Breen controls these shares.

●

John Breen is the father of Ryan Breen. Neither Nicole Breen nor Ryan Breen controls these shares.

●

Nakai Breen was the grandmother of Ryan Breen. She has passed away and the shares are controlled by her estate. Neither Nicole Breen nor Ryan Breen controls these shares.

PLAN OF DISTRIBUTION

We are not offering any of the Selling Shareholders’ securities. These shares may be sold by the Selling Shareholders from time to time at prevailing market prices. We will not receive any of the proceeds from any sale by the Selling Shareholders. The Selling Shareholders may sell or distribute their shares in transactions through underwriters, brokers, dealers or agents from time to time or through privately negotiated transactions, including in distributions to shareholders or partners or other persons affiliated with the Selling Shareholders. If the Selling Shareholder enters into an agreement after the date of this prospectus to sell their shares to a broker-dealer as a principal and that broker-dealer is acting as an underwriter, we will file a post-effective amendment to the registration statement containing this prospectus identifying the broker-dealer and disclosing required information on the plan of distribution. Additionally, prior to any involvement of any broker-dealer in the offering, such broker-dealer must seek and obtain clearance of the underwriting compensation and arrangements from the Financial Industry Regulatory Agency.

Penny Stock Rules / Section 15(g) of the Exchange Act

Our shares may be considered penny stock covered by Section 15(g) of the Securities Exchange Act of 1934, as amended, and Rules 15g-1 through 15g-6 promulgated thereunder. They impose additional sales practice requirements on broker/dealers who sell our securities to persons other than established customers and accredited investors who are generally institutions with assets in excess of $5,000,000 or individuals with net worth in excess of $1,000,000 (including spouse's net worth and may include the fair market value of home furnishings and automobiles, but excluding from the calculation the value any primary residence and the related amount of any indebtedness on primary residence up to the fair market value of the primary residence (any indebtedness that exceeds the fair market value of the primary residence must be deducted from net worth calculation)) or annual income exceeding $200,000 or $300,000 jointly with their spouses.

Rule 15g-1 exempts a number of specific transactions from the scope of the penny stock rules. Rule 15g-2 declares unlawful broker/dealer transactions in penny stocks unless the broker/dealer has first provided to the customer a standardized disclosure document.

Rule 15g-3 provides that it is unlawful for a broker/dealer to engage in a penny stock transaction unless the broker/dealer first discloses and subsequently confirms to the customer current quotation prices or similar market information concerning the penny stock in question.

Rule 15g-4 prohibits broker/dealers from completing penny stock transactions for a customer unless the broker/dealer first discloses to the customer the amount of compensation or other remuneration received as a result of the penny stock transaction.

Rule 15g-5 requires that a broker/dealer executing a penny stock transaction, other than one exempt under Rule 15g-1, disclose to its customer, at the time of or prior to the transaction, information about the sales person’s compensation.

Rule 15g-6 requires broker/dealers selling penny stocks to provide their customers with monthly account statements.

Rule 15g-9 requires broker/dealers to approved the transaction for the customer’s account; obtain a written agreement from the customer setting forth the identity and quantity of the stock being purchased; obtain from the customer information regarding his investment experience; make a determination that the investment is suitable for the investor; deliver to the customer a written statement for the basis for the suitability determination and that it is unlawful to effect the transaction without written authorization for the transaction from the customer.

The application of the penny stock rules may affect your ability to resell your shares due to broker-dealer reluctance to undertake the above-described regulatory burdens.

DESCRIPTION OF SECURITIES

Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001, and 20,000,000 shares of preferred stock, par value $0.001. As of June 30, 2017, there are 99,991,020 shares of our common stock issued and outstanding, held by approximately 258 shareholders of record. There are no shares of our preferred stock outstanding as of the date of this filing.

Common Stock . Each shareholder of our common stock is entitled to a pro rata share of cash distributions made to shareholders, including dividend payments. The holders of our common stock are entitled to one vote for each share of record on all matters to be voted on by shareholders. There is no cumulative voting with respect to the election of our directors or any other matter. Therefore, the holders of more than 50% of the shares voted for the election of those directors can elect all of the directors. The holders of our common stock are entitled to receive dividends when and if declared by our Board of Directors from funds legally available therefore. Cash dividends are at the sole discretion of our Boardof Directors. In the event of our liquidation, dissolution or winding up, the holders of common stock are entitled to share ratably in all assets remaining available for distribution to them after payment of our liabilities and after provision has been made for each class of stock, if any, having any preference in relation to our common stock. Holders of shares of our common stock have no conversion, preemptive or other subscription rights, and there are no redemption provisions applicable to our common stock.

Dividend Policy . We have never issued any dividends and do not expect to pay any stock dividend or any cash dividends on our common stock in the foreseeable future. We currently intend to retain our earnings, if any, for use in our business. Any dividends declared on our common stock in the future will be at the discretion of our Board of Directors and subject to any restrictions that may be imposed by our lenders.

Preferred Stock . We are authorized to issue 20,000,000 shares of preferred stock, par value $0.001. We have not issued, nor established any series for, any of our preferred stock. Our preferred stock is “blank check preferred” whereby our Board of Directors may create a series of preferred stock and set the rights and preferences of such preferred stock, without further shareholder approval. The availability or issuance of preferred shares in the future could delay, defer, discourage or prevent a change in control. On January 14, 2016, our Board of Directors approved the creation of a class of preferred stock to be entitled “Series B Convertible Preferred Stock” with the following rights and preferences: (i) no dividend rights; (ii) no liquidation preference over the Company’s common stock; (iii) conversion rights into shares of common stock at a ratio of 20 shares of common stock for each share of Series B Convertible Preferred Stock; (iv) no redemption rights; (v) no call rights by the Company; and (vi) voting rights on an “as converted” basis on all matters properly brought before our common stockholders for a vote. This class of preferred stock has not been created yet and no shares have been issued, but we agreed to create this class of preferred stock and issue shares as set forth in the employment agreements we have with Glenn E. Martin, Nicole Breen and Ryan Breen, as detailed herein.

INTEREST OF NAMED EXPERTS AND COUNSEL

Law Offices of Craig V. Butler serves as our legal counsel in connection with this offering. Mr. Butler does not own any of our securities.

DESCRIPTION OF BUSINESS

General

We are an early stage holding company currently focused on the development and application of cannabis-derived compounds for the treatment of human disease. Our wholly-owned subsidiary, Sangre AT, LLC (“Sangre”), has begun a planned five-year Cannabis Genomic Study, complete a genetic blueprint of the Cannabis plant genus, by creating a global genomic classification of the entire plant. By targeting cannabis-derived molecules that stimulate the endocannabinoid system, Sangre’s research team plans to develop scientifically-valid and evidence-based cannabis strains for the production of disease-specific medicines. The goal of the research is to identify, collect, patent, and archive a collection of highly-active medicinal strains. We plan to conduct this study only in states where cannabis has been legalized for medicinal purposes.

Using annotated genomic data and newly generated phenotypic data, Sangre plans to identify and isolate regions of the plant genome which are related to growth, synthesis of desired molecules, and drought and pest resistance. This complex data set would then be utilized in a breeding program to generate and establish newhybrid cultivars which exemplify the traits that are desired by the medical and patient community. This breeding program would produce new seed stocks and clones, which we plan on patenting. If successful this intellectual property should generate immense value for the Company. After developing a comprehensive understanding of the annotated genome of a variety of cannabis strains, and obtaining intellectual property protection over the most promising strains, we plan to move forward either independently or with strategic partners to develop medicinal products for the treatment of a multitude of human diseases.

Our current, short-term goals relate to the Cannabis Genomic Study and the resulting development of a variety of new cannabis strains, and, over the next 5 years, we plan to process those results in order to become an international cannabis research and product development company, with a globally-recognized brand focusing on building and purchasing labs, land and building commercial grade “Cultivation Centers” to consult, assist, manage & lease to universities, state governments, licensed dispensary owners and organic grow operators on a contract basis with a concentration on the legal and medical cannabis sector..

Our long-term plan is to become a true “Seed-to-Sale” global holding company providing infrastructure, financial solutions, product development, and real estate options in this new emerging market. Our long term growth may also come from the acquisition of synergistic businesses, such as distilleries, to make anything from infused beverages to super oxygenated water with CBD and THC. Currently, WEED Inc has formed WEED Australia Ltd., registered as an unlisted public company in Australia to address this Global demand. We have also formed WEED Australia Ltd., registered as an unlisted public company in Australia, to address future global demand, however the entity has been dormant since its inception.

Our website is www.weedunitedstates.com.

Cannabis Genomic Study

After more than 40 years of illicit, underground breeding programs, the genetic integrity of Cannabis has been significantly degraded. Our subsidiary, Sangre AT, LLC (“Sangre”) plans to use a gene-based breeding program to root out inferior cultivars and replace them with fully-validated and patentable cultivars which produce consistent plant products for the medicinal markets. We believe our unique gene-based breeding program will improve cultivars and introduce integrity, stability, and quality to the market in the following ways:

● Accelerated and optimized growth rates; modern genomic resources will enhance traditional breeding methods

● Generation of new cultivars, accelerating and perfecting the art of selective breeding

● Provide the ability to assay for specific genes within the crop, which is critical to strain tracking and market quality assurance

● Improve disease and drought resistance

We believe our gene-based breeding program will facilitate and accelerate:

● Improved therapeutic properties

● New therapies for migraines/chronic pain, epilepsy, cancer, PTSD, chronic head injury, and others

● Enhanced opportunities for new drug discovery through collaborations with national medical research and treatment centers and Bio-pharma companies

● Development and protection of intellectual property

The Research Plan

In order to achieve the desired results outlined above, Sangre has developed a research plan entitled the “Cannabis Genomic Study.” The goal of the study is to complete a global genomic classification of the Cannabis plant genus. Once the classification is complete, the research team plans to develop new cannabis strains that show the highest likelihood of being successful in the treatment of a variety of human diseases, test those strains and then work to produce those strains in a medicinal form for the treatment of disease. The research plan will be conducted using the following steps: Extraction, Purification, Sequencing. Annotation, and Cloning (micro-propagation).

Extraction : The extraction of genomic DNA from cannabis is a complex process of cell lysis and DNA recovery. Sangre AgroTech has evaluated, updated, and validated new methods for DNA recovery.

Purification : Using next generation purification chemistries, the DNA is cleaned and concentrated for downstream applications.

Sequencing : The Cannabis DNA is sequenced using both the Illumina MiSeq and MinIon instruments.

Annotation : The genomic data is assembled and annotated using proprietary bioinformatic systems and the data provided to the Sangre AgroTech genetic breeders and cellular cloners.

Cloning : Through this process, new, high-value cannabis strains are developed.

The objectives of the research plan are as follows:

Technical Objective 1 : Using two next generation sequencing platforms and proprietary bioinformatics programs, we will sequence five cultivars of Cannabis, and generate fully annotated genomic data.

Technical Objective 2 : Using the selected cultivars, backcross and forward hybridization studies will be performed to produce a new generation of stock. The progeny of these crosses will be grown, genetically finger-printed, and introduced to the market under patent protection. Up-selection and cultivation of cultivars for quality assurance.

Technical Objective 3 : Genotypic and phenotypic measurements of the offspring will be performed using Next Generation Sequence Analysis, Genotyping, and Phenotyping analysis. Product focus groups will evaluate new cultivars. Patent protection will be initiated for new cultivars which meet product development criteria.

Technical Objective 4 : Utilize gene-driven breeding of up-selected cultivars to initiate the generation of “designer” cultivars for clinical research.

Technical Objective 5 : Market placement of selected, genetically enhanced cultivars for the medicinal and bio-pharma markets.

Where We Are in the Research Plan

As noted above, phase one of our planned five year “Cannabis Genomic Study” is “extraction”. On April 20, 2017, Sangre initiated the genomic study by extracting DNA from seven cannabis strains in Tucson, Arizona. Sangre followed the initial extraction with a second round of extractions in July 2017. The extracted DNA is currently being sequenced by the Sangre team using a binary sequencing approach based on the use of two distinct sequencing technologies and a proprietary bioinformatics database. Following the generation of genomic data, the sequences will be annotated (compared) against over 300,000 plant genes to elucidate specific de novo pathways responsible for the synthesis of specific compounds and classes of compounds.

As noted herein, on July 26, 2017, we acquired property located in La Veta, Colorado in order for Sangre to complete its 5-Year, $15+ million Cannabis Genomic Study. The acquisition of this property was not essential for the Sangre team to begin the extraction and sequencing phases, however, the once completed, the property will allow Sangre to expand the genomic study. The facility is currently under re-design and renovation to convert the existing structures into a world-class genetics research center. Additionally, under the genome project directives, additional strains are slated for sequencing and annotation as part of the overall expansion of this research project. An integral part of this expansion is the acquisition of additional DNA extraction, amplification, and sequencing technologies. The expansion also includes the installation of high-level IT networks for data acquisition, analysis, and storage. The La Veta property, when completed will allow us to expand the scope of the study, as well as, complete the future steps in the study. Once completed, the La Veta facility will also contain laboratories for cellular cloning, in vitro protoplast fusions, and plant developmental studies.

Competitive Advantages

Sangre’s research and development team works with next generation sequencing (NGS) and emerging third generation instruments, and has developed the most advanced proprietary bioinformatics data systems available. Sangre uses a unique two sequencing approach. One system provides DNA reads of up to 300,000 base pair reads and an NGS system which provides highly accurate short reads. This allows the genomic data to be assembled in a scaffold construct; the long reads forming the scaffold andthe short reads providing highly accurate verification and quality assurance of the genomic data. This approach, together with the bioinformatics program, facilitates a highly accurate construct of the Cannabis genome which can be annotated and facilitate gene discovery and gene location. Sangre combination of personnel, skill-sets, and data analytics capabilities will allow us to accomplish our goals in months, rather than years.

Using annotated genomic data and newly generated phenotypic data, we plan to identify and isolate regions of the genome which are related to growth, synthesis of desired molecules, and environmental compatibility. This complex data set will be utilized in a breeding program to generate and establish new hybrid cultivars which exemplify the traits that are desired by the medical community. This breeding program will produce new seed stocks, clones, cultivars, and intellectual property which will generate value for the business organization.

Sangre will develop a translational breeding program to establish a new collection of Cannabis cultivars for the national market. Using genetic screening technology and micro-propagation, cultivars can be up-selected for specific traits and grown to address the needs of consumers in the medicinal and drug discovery markets. The combination of next generation genomics, selective hybridization, and In Vitro cloning provide us with the tools to enhance new cultivars of patentable Cannabis.

Marketing

We have not developed a marketing plan and do not intend to until we are in the latter stages of the Cannabis Genomic Study and believe we have strains that are marketable for the treatment of disease. At that time we plan to develop a marketing plan for our newly-developed strains of Cannabis. We believe that if we are successful in developing strains of Cannabis that effectively treat human diseases then the market for our products will be a vibrant market.

Manufacturing

We are not currently manufacturing any products and do not intend to do so until we are in the latter stages of the Cannabis Genomic Study and believe we have strains that are marketable for the treatment of disease such that we could begin the manufacturing of such products, either in-house or through relationships with third party companies. We do not currently have any relationships with third party companies for the manufacturing of any products.

Competition

The cannabis industry, taken as a whole, is an emerging industry with many new entrants, with some of them focused on research, some on medicinal cannabis and others focused on cannabis for legal, adult use, i.e. “recreational” use. We are focused solely on the research and medicinal cannabis part of the industry. Additionally, many cannabis companies are international companies due to the restrictions on the cannabis industry in the U.S.

At this point in our development, we believe our competitors are those companies that are attempting study and sequence cannabis DNA with the goal of creating medicines from that research. We do not view ourselves in competition with those companies currently growing and/or selling cannabis for medicinal or recreational use since we are a research company. We are aware of companies that supply synthetic cannabinoids and cannabis extracts to researchers for pre-clinical and clinical investigation. We are also aware of various companies that cultivate cannabis plants with a view to supplying herbal cannabis or non-pharmaceutical cannabis-based formulations to patients. These activities have not been approved by the FDA.

We have never endorsed or supported the idea of distributing or legalizing crude herbal cannabis, or preparations derived from crude herbal cannabis for medical use and do not believe our research to hopefully create prescription cannabinoids are the same, and therefore competitive, with crude herbal cannabis. We believe that only a cannabinoid medication, one that is standardized in composition, formulation and dose, administered by means of an appropriate delivery system, and tested in properly controlled pre-clinical and clinical studies, can meet the standards of regulatory authorities around the world, including those of the FDA. We believe that any cannabinoid medication must be subjected to, and satisfy, such rigorous scrutiny through proper accredited education and federal regulations.

As Cannabis has moved through the legalization process in North America, research groups in Canada and the Unites States have initiated work on understanding the Cannabis genome.

Next Generation Sequencing

Next-generation sequencing (NGS), introduced nearly ten years ago, is the catch-all term used to describe several sequencing technologies including:

● Illumina (Solexa) sequencing

● Roche 454 sequencing

● Ion torrent: Proton / PGM sequencing

● SOLiD sequencing

These recent sequencing technologies allow scientists to sequence DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing, and as such, have greatly expanded the study of genomics and molecular biology. Numerous laboratories within the Cannabis community are currently employing this technology.

Colorado State University – Boulder

To the best of our knowledge, Colorado State University – Boulder is conducting a Cannabis Genomic Research Initiative, which is currently seeking to describe the Cannabis genome. The data generated through this effort is provided through the public domain to growers in an effort to stimulate the production of new, high-value stains of Cannabis.

Anandia Labs

Anandia Labs is conducting work in the area of Cannabis genomics based on sequence work which was completed in 2011. The sequencing work conducted was based on “next generation sequencing” technology and resulted in the generation of tens-of-thousands of DNA segments that have yet to be completely and correctly reassembled. Much of the sequence data that was generated through their sequencing efforts has been placed into the public domain and shared with other laboratories. In some instances, the data has been found to be less than accurate.

Phylos Biosciences

Phylos Biosciences is currently using DNA-based genetic fingerprinting to establish relationships between strains and to assist in the development of phenotypic databases to accelerate traditional breeding programs. Phylos Biosciences has a primary goal of bringing clarity to the Cannabis market and promote the generation of IP held by individual growers. To the best of our knowledge, Phylos Biosciences is not engaged in whole genome sequencing and is not engaged in any genetic enhancements of the Cannabis strains. They simply supply genetic data to their customer base to more effectively drive the traditional breeding process.

New West Genetics

New West Genetics aims to improve and develop industrial hemp as a viable crop for the United States. New West Genetics seeks to exploit the diverse end uses of hemp and optimize the genetics of hemp to create a lucrative crop to add to the rotation of US farmers. Industrial hemp’s uses and potential are as great as many major crops, if not more. We believe NWG is utilizing modern sequencing technology and statistical genomics approaches to understand these factors as they apply to hemp production in states where it is legal to grow. Understanding the genotype to phenotype map will be increasingly useful for expanding production of hemp.

While we do not believe any of the above companies or universities are direct competitors of ours based on what we believe about their work in the industry, they could be competitors for research funding dollars. We are not aware of the financial situation of many of the above companies and universities, but we will need to raise substantial additional capital in order to fully-fund the five year genomic study and the facilities to complete the study. Most of the above companies and universities are likely better financed than we are and we will need to raise substantial funds in order to compete in the cannabis research industry.

Intellectual Property

Currently, we do not have any patents, but consider certain elements of our Cannabis Genomic Study to be trade secrets and we protect it as our intellectual property. In the future, if we are successful in identifying certain Cannabis strains as promising for the treatment of diseases we will seek to patent those strains.

Government Regulation

As of the end of February 2017, 28 states and the District of Columbia allow its citizens to use medical marijuana. Voters in the states of Colorado, Washington, Alaska, Oregon and the District of Columbia have approved ballot measures to legalize cannabis for adult use. The state laws are in conflict with the Federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The prior administration (President Obama) effectively stated that it is not an efficient use of resources to direct law federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical marijuana. However, the Trumpadministration has indicated the potential for stricter enforcement of the marijuana industry at the federal level, but to date there has been very little in terms of action. There is no guarantee that the Trump administration or future administrations will maintain the low-priority enforcement of federal laws in the marijuana industry that was adopted by the Obama administration. The Trump administration or any new administration that follows could change this policy and decide to enforce the federal laws strongly. Any such change in the federal government’s enforcement of current federal laws could cause significant financial damage to our business and our shareholders.

Further, and while we do not intend to harvest, distribute or sell cannabis, if we conduct research with the cannabis plant or lease buildings to growers of marijuana, etc., we could be deemed to be participating in marijuana cultivation, which remains illegal under federal law, and exposes us to potential criminal liability, with the additional risk that our properties could be subject to civil forfeiture proceedings.

Currently, there are no approvals needed in order to sequence the cannabis genome, which is what is currently being conducted by Sangre. However, prior to doing any research into the medical applications of the cannabis plant once the study is completed, we will need to obtain medicinal cannabis and hemp research licenses from the State of Colorado. Additionally, if we ever cultivate and process cannabis plants, we will need cultivation and processing licenses from the State of Colorado, which covers cannabis and hemp. These licenses will cost approximately $1,000 to $5,000 per license, and likely take approximately six months to obtain.

Sangre Agreement

On April 20, 2017, we entered into a Share Exchange Agreement with Sangre AT, LLC, a Wyoming limited liability company, under which we acquired all of the issued and outstanding limited liability company membership units of Sangre in exchange for Five Hundred Thousand (500,000) shares of our common stock, restricted in accordance with Rule 144. As a result of this agreement, Sangre is a wholly-owned subsidiary of WEED, Inc.

Employees

As of June 30, 2017 we employed three persons on a full time basis, namely Glenn E. Martin, Nicole Breen and Ryan Breen. Sangre contracts with two individuals on full-time basis and three individuals on a part-time basis. All these individuals are independent contractors.

Le Veta, Co. Property

On July 26, 2017, we acquired property located in La Veta, Colorado in order for Sangre to complete its 5-Year, $15+ million Cannabis Genomic Study. The site includes a 10,000+ sq. ft. building that will house Sangre’s genomic research facility, a 4,000+ square foot building for plant product analytics and plant product extraction, a 3,500 sq. ft. corporate office center, and 25 RV slots with full water and electric, which we plan to convert into a series of small research pods. Under the terms of the purchase agreement, we paid $525,000 down, including 25,000 shares of our common stock, and Sangre took immediate possession of the property. We are obligated to pay an additional $400,000 in cash and issue an additional 75,000 shares of our common stock over the next two years in order to pay the entire purchase price. We estimate it will take approximately $675,000 in order to convert the existing buildings into the facilities necessary for Sangre AgroTech to conduct its research, plus an additional $1,000,000 for security & ground buildout. An additional $1 million for scientific equipment has been ordered for plant production and product extraction. We plan to complete the initial property renovations by Q1 of 2018. The equipment is scheduled to be delivered in Q2 2018. We will need to raise additional funds in order to pay the remainder of the purchase price, as well as to complete the planned renovations.

New York Property

On October 24, 2017, we entered into an amended Purchase and Sale Agreement with Greg DiPaolo’s Pro Am Golf, LLC (“DiPaolo”), under which we agreed to purchase certain improved property located in Westfield, New York from DiPaolo for a total purchase price of Eight Hundred Thousand Dollars ($800,000). Under the terms of the agreement, we paid a Ten Thousand Dollar ($10,000) deposit on October 26, 2017, with the remaining purchase price to be paid on or before the date closing date, which is scheduled for February 1, 2018. The property is approximately 43 acres and has unlimited water extraction rights from the State of New York. We plan to use this property as our inroads to the New York hemp and infused beverage markets in the future. There are no current plans or budget to proceed with operations in New York, and there will not be until proper funding is secured after acquiring this property.

ORGANIZATION WITHIN LAST FIVE YEARS

We were originally incorporated under the name Plae, Inc., in the State of Arizona on August 20, 1999. At the time we operated under the name Plae, Inc., no business was conducted. No books or records were maintained and no meetings were held. In essence, nothing was done after incorporation until Glenn E. Martin took possession of Plae, Inc. in January 2005. On February 18, 2005, the corporate name was changed to King Mines, Inc. and then subsequently changed to its current name, United Mines, Inc., on March 30, 2005. No shares were issued until the Company became United Mines, Inc. From 2005 until 2015, we were an exploration stage mineral exploration company that owned a number of unpatented mining claims and Arizona State Land Department claims.

These changes were effected in order to make our corporate name and ticker symbol better align with our short-term and long-term business focus. Our current, short-term goals relate to the Cannabis Genomic Study and the resulting development of a variety of new cannabis strains, and, over the next 5 years, we plan to process those results in order to become an international cannabis research and product development company, with a globally-recognized brand focusing on building and purchasing labs, land and building commercial grade “Cultivation Centers” to consult, assist, manage & lease to universities, state governments, licensed dispensary owners and organic grow operators on a contract basis with a concentration on the legal and medical cannabis sector.

DESCRIPTION OF PROPERTY

Our company headquarters and executive offices are located at 4920 N. Post Trail, Tucson, AZ 85750. Our offices are currently located in office space provided by our President on a month-to-month basis at a monthly rent of $1,000, which began on April 1, 2017. Our office space is approximately 1,000 square feet. We also maintain two virtual office locations, located at 1 South Church Avenue, Suite 1200, Tucson, AZ 85750, and 3960 Howard Hughes Parkway, Suite 500, Las Vegas NV 89169.

LEGAL PROCEEDINGS

We are not currently involved in any legal proceedings.

In the ordinary course of business, we are from time to time involved in various pending or threatened legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon our financial condition and/or results of operations. However, in the opinion of our management, other than as set forth herein, matters currently pending or threatened against us are not expected to have a material adverse effect on our financial position or results of operations.

MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

Our stock is quoted on the OTC Markets’ “Pink Current Information” tier under the symbol “BUDZ.” We were originally quoted over-the-counter on November 2009. We have 99,991,020 shares of our common stock outstanding. The following table sets forth the high and low bid information for each quarter within the two most recent fiscal years, as well as from 2017 year-to-date, as estimated based on information on OTC Markets. The information reflects prices between dealers, and does not include retail markup, markdown, or commission, and may not represent actual transactions.

		Bid Prices
Fiscal Year Ended December 31,	Period	High	Low

2017	First Quarter	$ 5.05	$ 1.67
	Second Quarter	$ 2.25	$ 0.41
	Third Quarter	$ 1.20	$ 0.88
	Fourth Quarter (thru 11/2/17)	$ 1.33	$ 1.17

2016	First Quarter	$ 0.13	$ 0.043
	Second Quarter	$ 0.10	$ 0.055
	Third Quarter	$ 0.14	$ 0.07
	Fourth Quarter	$ 0.89	$ 0.15

2015	First Quarter	$ 0.115	$ 0.07
	Second Quarter	$ 0.10	$ 0.06
	Third Quarter	$ 0.085	$ 0.05
	Fourth Quarter	$ 0.08	$ 0.043

As of November 2, 2017, our common stock was closed at $1.22 per share, as quoted on OTC Markets.

The Securities Enforcement and Penny Stock Reform Act of 1990 requires additional disclosure relating to the market for penny stocks in connection with trades in any stock defined as a penny stock. The Commission has adopted regulations that generally define a penny stock to be any equity security that has a marketprice of less than $5.00 per share, subject to a few exceptions which we do not meet. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the risks associated therewith.

There is currently no outstanding options to purchase WEED, Inc. common stock. We do not have any convertible debentures outstanding that permit the holder to convert the outstanding obligation into shares of our common stock.

The number of holders of record of shares of our common stock is Two Hundred Fifty Eight (258).

There have been no cash dividends declared on our common stock. Dividends are declared at the sole discretion of our Board of Directors.

We have not adopted any stock option or stock bonus plans.

FINANCIAL STATEMENTS

Index to Financial Statements

Independent Auditors’ Report		F-1
Consolidated Balance Sheets of WEED, Inc. as of December 31, 2016 and 2015		F-2
Consolidated Statements of Operations of WEED, Inc. for the Years Ended December 31, 2016 and 2015		F-3
Consolidated Statements of Changes in Stockholders’ Equity of WEED, Inc. for the Years Ended December 31, 2016 and 2015		F-4
Consolidated Statements of Cash Flows of WEED, Inc. for the Years Ended December 31, 2016 and 2015		F-5
Notes to Financial Statements		F-6

Consolidated Balance Sheets of WEED, Inc. as of March 31, 2017 (Unaudited)		F-21
Consolidated Statement of Operations of WEED, Inc. for the Three Months Ended March 31, 2017 and 2016 (Unaudited)		F-22
Consolidated Statements of Cash Flows of WEED, Inc. for the Three Months Ended March 31, 2017 and March 31, 2016 (Unaudited)		F-23
Notes to Condensed Consolidated Financial Statements		F-24

Consolidated Balance Sheets of WEED, Inc. as of June 30, 2017 (Unaudited)		F-33
Consolidated Statement of Operations of WEED, Inc. for the Three and Six Months Ended June 30, 2017 and 2016 (Unaudited)		F-34
Consolidated Statements of Cash Flows of WEED, Inc. for the Six Months Ended June 30, 2017 and 2016 (Unaudited)		F-35
Notes to Condensed Consolidated Financial Statements		F-36

Independent Auditors' Report for Audit of Sangre AT, LLC		F-50
Balance Sheets of Sangre AT, LLC, as of December 31, 2016		F-51
Statement of Operations of Sangre AT, LLC for the Year Ended December 31, 2016		F-52
Statement of Stockholders' Equity of Sangre AT, LLC for the Year Ended December 31, 2016		F-53
Statement of Cash Flows for the Year Ended December 31, 2016		F-54
Notes to Financial Statements of Sangre AT, LLC for the Year Ended December 31, 2016		F-55

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of Weed, Inc.

We have audited the accompanying balance sheets of Weed, Inc. as of December 31, 2016 and 2015, and the related statements of income, comprehensive income, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2016. Weed, Inc’s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Weed, Inc. as of December 31, 2016 and 2015, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2016, in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company suffered a net loss from operations and has a net capital deficiency, which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ M&K CPAS, PLLC

Houston, Texas

August 11, 2017

F-1

WEED, INC. (Formerly United Mines, Inc.)
BALANCE SHEETS


	December 31,	December 31,
	2016	2015
ASSETS

Current assets:
Cash	$ 231	$ 7
Prepaid expenses	5,053	2,067
Total current assets	5,284	2,074

Property and equipment, net	264	394

Total assets	$ 5,548	$ 2,468


LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current liabilities:
Accounts payable	$ 35,661	$ 51,748
Accrued officer compensation	157,505	86,000
Accrued interest	36,760	32,022
Convertible notes payable	35,000	35,000
Notes payable, related parties	16,300	13,300
Total current liabilities	281,226	218,070

Commitments and contingencies	-	-

Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 20,000,000 shares
authorized, no shares designated, issued and outstanding	-	-
Common stock, $0.001 par value, 200,000,000 shares
authorized, 103,953,307 and 61,118,307 shares issued and
outstanding at December 31, 2016 and 2015, respectively	103,953	61,118
Additional paid in capital	15,219,762	11,056,712
Subscriptions payable, consisting of -0- and 1,770,000
shares at December 31, 2016 and 2015, respectively	-	114,990
Accumulated deficit	(15,599,393 )	(11,448,422 )
Total stockholders' equity (deficit)	(275,678 )	(215,602 )

Total liabilities and stockholders' equity (deficit)	$ 5,548	$ 2,468

The accompanying notes are an integral part of these financial statements.

F-2

WEED, INC. (Formerly United Mines, Inc.)
STATEMENTS OF OPERATIONS


	For the Years
	Ended December 31,
	2016	2015

Revenue	$ -	$ -

Operating expenses:
General and administrative	2,211,787	594,446
Professional fees	1,933,733	639,149
Depreciation and amortization	130	130
Total operating expenses	4,145,650	1,233,725

Net operating loss	(4,145,650 )	(1,233,725 )

Other expense:
Interest expense	(5,321 )	(4,824 )

Net loss	$ (4,150,971 )	$ (1,238,549 )


Weighted average number of common shares
outstanding - basic and fully diluted	71,250,288	54,390,978

Net loss per share - basic and fully diluted	$ (0.06 )	$ (0.02 )

The accompanying notes are an integral part of these financial statements.

F-3

WEED, INC. (Formerly United Mines, Inc.)
STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)


					Additional			Total
	Preferred Stock		Common Stock		Paid-In	Subscriptions	Accumulated	Stockholders'
	Shares	Amount	Shares	Amount	Capital	Payable	Deficit	Equity (Deficit)

Balance, December 31, 2014	-	$ -	44,333,307	$ 44,333	$ 9,901,547	$ 156,100	$ (10,209,873 )	$ (107,893 )

Common stock sold for cash	-	-	555,000	555	60,945	(37,500 )	-	24,000

Common stock issued for services, related parties	-	-	12,000,000	12,000	828,000	-	-	840,000

Common stock issued for services	-	-	4,230,000	4,230	266,020	(3,610 )	-	266,640

Imputed interest on non-interest bearing related party debts	-	-	-	-	200	-	-	200

Net loss for the year ended December 31, 2015	-	-	-	-	-	-	(1,238,549 )	(1,238,549 )

Balance, December 31, 2015	-	$ -	61,118,307	$ 61,118	$ 11,056,712	$ 114,990	$ (11,448,422 )	$ (215,602 )

Common stock sold for cash	-	-	325,000	325	69,675	-	-	70,000

Common stock issued for down payment on land purchase	-	-	50,000	50	42,450	-	-	42,500

Common stock issued for services, related parties	-	-	36,000,000	36,000	3,564,000	-	-	3,600,000

Common stock issued for services	-	-	6,460,000	6,460	486,342	(114,990 )	-	377,812

Imputed interest on non-interest bearing related party debts	-	-	-	-	583	-	-	583

Net loss for the year ended December 31, 2016	-	-	-	-	-	-	(4,150,971 )	(4,150,971 )

Balance, December 31, 2016	-	$ -	103,953,307	$ 103,953	$ 15,219,762	$ -	$ (15,599,393 )	$ (275,678 )

The accompanying notes are an integral part of these financial statements.

F-4

WEED, INC. (Formerly United Mines, Inc.)
STATEMENTS OF CASH FLOWS


	For the Years
	Ended December 31,
	2016	2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss)	$ (4,150,971 )	$ (1,238,549 )
Adjustments to reconcile net loss
to net cash used in operating activities:
Depreciation	130	130
Imputed interest on non-interest bearing related party debts	583	200
Shares issued for down payment on land purchase	42,500	-
Shares issued for services, related parties	3,600,000	840,000
Shares issued for services	377,812	266,640
Decrease (increase) in assets:
Prepaid expenses	(2,986 )	7,956
Increase (decrease) in liabilities:
Accounts payable	(16,087 )	19,199
Accrued compensation	71,505	74,000
Accrued interest	4,738	4,624
Net cash used in operating activities	(72,776 )	(25,800 )

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable, related parties	16,005	1,300
Repayments on notes payable, related parties	(13,005 )	(5,115 )
Proceeds from the sale of common stock	70,000	24,000
Net cash provided by financing activities	73,000	20,185

NET CHANGE IN CASH	224	(5,615 )
CASH AT BEGINNING OF PERIOD	7	5,622

CASH AT END OF PERIOD	$ 231	$ 7

SUPPLEMENTAL INFORMATION:
Interest paid	$ -	$ -
Income taxes paid	$ -	$ -

The accompanying notes are an integral part of these financial statements.

F-5

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

Note 1 – Nature of Business and Significant Accounting Policies

Nature of Business

WEED, Inc. (the “Company”), (formerly United Mines, Inc.) was incorporated under the laws of the State of Arizona on August 20, 1999 (“Inception Date”) as Plae, Inc. to engage in the exploration of gold and silver mining properties. On November 26, 2014, the Company was renamed from United Mines, Inc. to WEED, Inc. and was repurposed to pursue a business involving the purchase of land, and building Commercial Grade “Cultivation Centers” to consult, assist, manage & lease to Licensed Dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana sector. The Company’s plan is to become a True “Seed-to-Sale” company providing infrastructure, financial solutions and real estate options in this new emerging market. The Company, under United Mines, was formerly in the process of acquiring mineral properties or claims located in the State of Arizona, USA. The name was previously changed on February 18, 2005 to King Mines, Inc. and then subsequently changed to United Mines, Inc. on March 30, 2005. The Company trades on the OTC Pink Sheets under the stock symbol: BUDZ.

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.

The Company has a calendar year end for reporting purposes.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. There were no cash equivalents on hand for the periods presented herein.

Fair Value of Financial Instruments

Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.

Property and Equipment

Property and equipment is stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy:

Software	3 years
Furniture and fixtures	5 years
Equipment	5-7 years

Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which have extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations.

F-6

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

Impairment of Long-Lived Assets

Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations.

Basic and Diluted Loss Per Share

The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

Stock-Based Compensation

Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation consisted of the following during the years ended December 31, 2016 and 2015, respectively:

	December 31,	December 31,
	2016	2015

Common stock issued for down payment on land purchase	$ 42,500	$ -
Common stock issued for services, related parties	3,600,000	840,000
Common stock issued for services	377,812	266,640
Total stock based compensation	$ 4,020,312	$ 1,106,640

Revenue Recognition

Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company will defer any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales have not yet commenced on the MMJ business. The Company also did not recognize revenues from its previous mining operations during the periods presented herein.

Advertising and Promotion

All costs associated with advertising and promoting products are expensed as incurred. These expenses were $-0- and $-0- for the years ended December 31, 2016 and 2015, respectively.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.

Uncertain Tax Positions

In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

F-7

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities.

The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.

Recently Issued Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350) . ASU 2017-04 simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reportingunit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company intends to early adopt the ASU in 2017.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business , which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard will be effective for the Company in the first quarter of 2018. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements.

In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers . ASU 2016-20 amended guidance regarding accounting for Revenue from Contracts with Customers , which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. When effective, this standard will replace most existing revenue recognition guidance in generally accepted accounting principles (“GAAP”). The standard also requires more detailed disclosures and provides additional guidance for transactions that were not comprehensively addressed in GAAP. This guidance is required to be adopted by us in the first quarter of fiscal 2019 by either recasting all years presented in our financial statements or by recording the impact of adoption as an adjustment to retained earnings at the beginning of the year of adoption. We are currently evaluating the impact this guidance will have on our consolidated financial statements.

In October 2016, the FASB issued ASU No. 2016-17, Consolidation (Topic 810): Interests Held through Related Parties that are under Common Control . The amendments in this Update improve GAAP involving situations consisting of common control, wherein a single decision maker focuses on the economics to which it is exposed when determining whether it is the primary beneficiary of a variable interest entity (“VIE”) before potentially evaluating which party is most closely associated with the VIE. ASU 2016-17 is effective for public entities for fiscal periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements.

In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory , which reduces the complexity in the accounting standards by allowing the recognition of current and deferred income taxes for an intra-entity asset transfer, other than inventory, when the transfer occurs. Historically, recognition of the income tax consequence was not recognized until the asset was sold to an outside party. This amendment should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. ASU 2016-16 is effective for annual periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities as of the beginning of an annual reporting period for which financial statements (interim or annual) have not been issued or made available for issuance. That is, earlier adoption should be in the first interim period if an entity issues interim financial statements. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements.

F-8

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

No other new accounting pronouncements, issued or effective during the years ended December 31, 2016 and 2015, have had or are expected to have a significant impact on the Company’s financial statements.

Note 2 – Going Concern

As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $15,599,393, and had negative working capital of ($275,942) at December 31, 2016. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new products and services to begin generating revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern.

The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 3 – Related Party

Notes Payable

From time to time, the Company has received short term loans from officers and directors as disclosed in Note 7 below.

Common Stock

On October 1, 2016, the Company granted 7,000,000 shares of common stock to our CEO, Glenn E. Martin, as a bonus for services performed pursuant to an amended employment agreement. The total fair value of the common stock was $700,000 based on the closing price of the Company’s common stock on the date of grant.

In addition, on October 1, 2016, the Company granted a total of 14,000,000 shares of common stock to Mr. Martin for services performed pursuant to his previous employment agreement. The total fair value of the common stock was $1,400,000 based on the closing price of the Company’s common stock on the date of grant.

On October 1, 2016, the Company granted 4,000,000 shares of common stock to a related party as a bonus for services performed pursuant to an amended employment agreement. The total fair value of the common stock was $400,000 based on the closing price of the Company’s common stock on the date of grant.

In addition, on October 1, 2016, the Company granted a total of 8,000,000 shares of common stock to a related party for services performed pursuant to their previous employment agreement. The total fair value of the common stock was $800,000 based on the closing price of the Company’s common stock on the date of grant.

On October 1, 2016, the Company granted 1,000,000 shares of common stock to a related party as a bonus for services performed pursuant to an amended employment agreement. The total fair value of the common stock was $100,000 based on the closing price of the Company’s common stock on the date of grant.

In addition, on October 1, 2016, the Company granted a total of 2,000,000 shares of common stock to a related party for services performed pursuant to their previous employment agreement. The total fair value of the common stock was $200,000 based on the closing price of the Company’s common stock on the date of grant.

On January 1, 2015, the Company granted 7,000,000 shares of common stock to our CEO, Glenn E. Martin, for services performed. The total fair value of the common stock was $490,000 based on the closing price of the Company’s common stock on the date of grant. The shares were subsequently issued on June 29, 2015.

F-9

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

On January 1, 2015, the Company granted 4,000,000 shares of common stock to a related party for services performed. The total fair value of the common stock was $280,000 based on the closing price of the Company’s common stock on the date of grant. The shares were subsequently issued on June 29, 2015.

On January 1, 2015, the Company granted 1,000,000 shares of common stock to a related party for services performed. The total fair value of the common stock was $70,000 based on the closing price of the Company’s common stock on the date of grant. The shares were subsequently issued on June 29, 2015.

A total of $157,505 and $86,000 of officer compensation was unpaid and outstanding at December 31, 2016 and 2015, respectively.

Capital Contributions

The Company imputed interest on non-interest bearing, related party loans, resulting in a total of $583 and $200 of contributed capital during the years ended December 31, 2016 and 2015, respectively.

Note 4 – Fair Value of Financial Instruments

Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value.

The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows:

Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability.

F-10

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of December 31, 2016 and 2015, respectively:

	Fair Value Measurements at December 31, 2016
	Level 1	Level 2	Level 3
Assets
Cash	$ 7	$ -	$ -
Total assets	7	-	-
Liabilities
Convertible notes payable	-	35,000	-
Notes payable, related parties	-	16,300	-
Total liabilities	-	51,300	-
	$ 7	$ (51,300 )	$ -

	Fair Value Measurements at December 31, 2015
	Level 1	Level 2	Level 3
Assets
Cash	$ 7	$ -	$ -
Total assets	7	-	-
Liabilities
Convertible notes payable	-	35,000	-
Notes payable, related parties	-	13,300	-
Total liabilities	-	48,300	-
	$ 7	$ (48,300 )	$ -

The fair values of our related party debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35.

There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the years ended December 31, 2016 or the year ended December 31, 2015.

Note 5 – Property and Equipment

Property and equipment consist of the following at December 31, 2016 and 2015, respectively:

	December 31,
	2016	2015
Office equipment	$ 650	$ 650
Less accumulated depreciation	(386 )	(256 )
	$ 264	$ 394

Depreciation and amortization expense totaled $130 and $130 for the years ended December 31, 2016 and 2015, respectively.

F-11

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

Note 6 – Convertible Notes Payable

Convertible notes payable consist of the following at December 31, 2016 and 2015, respectively:

	December 31,	December 31,
	2016	2015

On December 7, 2007, the Company issued a 10% note payable to the Lebrecht Group, PC (“Lebrecht Note”) for services rendered related to the registration of certain securities of the Company. The note and accrued interest were due December 7, 2008 and at the option of the holder payable in full on the maturity date or in 12 monthly payments beginning on the maturity date. The note and accrued interest are convertible to common shares at any time at the option of the holder at 75% of the average closing bid price on the five trading days immediately preceding the conversion. Management estimates, at this time, that 1,650,000 shares may be issued if this conversion feature is exercised. In accordance with generally accepted accounting principles, the 25% discount to market related to the beneficial conversion feature has been reported as a component of additional paid in capital. Additionally, since this represents a prepayment for services related to a future public offering, management had elected to offset the cost to future capital raised as a result of the offering, if any. Currently in default.	$ 35,000	$ 35,000
Total convertible notes payable	35,000	35,000
Less unamortized debt discounts:
Discount on beneficial conversion feature	-	-
Convertible notes payable (in default)	$ 35,000	$ 35,000

The Company recognized interest expense related to the convertible debts for the years ended December 31, 2016 and 2015, respectively, as follows:

	December 31,	December 31,
	2016	2015

Interest	$ 3,500	$ 3,500
Amortization of beneficial conversion feature	-	-
Total interest expense	$ 3,500	$ 3,500

In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible debts by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible debt. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt.

Furthermore, the Company confirmed and agreed with Lebrecht Law Group, PC that they would not force the Company to settle in shares of common stock in the event there are not enough authorized shares at time of conversion.

F-12

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

Note 7 – Notes Payable, Related Parties

Notes payable, related parties consist of the following at December 31, 2016 and 2015, respectively:

	December 31,	December 31,
	2016	2015

On various dates, the Company received advances from the Company’s CEO. The unsecured non-interest bearing loans were due on demand. The loans were repaid in full over various dates from March 15, 2016 through November 3, 2016.	$ -	$ -

On August 23, 2016, the Company received an unsecured, non-interest bearing loan in the amount of $3,000, due on demand from an affiliate, bearing interest at 10% per annum.	3,000	-

On January 21, 2015, the Company received an unsecured loan in the amount of $1,300, due on demand from an affiliate, bearing interest at 10% per annum.	1,300	1,300

On April 12, 2010, the Company received an unsecured, non-interest bearing loan in the amount of $2,000, due on demand from an affiliate. Interest is being imputed at the Company’s estimated borrowing rate, or 10% per annum.	2,000	2,000

Over various dates in 2011 and 2012, the Company received unsecured loans in the aggregate amount of $10,000, due on demand, bearing interest at 10%, from an affiliate.	10,000	10,000

Notes payable, related parties	$ 16,300	$ 13,300

The Company recorded interest expense in the amount of $1,821 and $1,324 for the years ended December 31, 2016 and 2015, respectively, including imputed interest expense in the amount of $583 and $200 for the years ended December 31, 2016 and 2015, respectively related to notes payable, related parties.

Note 8 – Commitments and Contingencies

On November 8, 2016, the Company entered into an agreement with Gregory DiPaolo’s Pro Am Golf, LLC to acquire land currently housing a golf course and restaurant. The total purchase price of $1,600,000 is to be paid with a deposit of 50,000 shares of common stock, followed by cash of $1,250,000 and 300,000 shares of the Company’s common stock to be delivered at closing. The deposit of 50,000 shares issued as a deposit was $42,500 based on the closing price of the Company’s common stock on the date of grant. The Company subsequently closed on the property on July 27, 2017.

On September 30, 2014, the majority of shareholders approved a Settlement Agreement dated December 11, 2013 and signed on August 19, 2014 pursuant to Case No. C20125545 in the Superior Court of the State of Arizona, whereby among other provisions, the Plaintiffs, consisting of United Mines, Inc. (“UMI”) and its then principals, agreed to the cancellation of a total of 4,820,953 shares of common stock and control of the Company in exchange for (i) sixty five (65) of the unpatented Bureau of Land Management (“BLM”) mining claims, the mill site, buildings and equipment, (ii) the four (4) Arizona State Land Department Exploration Permits registered to the Company, (iii) any permits, financial and reclamation guaranties, bonds and licenses connected with the foregoing assets. In addition, thirty-three (33) unpatented BLM mining claims remained the property of UMI, along with any associated permits, financial and reclamation guaranties, bonds, licenses, and the rights to the corporation, the corporation’s name, stock symbol, or any other asset of UMI, shall remain the property of UMI under the management of Glenn E. Martin. As of the date of this report, the Plaintiffs have not surrendered the stock certificates to the Company.

Note 9 – Stockholders’ Equity

Preferred Stock

On December 5, 2014, the Company amended the Articles of Incorporation, pursuant to which 20,000,000 shares of “blank check” preferred stock with a par value of $0.001 were authorized. No series of preferred stock has been designated to date.

F-13

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

Common Stock

On December 5, 2014, the Company amended the Articles of Incorporation, and increased the authorized shares to 200,000,000 shares of $0.001 par value common stock.

Common Stock Sales (2016)

On October 31, 2016, the Company sold 50,000 units at $0.10 per unit, consisting of 50,000 shares of common stock and warrants to purchase 50,000 shares of common stock at an exercise price of $1.50 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $5,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On October 25, 2016, the Company sold 150,000 units at $0.3333 per unit, consisting of 150,000 shares of common stock and warrants to purchase 150,000 shares of common stock at an exercise price of $1.50 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $50,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On October 19, 2016, the Company sold 25,000 units at $0.20 per unit, consisting of 25,000 shares of common stock and warrants to purchase 25,000 shares of common stock at an exercise price of $1.50 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $5,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On October 19, 2016, the Company sold 100,000 units at $0.10 per unit, consisting of 100,000 shares of common stock and warrants to purchase 100,000 shares of common stock at an exercise price of $1.50 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $10,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

Common Stock Sales (2015)

On August 17, 2015, the Company sold 90,000 units at $0.10 per unit, consisting of 90,000 shares of common stock and warrants to purchase 90,000 shares of common stock at an exercise price of $0.50 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $9,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On February 20, 2015, the Company sold 40,000 units at $0.25 per unit, consisting of 40,000 shares of common stock and warrants to purchase 100,000 shares of common stock at an exercise price of $0.75 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $10,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On January 30, 2015, the Company sold 50,000 units at $0.10 per unit, consisting of 50,000 shares of common stock and warrants to purchase 50,000 shares of common stock at an exercise price of $0.75 per share, exercisable until December 31, 2015, in exchange for total proceeds of $5,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

Common Stock in Satisfaction of Subscriptions Payable (2016)

On October 27, 2016, the Company issued a total of 4,650,000 shares of common stock in satisfaction of common stock granted during the year ended December 31, 2015, in the aggregate value of $304,302.

Common Stock Issued as Down Payment for Land Purchase (2016)

On November 8, 2016, the Company granted 50,000 shares of common stock as a good faith deposit on a potential land purchase agreement that has not yet closed, as the Company does not currently have sufficient resources. The total fair value of the common stock was $42,500 based on the closing price of the Company’s common stock on the date of grant.

Common Stock Issued for Services, Related Parties (2016)

F-14

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

Common Stock Issued for Services (2016)

On October 19, 2016, the Company granted 10,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $8,500 based on the closing price of the Company’s common stock on the date of grant.

On September 28, 2016, the Company granted 600,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $60,000 based on the closing price of the Company’s common stock on the date of grant.

On September 28, 2016, the Company granted 600,000 shares of common stock to another consultant for services performed. The total fair value of the common stock was $60,000 based on the closing price of the Company’s common stock on the date of grant.

On September 28, 2016, the Company granted 600,000 shares of common stock to a third consultant for services performed. The total fair value of the common stock was $60,000 based on the closing price of the Company’s common stock on the date of grant.

On July 1, 2016, the Company granted 500,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $35,000 based on the closing price of the Company’s common stock on the date of grant.

On July 1, 2016, the Company granted 500,000 shares of common stock to another consultant for services performed. The total fair value of the common stock was $35,000 based on the closing price of the Company’s common stock on the date of grant.

On March 18, 2016, the Company granted 60,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $5,820 based on the closing price of the Company’s common stock on the date of grant.

On March 18, 2016, the Company granted 500,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $48,500 based on the closing price of the Company’s common stock on the date of grant.

On March 18, 2016, the Company granted 120,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $11,640 based on the closing price of the Company’s common stock on the date of grant.

On February 12, 2016, the Company granted 120,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $5,832 based on the closing price of the Company’s common stock on the date of grant.

On February 1, 2016, the Company granted 500,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $22,000 based on the closing price of the Company’s common stock on the date of grant.

On February 1, 2016, the Company granted 500,000 shares of common stock to another consultant for services performed. The total fair value of the common stock was $22,000 based on the closing price of the Company’s common stock on the date of grant.

On February 1, 2016, the Company granted 20,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $880 based on the closing price of the Company’s common stock on the date of grant.

F-15

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

On February 1, 2016, the Company granted 60,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $2,640 based on the closing price of the Company’s common stock on the date of grant.

Common Stock Issued for Services (2015)

On November 25, 2015, the Company granted 500,000 shares of common stock to another consultant for services performed. The total fair value of the common stock was $30,000 based on the closing price of the Company’s common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

On November 1, 2015, the Company granted 260,000 shares of common stock to another consultant for services performed. The total fair value of the common stock was $20,800 based on the closing price of the Company’s common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

On October 1, 2015, the Company granted 600,000 shares of common stock to another consultant for services performed. The total fair value of the common stock was $33,000 based on the closing price of the Company’s common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

On September 24, 2015, the Company granted 100,000 shares of common stock to another consultant for services performed. The total fair value of the common stock was $5,500 based on the closing price of the Company’s common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

On September 1, 2015, the Company granted 250,000 shares of common stock to another consultant for services performed. The total fair value of the common stock was $21,250 based on the closing price of the Company’s common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

On August 12, 2015, the Company granted 60,000 shares of common stock to another consultant for services performed. The total fair value of the common stock was $4,440 based on the closing price of the Company’s common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

On April 1, 2015, the Company granted 600,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $48,000 based on the closing price of the Company’s common stock on the date of grant.

On April 1, 2015, the Company granted 500,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $40,000 based on the closing price of the Company’s common stock on the date of grant.

On March 16, 2015, the Company granted 50,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $4,000 based on the closing price of the Company’s common stock on the date of grant.

On March 16, 2015, the Company granted 60,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $4,800 based on the closing price of the Company’s common stock on the date of grant.

On March 16, 2015, the Company granted 120,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $9,600 based on the closing price of the Company’s common stock on the date of grant.

On March 16, 2015, the Company granted 40,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $3,200 based on the closing price of the Company’s common stock on the date of grant.

On March 16, 2015, the Company granted 40,000 shares of common stock to another consultant for services performed. The total fair value of the common stock was $3,200 based on the closing price of the Company’s common stock on the date of grant.

On February 20, 2015, the Company granted 240,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $21,600 based on the closing price of the Company’s common stock on the date of grant.

On February 12, 2015, the Company granted 60,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $8,850 based on the closing price of the Company’s common stock on the date of grant.

F-16

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

On January 1, 2015, the Company granted 120,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $8,400 based on the closing price of the Company’s common stock on the date of grant.

Capital Contributions

Note 10 – Common Stock Warrants

Common Stock Warrants Granted (2016)

On October 31, 2016, the Company sold warrants to purchase 50,000 shares of common stock at $1.50 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $5,000 in conjunction with the sale of 50,000 shares of common stock. The relative fair value of the 50,000 common stock warrants using the Black-Scholes option-pricing model was $914, or $0.01828 per share, based on a volatility rate of 217%, a risk-free interest rate of 0.66% and an expected term of 1.0 year. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On October 25, 2016, the Company sold warrants to purchase 150,000 shares of common stock at $1.50 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $50,000 in conjunction with the sale of 150,000 shares of common stock. The relative fair value of the 150,000 common stock warrants using the Black-Scholes option-pricing model was $2,725, or $0.01817 per share, based on a volatility rate of 217%, a risk-free interest rate of 0.66% and an expected term of 1.0 year. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On October 19, 2016, the Company sold warrants to purchase 25,000 shares of common stock at $1.50 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $5,000 in conjunction with the sale of 25,000 shares of common stock. The relative fair value of the 25,000 common stock warrants using the Black-Scholes option-pricing model was $608, or $0.02432 per share, based on a volatility rate of 216%, a risk-free interest rate of 0.65% and an expected term of 1.0 year. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On October 19, 2016, the Company sold warrants to purchase 100,000 shares of common stock at $1.50 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $10,000 in conjunction with the sale of 100,000 shares of common stock. The relative fair value of the 100,000 common stock warrants using the Black-Scholes option-pricing model was $2,856, or $0.02856 per share, based on a volatility rate of 216%, a risk-free interest rate of 0.65% and an expected term of 1.0 year. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

Common Stock Warrants Granted (2015)

On August 17, 2015, the Company sold warrants to purchase 90,000 shares of common stock at $0.50 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $9,000 in conjunction with the sale of 90,000 shares of common stock. The relative fair value of the 90,000 common stock warrants using the Black-Scholes option-pricing model was $2,501, or $0.02779 per share, based on a volatility rate of 207%, a risk-free interest rate of 0.40% and an expected term of 1.0 year. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

F-17

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

On February 20, 2015, the Company sold warrants to purchase 100,000 shares of common stock at $0.75 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $10,000 in conjunction with the sale of 40,000 shares of common stock. The relative fair value of the 100,000 common stock warrants using the Black-Scholes option-pricing model was $3,179, or $0.03179 per share, based on a volatility rate of 210%, a risk-free interest rate of 0.23% and an expected term of 1.0 year. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On January 30, 2015, the Company sold warrants to purchase 50,000 shares of common stock at $0.75 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $5,000 in conjunction with the sale of 50,000 shares of common stock. The relative fair value of the 50,000 common stock warrants using the Black-Scholes option-pricing model was $1,890, or $0.03781 per share, based on a volatility rate of 212%, a risk-free interest rate of 0.18% and an expected term of 1.0 year. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

Common Stock Warrants Cancelled

No warrants were cancelled during the years ended December 31, 2016 and 2015.

Common Stock Warrants Expired

A total of 190,000 and 325,000 warrants expired during years ended December 31, 2016 and 2015, respectively.

Common Stock Warrants Exercised

No warrants were exercised during the years ended December 31, 2016 and 2015.

The following is a summary of information about the Common Stock Warrants outstanding at December 31, 2016.

				Shares Underlying
Shares Underlying Warrants Outstanding				Warrants Exercisable

		Weighted
	Shares	Average	Weighted	Shares	Weighted
Range of	Underlying	Remaining	Average	Underlying	Average
Exercise	Warrants	Contractual	Exercise	Warrants	Exercise
Prices	Outstanding	Life	Price	Exercisable	Price

$1.50	325,000	9.75 months	$1.50	325,000	$1.50

The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan:

	December 31,	December 31,
	2016	2015

Average risk-free interest rates	0.66 %	0.27 %
Average expected life (in years)	1.0	1.0

The Black-Scholes option pricing model was developed for use in estimating the fair value of short-term traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including expected stock price volatility. Because the Company’s common stock warrants have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models do not necessarily provide a reliable single measure of the fair value of its common stock warrants. During the years ended December 31, 2016 and 2015 there were no warrants granted with an exercise price below the fair value of the underlying stock at the grant date.

The weighted average fair value of warrants granted with exercise prices at the current fair value of the underlying stock was approximately $0.02186 and $0.03154 per warrant granted during the years ended December 31, 2016 and 2015, respectively.

F-18

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

The following is a summary of activity of outstanding common stock warrants:

		Weighted
		Average
	Number of	Exercise
	Shares	Price

Balance, December 31, 2014	275,000	$ 0.50
Warrants expired	(325,000 )	0.54
Warrants granted	240,000	0.66
Balance, December 31, 2015	190,000	$ 0.63
Warrants expired	(190,000 )	0.63
Warrants granted	325,000	1.50
Balance, December 31, 2016	325,000	$ 1.50

Exercisable, December 31, 2016	325,000	$ 1.50

Note 11 – Income Taxes

The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences.

For the years ended December 31, 2016 and 2015, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2016 and December 31, 2015, the Company had approximately $10,212,000 and $8,050,000 of federal net operating losses, respectively. The net operating loss carry forwards, if not utilized, will begin to expire in 2031.

The components of the Company’s deferred tax asset are as follows:

	December 31,	December 31,
	2016	2015
Deferred tax assets:
Net operating loss carry forwards	$ 3,574,200	$ 2,817,500

Net deferred tax assets before valuation allowance	$ 3,574,200	$ 2,817,500
Less: Valuation allowance	(3,574,200 )	(2,817,500 )
Net deferred tax assets	$ -	$ -

Based on the available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2016 and 2015, respectively.

A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and State statutory income tax rate to pre-tax loss is as follows:

	December 31,	December 31,
	2016	2015

Federal and state statutory rate	35 %	35 %
Change in valuation allowance on deferred tax assets	(35 %)	(35 %)

In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

F-19

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Years Ended December 31, 2016 and 2015

Note 12 – Subsequent Events

Common Stock Sales

On January 23, 2017, the Company sold 2,000 units at $2.00 per unit, consisting of 2,000 shares of common stock and warrants to purchase 2,000 shares of common stock at an exercise price of $3.00 per share, exercisable until January 23, 2018, in exchange for total proceeds of $4,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On January 9, 2017, the Company sold 50,000 units at $1.00 per unit, consisting of 50,000 shares of common stock and warrants to purchase 50,000 shares of common stock at an exercise price of $3.00 per share, exercisable until January 9, 2018, in exchange for total proceeds of $50,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

Warrants Exercised

On January 7, 2017, a warrant holder exercised warrants to purchase 2,666 shares of common stock at a strike price of $1.50 in exchange for proceeds of $3,999.

Common Stock Issued for Bartered Assets

On January 18, 2017, the Company exchanged 66,000 units, consisting of 66,000 shares of common stock and warrants to purchase 66,000 shares of common stock at an exercise price of $3.00 per share, exercisable until January 18, 2018, in exchange for a 2017 Audi Q7 and a 2017 Audi A4. The total fair value received, based on the market price of the stock at $4.02 per share, was allocated to the $105,132 purchase price of the vehicles and the $160,188 excess value of the common stock and warrants was expensed as stock based compensation.

Common Stock Issued for Services

On March 2, 2017, the Company granted 12,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $34,200 based on the closing price of the Company’s common stock on the date of grant.

Common Stock Cancellations

On January 26, 2017, the Company cancelled a total of 1,000,000 shares of common stock previously granted to two individuals for non-performance of services.

F-20

WEED, INC. (Formerly United Mines, Inc.)
BALANCE SHEETS


	March 31,	December 31,
	2017	2016
ASSETS	(Unaudited)

Current assets:
Cash	$ 167,015	$ 231
Prepaid expenses	40,508	5,053
Total current assets	207,523	5,284

Property and equipment, net	101,158	264

Total assets	$ 308,681	$ 5,548


LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current liabilities:
Accounts payable	$ 22,557	$ 35,661
Accrued officer compensation	177,005	157,505
Accrued interest	37,993	36,760
Convertible notes payable	35,000	35,000
Notes payable, related parties	21,126	16,300
Total current liabilities	293,681	281,226

Commitments and contingencies	-	-

Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 20,000,000 shares
authorized, no shares designated, issued and outstanding	-	-
Common stock, $0.001 par value, 200,000,000 shares
authorized, 103,135,973 and 103,953,307 shares issued and
outstanding at March 31, 2017 and December 31, 2016, respectively	103,136	103,953
Additional paid in capital	15,788,499	15,219,762
Subscriptions payable, consisting of 425,000 and -0- shares
at March 31, 2017 and December 31, 2016, respectively	377,500	-
Accumulated deficit	(16,254,135 )	(15,599,393 )
Total stockholders' equity (deficit)	15,000	(275,678 )

Total liabilities and stockholders' equity (deficit)	$ 308,681	$ 5,548

See accompanying notes to financial statements.

F-21

WEED, INC. (Formerly United Mines, Inc.)
STATEMENTS OF OPERATIONS
(Unaudited)


	For the Three Months
	Ended March 31,
	2017	2016

Revenue	$ -	$ -

Operating expenses:
General and administrative	68,134	24,720
Professional fees	580,986	120,348
Depreciation and amortization	4,238	33
Total operating expenses	653,358	145,101

Net operating loss	(653,358 )	(145,101 )

Other expense:
Interest expense	(1,384 )	(1,227 )

Net loss	$ (654,742 )	$ (146,328 )


Weighted average number of common shares
outstanding - basic and fully diluted	103,393,921	61,118,307

Net loss per share - basic and fully diluted	$ (0.01 )	$ (0.00 )

See accompanying notes to financial statements.

F-22

WEED, INC. (Formerly United Mines, Inc.)
STATEMENTS OF CASH FLOWS
(Unaudited)


	For the Three Months
	Ended March 31,
	2017	2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss)	$ (654,742 )	$ (146,328 )
Adjustments to reconcile net loss
to net cash used in operating activities:
Depreciation	4,238	33
Imputed interest on non-interest bearing related party debts	151	69
Shares issued for services	547,138	119,312
Decrease (increase) in assets:
Prepaid expenses	(35,455 )	775
Increase (decrease) in liabilities:
Accounts payable	(13,104 )	1,544
Accrued compensation	19,500	19,500
Accrued interest	1,233	1,158
Net cash used in operating activities	(131,041 )	(3,937 )

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable, related parties	9,000	10,000
Repayments on notes payable, related parties	(4,174 )	(6,000 )
Proceeds from the sale of common stock	292,999	-
Net cash provided by financing activities	297,825	4,000

NET CHANGE IN CASH	166,784	63
CASH AT BEGINNING OF PERIOD	231	7

CASH AT END OF PERIOD	$ 167,015	$ 70

SUPPLEMENTAL INFORMATION:
Interest paid	$ -	$ -
Income taxes paid	$ -	$ -

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Value of fixed assets acquired in exchange for stock	$ 105,132	$ -

See accompanying notes to financial statements.

F-23

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three Months Ended March 31, 2017 and 2016

(Unaudited)

Note 1 – Nature of Business and Significant Accounting Policies

Nature of Business

The Company has a calendar year end for reporting purposes.

Use of Estimates

Cash and Cash Equivalents

Fair Value of Financial Instruments

Property and Equipment

Software	3 years
Furniture and fixtures	5 years
Equipment	5-7 years

F-24

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three Months Ended March 31, 2017 and 2016

(Unaudited)

Impairment of Long-Lived Assets

Basic and Diluted Loss Per Share

Stock-Based Compensation

Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation issued for services was $547,138 and $119,312 for the three months ended March 31, 2017 and 2016, respectively.

Revenue Recognition

Advertising and Promotion

All costs associated with advertising and promoting products are expensed as incurred. These expenses were $1,621 and $-0- for the three months ended March 31, 2017 and 2016, respectively.

Income Taxes

Uncertain Tax Positions

The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.

F-25

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three Months Ended March 31, 2017 and 2016

(Unaudited)

Recently Issued Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350) . ASU 2017-04 simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company intends to early adopt the ASU in 2017.

No other new accounting pronouncements, issued or effective during the three months ended March 31, 2017, have had or are expected to have a significant impact on the Company’s financial statements.

Note 2 – Going Concern

As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $16,254,135, and had negative working capital of ($86,158) at March 31, 2017. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new products and services to begin generating revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern.

Note 3 – Related Party

Notes Payable

From time to time, the Company has received short term loans from officers and directors as disclosed in Note 7 below.

Capital Contributions

The Company imputed interest on non-interest bearing, related party loans, resulting in a total of $151 and $69 of contributed capital during the three months ended March 31, 2017 and 2016, respectively.

Common Stock Issued for Bartered Assets

On January 18, 2017, the Company exchanged 66,000 units, consisting of 66,000 shares of common stock and warrants to purchase 66,000 shares of common stock at an exercise price of $3.00 per share, exercisable until January 18, 2018, in exchange for a 2017 Audi Q7 and a 2017 Audi A4 driven by the Officers. The total fair value received, based on the market price of the stock at $4.02 per share, was allocated to the $105,132 purchase price of the vehicles and the $160,188 excess value of the common stock and warrants was expensed as stock based compensation.

A total of $177,005 and $157,505 of officer compensation was unpaid and outstanding at March 31, 2017 and December 31, 2016, respectively.

F-26

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three Months Ended March 31, 2017 and 2016

(Unaudited)

Note 4 – Fair Value of Financial Instruments

Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability.

The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of March 31, 2017 and December 31, 2016, respectively:

	Fair Value Measurements at March 31, 2017
	Level 1	Level 2	Level 3
Assets
Cash	$ 167,015	$ -	$ -
Total assets	167,015	-	-
Liabilities
Convertible notes payable	-	35,000	-
Notes payable, related parties	-	21,126	-
Total liabilities	-	56,126	-
	$ 167,015	$ (56,126 )	$ -

	Fair Value Measurements at December 31, 2016
	Level 1	Level 2	Level 3
Assets
Cash	$ 231	$ -	$ -
Total assets	231	-	-
Liabilities
Convertible notes payable	-	35,000	-
Notes payable, related parties	-	16,300	-
Total liabilities	-	51,300	-
	$ 231	$ (51,300 )	$ -

The fair values of our related party debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35.

There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the three months ended March 31, 2017 and the year ended December 31, 2016.

F-27

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three Months Ended March 31, 2017 and 2016

(Unaudited)

Note 5 – Property and Equipment

Property and equipment consist of the following at March 31, 2017 and December 31, 2016, respectively:

	March 31,	December 31,
	2017	2016
Automobiles	$ 105,132	$ -
Office equipment	650	650
	105,782	650
Less accumulated depreciation	(4,624 )	(386 )
	$ 101,158	$ 264

Depreciation and amortization expense totaled $4,238 and $33 for the three months ended March 31, 2017 and 2016, respectively.

Note 6 – Convertible Notes Payable

Convertible notes payable consist of the following at March 31, 2017 and December 31, 2016, respectively:

	March 31,	December 31,
	2017	2016

On December 7, 2007, the Company issued a 10% note payable to the Lebrecht Group, PC (“Lebrecht Note”) for services rendered related to the registration of certain securities of the Company. The note and accrued interest were due December 7, 2008 and at the option of the holder payable in full on the maturity date or in 12 monthly payments beginning on the maturity date. The note and accrued interest are convertible to common shares at any time at the option of the holder at 75% of the average closing bid price on the five trading days immediately preceding the conversion. Management estimates, at this time, that 1,650,000 shares may be issued if this conversion feature is exercised. In accordance with generally accepted accounting principles, the 25% discount to market related to the beneficial conversion feature has been reported as a component of additional paid in capital. Additionally, since this represents a prepayment for services related to a future public offering, management had elected to offset the cost to future capital raised as a result of the offering, if any. Currently in default.$	35,000	$ 35,000

The Company recognized interest expense of $875 and $875 related to the convertible debts for the three months ended March 31, 2017 and 2016, respectively.

F-28

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three Months Ended March 31, 2017 and 2016

(Unaudited)

Note 7 – Notes Payable, Related Parties

Notes payable, related parties consist of the following at March 31, 2017 and December 31, 2016, respectively:

	March 31,	December 31,
	2017	2016

On various dates, the Company received advances from the Company’s CEO. The unsecured non-interest bearing loans were due on demand.	$ 4,826	$ -

On August 23, 2016, the Company received an unsecured, non-interest bearing loan in the amount of $3,000, due on demand from an affiliate, bearing interest at 10% per annum.	3,000	3,000

On January 21, 2015, the Company received an unsecured loan in the amount of $1,300, due on demand from an affiliate, bearing interest at 10% per annum.	1,300	1,300

On April 12, 2010, the Company received an unsecured, non-interest bearing loan in the amount of $2,000, due on demand from an affiliate. Interest is being imputed at the Company’s estimated borrowing rate, or 10% per annum.	2,000	2,000

Over various dates in 2011 and 2012, the Company received unsecured loans in the aggregate amount of $10,000, due on demand, bearing interest at 10%, from an affiliate.	10,000	10,000

Notes payable, related parties	$ 21,126	$ 16,300

The Company recorded interest expense in the amount of $509 and $352 for the three months ended March 31, 2017 and 2016, respectively, including imputed interest expense in the amount of $151 and $69 for the three months ended March 31, 2017 and 2016, respectively related to notes payable, related parties.

Note 8 – Commitments and Contingencies

Note 9 – Stockholders’ Equity

Preferred Stock

Common Stock

On December 5, 2014, the Company amended the Articles of Incorporation, and increased the authorized shares to 200,000,000 shares of $0.001 par value common stock.

F-29

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three Months Ended March 31, 2017 and 2016

(Unaudited)

Common Stock Sales

On March 15, 2017 and March 31, 2017, the Company received an aggregate $235,000 of advances on the subsequent sale on April 20, 2017 of 375,000 units at $1.00 per unit, consisting of 375,000 shares of common stock and warrants to purchase 375,000 shares of common stock at an exercise price of $3.00 per share, exercisable until April 20, 2018, in exchange for total proceeds of $375,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. The $235,000 was presented as a subscriptions payable at March 31, 2017.

Warrants Exercised

On January 7, 2017, a warrant holder exercised warrants to purchase 2,666 shares of common stock at a strike price of $1.50 in exchange for proceeds of $3,999.

Common Stock Issued for Bartered Assets

Common Stock Issued for Services

On March 2, 2017, the Company granted 50,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $142,500 based on the closing price of the Company’s common stock on the date of grant. The shares were subsequently issued on April 28, 2017, therefore the issuance was presented as a subscription payable at March 31, 2017.

On January 7, 2017, the Company granted 50,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $210,250 based on the closing price of the Company’s common stock on the date of grant.

Common Stock Cancellations

On January 26, 2017, the Company cancelled a total of 1,000,000 shares of common stock previously granted to two individuals for non-performance of services.

Capital Contributions

Note 10 – Common Stock Warrants

Common Stock Warrants Granted

On January 23, 2017, the Company sold warrants to purchase 2,000 shares of common stock at $3.00 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $4,000 in conjunction with the sale of 2,000 shares of common stock. The relative fair value of the 2,000 common stock warrants using the Black-Scholes option-pricing model was $5,106, or $2.55281 per share, based on a volatility rate of 211%, a risk-free interest rate of 0.79% and an expected term of 1.0 year. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

F-30

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three Months Ended March 31, 2017 and 2016

(Unaudited)

On January 9, 2017, the Company sold warrants to purchase 50,000 shares of common stock at $3.00 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $50,000 in conjunction with the sale of 50,000 shares of common stock. The relative fair value of the 50,000 common stock warrants using the Black-Scholes option-pricing model was $108,228, or $2.16456 per share, based on a volatility rate of 210%, a risk-free interest rate of 0.82% and an expected term of 1.0 year. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

Warrants Exercised

On January 7, 2017, a warrant holder exercised warrants to purchase 2,666 shares of common stock at a strike price of $1.50 in exchange for proceeds of $3,999.

Common Stock Warrants Expired or Cancelled

No warrants were expired or cancelled during the three months ended March 31, 2017.

Note 11 – Income Taxes

For the three months ended March 31, 2017 and the year ended December 31, 2016, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At March 31, 2017 and December 31, 2016, the Company had approximately $10,334,000 and $1 0,212,000 of federal net operating losses, respectively. The net operating loss carry forwards, if not utilized, will begin to expire in 2031.

The components of the Company’s deferred tax asset are as follows:

	March 31,	December 31,
	2017	2016
Deferred tax assets:
Net operating loss carry forwards	$ 3,616,900	$ 3,574,200

Net deferred tax assets before valuation allowance	$ 3,616,900	$ 3,574,200
Less: Valuation allowance	(3,616,900 )	(3 ,574,200 )
Net deferred tax assets	$ -	$ -

A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and State statutory income tax rate to pre-tax loss is as follows:

	March 31,	December 31,
	2017	2016

Federal and state statutory rate	35 %	35 %
Change in valuation allowance on deferred tax assets	(35 %)	(35 %)

In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

F-31

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three Months Ended March 31, 2017 and 2016

(Unaudited)

Note 12 – Subsequent Events

Common Stock Sales

On April 20, 2017, the Company received the final payment of $140,000, in addition to the previously received $235,000, on the sale of 375,000 units at $1.00 per unit, consisting of 375,000 shares of common stock and warrants to purchase 375,000 shares of common stock at an exercise price of $3.00 per share, exercisable until April 20, 2018. The total proceeds of $375,000 received were allocated between the common stock and warrants on a relative fair value basis.

Common Stock Issued for Acquisition

On May 9, 2017, the Company issued a total of 500,000 shares of common to seven individuals pursuant to the closing of an acquisition of Sangre AT, LLC, a Wyoming limited liability company (“Sangre”) in exchange for 100% of the interests in Sangre. The total fair value of the common stock was $569,000 based on the closing price of the Company’s common stock on the date of grant.

Common Stock Issued on Subscriptions Payable

On April 28, 2017, the Company issued 50,000 shares of common stock on a subscriptions payable in the amount of $142,500 to a consultant for services performed in the prior period.

Common Stock Issued for Services

On April 20, 2017, the Company granted an aggregate of 216,000 shares of common stock to eleven consultants for services performed. The aggregate fair value of the common stock was $433,663 based on the closing price of the Company’s common stock on the date of grant.

Common Stock Cancellations

On May 9, 2017, the Company cancelled a total of 600,000 shares of common stock previously granted to a consultant for non-performance of services.

On April 25, 2017, a total of 4,820,953 shares were cancelled and returned to treasury pursuant to compliance with the September 30, 2014 approval by the majority of shareholders of the terms of a Settlement Agreement dated December 11, 2013 and signed on August 19, 2014 pursuant to Case No. C20125545 in the Superior Court of the State of Arizona, whereby among other provisions, the Plaintiffs, consisting of United Mines, Inc. (“UMI”) and its then principals, agreed to the cancellation of a total of 4,820,953 shares of common stock and control of the Company in exchange for (i) sixty five (65) of the unpatented Bureau of Land Management (“BLM”) mining claims, the mill site, buildings and equipment, (ii) the four (4) Arizona State Land Department Exploration Permits registered to the Company, (iii) any permits, financial and reclamation guaranties, bonds and licenses connected with the foregoing assets. In addition, thirty-three (33) unpatented BLM mining claims remained the property of UMI, along with any associated permits, financial and reclamation guaranties, bonds, licenses, and the rights to the corporation, the corporation’s name, stock symbol, or any other asset of UMI, shall remain the property of UMI under the management of Glenn E. Martin.

F-32

WEED, INC. (Formerly United Mines, Inc.) & Subsidiary
BALANCE SHEETS


	June 30,	December 31,
	2017	2016
ASSETS	(Unaudited)

Current assets:
Cash	$ 473,234	$ 231
Prepaid expenses	71,823	5,053
Total current assets	545,057	5,284

Property and equipment, net	114,401	264

Total assets	$ 659,458	$ 5,548


LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current liabilities:
Accounts payable	$ 42,577	$ 35,661
Accrued officer compensation	171,505	157,505
Accrued interest	5,407	36,760
Convertible notes payable	-	35,000
Notes payable, related parties	16,826	16,300
Total current liabilities	236,315	281,226

Commitments and contingencies	-	-

Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 20,000,000 shares
authorized, no shares designated, issued and outstanding	-	-
Common stock, $0.001 par value, 200,000,000 shares
authorized, 99,991,020 and 103,953,307 shares issued and
outstanding at June 30, 2017 and December 31, 2016, respectively	99,991	103,953
Additional paid in capital	18,027,290	15,219,762
Subscriptions payable, consisting of 100,000 and -0- shares
at June 30, 2017 and December 31, 2016, respectively	200,770	-
Accumulated deficit	(17,904,908 )	(15,599,393 )
Total stockholders' equity (deficit)	423,143	(275,678 )

Total liabilities and stockholders' equity (deficit)	$ 659,458	$ 5,548

See accompanying notes to financial statements.

F-33

WEED, INC. (Formerly United Mines, Inc.) & Subsidiary
STATEMENTS OF OPERATIONS
(Unaudited)


	For the Three Months		For the Six Months
	Ended June 30,		Ended June 30,
	2017	2016	2017	2016

Revenue	$ -	$ -	$ -	$ -

Operating expenses:
General and administrative	84,313	23,615	152,447	48,335
Professional fees	476,311	195	1,057,297	120,543
Depreciation and amortization	5,422	32	9,660	65
Total operating expenses	566,046	23,842	1,219,404	168,943

Net operating loss	(566,046 )	(23,842 )	(1,219,404 )	(168,943 )

Other expense:
Goodwill impairment	(1,015,910 )	-	(1,015,910 )	-
Loss on extinguishment of debt	(67,983 )	-	(67,983 )	-
Interest expense	(834 )	(1,348 )	(2,218 )	(2,575 )

Net loss	$ (1,650,773 )	$ (25,190 )	$ (2,305,515 )	$ (171,518 )


Weighted average number of common shares
outstanding - basic and fully diluted	100,614,469	61,118,307	101,996,517	61,118,307

Net loss per share - basic and fully diluted	$ (0.02 )	$ (0.00 )	$ (0.02 )	$ (0.00 )

See accompanying notes to financial statements.

F-34

WEED, INC. (Formerly United Mines, Inc.) & Subsidiary
STATEMENTS OF CASH FLOWS
(Unaudited)


	For the Six Months
	Ended June 30,
	2017	2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss)	$ (2,305,515 )	$ (171,518 )
Adjustments to reconcile net loss
to net cash used in operating activities:
Depreciation	9,660	65
Goodwill impairment	1,015,910	-
Imputed interest on non-interest bearing related party debts	321	259
Loss on extinguishment of debt	67,983	-
Shares issued for services	980,801	119,312
Decrease (increase) in assets:
Prepaid expenses	(66,770 )	1,550
Increase (decrease) in liabilities:
Accounts payable	(19,013 )	2,246
Accrued compensation	14,000	39,000
Accrued interest	1,897	2,316
Net cash used in operating activities	(300,726 )	(6,770 )

CASH FLOWS FROM INVESTING ACTIVITIES
Cash received in acquisition	54	-
Purchases of property and equipment	(4,850 )	-
Net cash used in investing activities	(4,796 )	-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable, related parties	9,000	12,900
Repayments on notes payable, related parties	(8,474 )	(6,000 )
Proceeds from the sale of common stock	777,999	-
Net cash provided by financing activities	778,525	6,900

NET CHANGE IN CASH	473,003	130
CASH AT BEGINNING OF PERIOD	231	7

CASH AT END OF PERIOD	$ 473,234	$ 137

SUPPLEMENTAL INFORMATION:
Interest paid	$ -	$ -
Income taxes paid	$ -	$ -

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Value of shares issued for acuisition of Sangre AT, LLC	$ 1,003,850	$ -
Value of shares issued in exchange for settlement of convertible debt	$ 86,800	$ -
Value of warrants issued in exchange for settlement of convertible debt	$ 49,433	$ -
Value of fixed assets acquired in exchange for stock	$ 105,132	$ -

See accompanying notes to financial statements.

F-35

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

Note 1 – Nature of Business and Significant Accounting Policies

Nature of Business

On April 20, 2017, the Company acquired Sangre AT, LLC, a Wyoming company doing business as Sangre AgroTech. (“Sangre”). Sangre is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. Sangre is working on a cannabis genomic study to complete a global genomic classification of the cannabis plant genus.

The Company has a calendar year end for reporting purposes.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the following entities, all of which are under common control and ownership:

	State of		Abbreviated
Name of Entity	Incorporation	Relationship (1)	Reference
WEED, Inc.	Nevada	Parent	WEED
Sangre AT, LLC (2)	Wyoming	Subsidiary	Sangre

(1) Sangre is a wholly-owned subsidiary of WEED, Inc.

(2) Sangre AT, LLC is doing business as Sangre AgroTech.

The consolidated financial statements herein contain the operations of the wholly-owned subsidiary listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company, WEED and subsidiary, Sangre will be collectively referred to herein as the “Company”, or “WEED”. The Company's headquarters are located in Tucson, Arizona and its operations are primarily within the United States, with minimal operations in Australia.

These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.

Use of Estimates

Cash and Cash Equivalents

F-36

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

Cash in Excess of FDIC Insured Limits

The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $250,000, under current regulations. The Company had $212,748 in excess of FDIC insured limits at June 30, 2017. The Company has not experienced any losses in such accounts.

Fair Value of Financial Instruments

Property and Equipment

Software	3 years
Furniture and fixtures	5 years
Equipment	5-7 years

Impairment of Long-Lived Assets

Goodwill

The Company evaluates the carrying value of goodwill during the fourth quarter of each year and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. Such circumstances could include, but are not limited to (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating whether goodwill is impaired, the Company compares the fair value of the reporting unit to which the goodwill is assigned to the reporting unit’s carrying amount, including goodwill. The fair value of the reporting unit is estimated using a combination of the income, or discounted cash flows, approach and the market approach, which utilizes comparable companies’ data. If the carrying amount of a reporting unit exceeds its fair value, then the amount of the impairment loss must be measured. The impairment loss would be calculated by comparing the implied fair value of reporting unit goodwill to its carrying amount. In calculating the implied fair value of reporting unit goodwill, the fair value of the reporting unit is allocated to all of the other assets and liabilities of that unit based on their fair values. The excess of the fair value of a reporting unit over the amount assigned to its other assets and liabilities is the implied fair value of goodwill. An impairment loss would be recognized when the carrying amount of goodwill exceeds its implied fair value. The Company’s evaluation of goodwill completed during the period resulted in an impairment loss of $1,015,910.

Basic and Diluted Loss Per Share

F-37

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

Stock-Based Compensation

Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation issued for services was $980,801 and $119,312 for the six months ended June 30, 2017 and 2016, respectively.

Revenue Recognition

Advertising and Promotion

All costs associated with advertising and promoting products are expensed as incurred. These expenses were $1,771 and $-0- for the six months ended June 30, 2017 and 2016, respectively.

Income Taxes

Uncertain Tax Positions

The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.

Recently Issued Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350) . ASU 2017-04 simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company intends to early adopt the ASU in 2017.

F-38

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

No other new accounting pronouncements, issued or effective during the six months ended June 30, 2017, have had or are expected to have a significant impact on the Company’s financial statements.

Note 2 – Going Concern

As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $17,904,908, and had working capital of $308,742 at June 30, 2017. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new products and services to begin generating revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern.

Note 3 – Business Combination

Business Combination – Sangre AT, LLC, April 20, 2017

On April 20, 2017, the Company closed on a Share Exchange Agreement (“SEA”) with Sangre AT, LLC, a Wyoming company doing business as Sangre AgroTech. Pursuant to the SEA, we purchased all of the outstanding membership interests in consideration for an a total of 500,000 shares of common to seven individuals, valued at $1,003,850 based on the closing price of the Company’s common stock on the date of grant.

Sangre is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. Sangre is working on a cannabis genomic study to complete a global genomic classification of the cannabis plant genus.

In connection with the SEA, two members of Sangre and the Company entered into Consulting Agreements, pursuant to which the members of Sangre agreed to provide consulting services to the Company for a period of one year following closing, with the option to extend for a two year period in annual increments, upon mutual written agreement by both parties. Pursuant to the agreement, the members were each awarded 50,000 shares of common stock with the issuances deferred until January 1, 2108.

This acquisition was accounted for as a business combination under the purchase method of accounting, given that substantially all of the Company’s assets and ongoing operations were acquired. The purchase resulted in $1,015,910 of goodwill, which was subsequently impaired and expensed in the current period. According to the purchase method of accounting, the Company recognized the identifiable assets acquired and liabilities assumed as follows:

F-39

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

	April 20,
	2017
Consideration:
Fair value of common stock paid at closing (1)	$ 1,003,850
Short term liabilities assumed (2)	25,929
Fair value of total consideration exchanged	$ 1,029,779

Fair value of identifiable assets acquired assumed:
Cash	$ 54
Fixed assets	13,815
Total fair value of assets assumed	13,869
Consideration paid in excess of fair value (Goodwill) (3)	$ 1,015,910

(1) Consideration consisted of 500,000 shares of the Company’s common stock valued at $1,003,850 based on the closing price of the Company’s common stock on the date of grant.

(2) Assumed liabilities consisted of trade payables and outstanding credit card debt.

(3) The fair value of the seller financed note in excess of the $100,000 principal balance attributable to the deferred payment terms will be amortized to interest expense over the deferred financing period.

(3) The consideration paid in excess of the net fair value of assets acquired and liabilities assumed has been recognized as goodwill and was expensed due to economic uncertainties and the absence of a revenue stream.

Management believes the intangible assets acquired, consisting of the personnel of Sangre, will enable the Company to launch their business model and take advantage of additional growth opportunities.

The unaudited supplemental pro forma results of operations of the combined entities had the dates of the acquisitions been January 1, 2017 are as follows:

	Combined Pro Forma:
	For the three months ended	For the six months ended
	June 30,	June 30,
	2017	2017
Revenue:	$ -	$ -

Expenses:
Operating expenses	584,208	1,247,481

Net operating loss	(584,208 )	(1,247,481 )

Other income (expense)	(614,259 )	(615,643 )

Net loss	$ (1,198,467 )	$ (1,863,124 )

Weighted average number of common shares
Outstanding – basic and fully diluted	100,724,359	102,300,384

Net loss per share – basic and fully diluted	$ (0.01 )	$ (0.02 )

F-40

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

Note 4 – Related Party

Notes Payable

From time to time, the Company has received short term loans from officers and directors as disclosed in Note 8 below.

Capital Contributions

The Company imputed interest on non-interest bearing, related party loans, resulting in a total of $321 and $259 of contributed capital during the six months ended June 30, 2017 and 2016, respectively.

Common Stock Issued for Bartered Assets

On January 18, 2017, the Company exchanged 66,000 units, consisting of 66,000 shares of common stock and warrants to purchase 66,000 shares of common stock at an exercise price of $3.00 per share, exercisable until January 18, 2018, in exchange for a 2017 Audi Q7 and a 2017 Audi A4 driven by the Officers. The total fair value received, based on the market price of the stock at $4.02 per share, was allocated to the $105,132 purchase price of the vehicles and the $160,188 excess value of the common stock and warrants was expensed as stock based compensation.

A total of $171,505 and $157,505 of officer compensation was unpaid and outstanding at June 30, 2017 and December 31, 2016, respectively.

Note 5 – Fair Value of Financial Instruments

Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability.

F-41

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2017 and December 31, 2016, respectively:

	Fair Value Measurements at June 30, 2017
	Level 1	Level 2	Level 3
Assets
Cash	$ 473,234	$ -	$ -
Total assets	473,234	-	-
Liabilities
Notes payable, related parties	-	16,826	-
Total liabilities	-	16,826	-
	$ 473,234	$ (16,826 )	$ -

	Fair Value Measurements at December 31, 2016
	Level 1	Level 2	Level 3
Assets
Cash	$ 231	$ -	$ -
Total assets	231	-	-
Liabilities
Convertible notes payable	-	35,000	-
Notes payable, related parties	-	16,300	-
Total liabilities	-	51,300	-
	$ 231	$ (51,300 )	$ -

The fair values of our related party debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35.

There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2017 and the year ended December 31, 2016.

Note 6 – Prepaid Expenses

Prepaid expenses consisted of the following as of June 30, 2017 and December 31, 2016, respectively:

	June 30,	December 31,
	2017	2016
Annual license and insurance fees	$ 5,767	$ 3,400
Legal services	15,643	-
Deposit on property purchase	50,000	-
Annual mining claim fees	413	1,653
	$ 71,823	$ 5,053

F-42

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

Note 6 – Property and Equipment

Property and equipment consist of the following at June 30, 2017 and December 31, 2016, respectively:

	June 30,	December 31,
	2017	2016
Automobiles	$ 105,132	$ -
Office equipment	4,113	650
Lab equipment	15,202	-
	124,447	650
Less accumulated depreciation	(10,046 )	(386 )
	$ 114,401	$ 264

Depreciation and amortization expense totaled $9,660 and $65 for the six months ended June 30, 2017 and 2016, respectively.

Note 7 – Convertible Notes Payable

Convertible notes payable consist of the following at June 30, 2017 and December 31, 2016, respectively:

	June 30,	December 31,
	2017	2016

On December 7, 2007, the Company issued a 10% note payable to the Lebrecht Group, PC (“Lebrecht Note”) for services rendered related to the registration of certain securities of the Company. The note and accrued interest were due December 7, 2008 and at the option of the holder payable in full on the maturity date or in 12 monthly payments beginning on the maturity date. The note and accrued interest are convertible to common shares at any time at the option of the holder at 75% of the average closing bid price on the five trading days immediately preceding the conversion. Management estimates, at this time, that 1,650,000 shares may be issued if this conversion feature is exercised. In accordance with generally accepted accounting principles, the 25% discount to market related to the beneficial conversion feature has been reported as a component of additional paid in capital. Additionally, since this represents a prepayment for services related to a future public offering, management had elected to offset the cost to future capital raised as a result of the offering, if any. Furthermore, the Company confirmed and agreed with Lebrecht Law Group, PC that they would not force the Company to settle in shares of common stock in the event there are not enough authorized shares at time of conversion.$	-	$ 35,000

The Company recognized interest expense of $1,759 and $1,750 related to the convertible debts for the six months ended June 30, 2017 and 2016, respectively.

On June 16, 2017, the note was assigned to another party and the debt, consisting of $35,000 of principal and $33,250 of interest, was exchanged for 70,000 shares of common stock and warrants to acquire 70,000 more shares at $3 per share over the following twelve months. The securities exchanged were valued at $136,233 based on the closing price of the Company’s common stock on the date of exchange, resulting in a loss on extinguishment of $67,983.

F-43

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

Note 8 – Notes Payable, Related Parties

Notes payable, related parties consist of the following at June 30, 2017 and December 31, 2016, respectively:

	June 30,	December 31,
	2017	2016

On various dates, the Company received advances from the Company’s CEO, Glenn Martin. Mr. Martin owns approximately 56% of our common stock. The unsecured non-interest bearing loans were due on demand. The largest aggregate amount outstanding was $9,000 and $10,000 during the periods ended June 30, 2017 and December 31, 2016, respectively.	$ 4,826	$ -

On August 23, 2016, the Company received an unsecured, non-interest bearing loan in the amount of $3,000, due on demand from Wendy Seabre, bearing interest at 10% per annum. Repaid on June 15, 2017. The largest aggregate amount outstanding was $3,000 during the periods ended June 30, 2017 and December 31, 2016. Mrs. Seabre is the wife of Mr. Roger Seabre, who owns approximately 2% of our common stock and has been a significant investor recently.	-	3,000

On January 21, 2015, the Company received an unsecured loan in the amount of $1,300, due on demand from Wendy Seabre, bearing interest at 10% per annum. Repaid on June 15, 2017. The largest aggregate amount outstanding was $1,300 during the periods ended June 30, 2017 and December 31, 2016. Mrs. Seabre is the wife of Mr. Roger Seabre, who owns approximately 2% of our common stock and has been a significant investor recently.	-	1,300

On April 12, 2010, the Company received an unsecured, non-interest bearing loan in the amount of $2,000, due on demand from Robert Leitzman. Interest is being imputed at the Company’s estimated borrowing rate, or 10% per annum. The largest aggregate amount outstanding was $2,000 during the periods ended June 30, 2017 and December 31, 2016. Mr. Leitzman owns less than 1% of the Company’s common stock, however, the Mr. Leitzman is deemed to be a related party given the non-interest bearing nature of the loan and the materiality of the debt at the time of origination.	2,000	2,000

Over various dates in 2011 and 2012, the Company received unsecured loans in the aggregate amount of $10,000, due on demand, bearing interest at 10%, from Sandra Orman. The largest aggregate amount outstanding was $10,000 during the periods ended June 30, 2017 and December 31, 2016. Mrs. Orman owns less than 1% of the Company’s common stock, however, Mrs. Orman is deemed to be a related party given the nature of the loan and the materiality of the debt at the time of origination.	10,000	10,000

Notes payable, related parties	$ 16,826	$ 16,300

The Company recorded interest expense in the amount of $459 and $825 for the six months ended June 30, 2017 and 2016, respectively, including imputed interest expense in the amount of $321 and $259 for the six months ended June 30, 2017 and 2016, respectively related to notes payable, related parties.

Note 9 – Commitments and Contingencies

On November 8, 2016, the Company entered into an agreement with Gregory DiPaolo’s Pro Am Golf, LLC to acquire land currently housing a golf course and restaurant. The total purchase price of $1,600,000 is to be paid with a deposit of 50,000 shares of common stock, followed by cash of $1,250,000 and 300,000 shares of the Company’s common stock to be delivered at closing. The deposit of 50,000 shares issued as a deposit was valued at $42,500 based on the closing price of the Company’s common stock on the date of grant. The Company does not currently have sufficient resources to close on the purchase and the good faith deposit of 50,000 shares was expensed upon the issuance in 2016.

F-44

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

Note 10 – Stockholders’ Equity

Preferred Stock

Common Stock

On December 5, 2014, the Company amended the Articles of Incorporation, and increased the authorized shares to 200,000,000 shares of $0.001 par value common stock.

Common Stock Sales

On May 31, 2017, the Company sold 20,000 units at $0.50 per unit, consisting of 20,000 shares of common stock and warrants to purchase 20,000 shares of common stock at an exercise price of $3.00 per share, exercisable until May 31, 2019, in exchange for total proceeds of $10,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On May 31, 2017, the Company sold 300,000 units at $0.50 per unit, consisting of 300,000 shares of common stock and warrants to purchase 150,000 shares of common stock at an exercise price of $3.00 per share, exercisable until May 31, 2019, in exchange for total proceeds of $150,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On May 25, 2017, the Company sold 20,000 units at $0.50 per unit, consisting of 20,000 shares of common stock and warrants to purchase 20,000 shares of common stock at an exercise price of $3.00 per share, exercisable until May 25, 2019, in exchange for total proceeds of $10,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On May 25, 2017, the Company sold 20,000 units at $0.50 per unit, consisting of 100,000 shares of common stock and warrants to purchase 100,000 shares of common stock at an exercise price of $3.00 per share, exercisable until May 25, 2019, in exchange for total proceeds of $50,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On April 20, 2017, the Company sold 500,000 units at $1.00 per unit, consisting of 500,000 shares of common stock and warrants to purchase 500,000 shares of common stock at an exercise price of $3.00 per share, exercisable until April 20, 2018, in exchange for total proceeds of $500,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

Warrants Exercised

On January 7, 2017, a warrant holder exercised warrants to purchase 2,666 shares of common stock at a strike price of $1.50 in exchange for proceeds of $3,999.

Common Stock Issued for Acquisition

On April 20, 2017, the Company issued a total of 500,000 shares of common to seven individuals pursuant to the closing of an acquisition of Sangre AT, LLC, a Wyoming limited liability company (“Sangre”) in exchange for 100% of the interests in Sangre. The total fair value of the common stock was $1,003,850 based on the closing price of the Company’s common stock on the date of grant.

F-45

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

Common Stock Issued for Bartered Assets

Common Stock and warrants Issued for Settlement of Convertible Debt

On June 16, 2017, a convertible note, consisting of $35,000 of principal and $33,250 of unpaid interest, was assigned to a third party and the debt was exchanged for a unit offering, consisting of 70,000 shares of common stock and warrants to purchase 70,000 shares of common stock at an exercise price of $3.00 per share, exercisable until June 16, 2018. The stock was valued at $86,800 based on the closing price of the Company’s common stock on the date of exchange and the warrants were valued at $49,433 using the Black-Scholes option-pricing model was $49,433, or $0.70618 per share, based on a volatility rate of 211%, a risk-free interest rate of 1.21% and an expected term of 1.0 year, resulting in a loss on extinguishment of $67,983.

Common Stock Issued for Services

On April 20, 2017, the Company granted an aggregate of 116,000 shares of common stock to eleven consultants for services performed. The aggregate fair value of the common stock was $232,893 based on the closing price of the Company’s common stock on the date of grant.

Common Stock Subscribed for Services

On April 20, 2017, the Company granted 50,000 shares of common stock to each of two consultants for services performed. The issuance of the shares has been deferred until January 1, 2018. The aggregate fair value of the common stock was $200,770 based on the closing price of the Company’s common stock on the date of grant.

Common Stock Cancellations

On January 26, 2017, the Company cancelled a total of 1,000,000 shares of common stock previously granted to two individuals for non-performance of services.

Capital Contributions

F-46

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

Note 11 – Common Stock Warrants

Common Stock Warrants Granted

On June 16, 2017, the Company issued warrants to purchase 70,000 shares of common stock at $3.00 per share over a one (1) year period from the date of exchange in conjunction with the issuance of 70,000 shares of common stock in exchange for the settlement of a convertible note, consisting of $35,000 of principal and $33,250 of interest. The relative fair value of the 70,000 common stock warrants using the Black-Scholes option-pricing model was $49,433, or $0.70618 per share, based on a volatility rate of 211%, a risk-free interest rate of 1.21% and an expected term of 1.0 year. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On May 31, 2017, the Company sold warrants to purchase 20,000 shares of common stock at $3.00 per share over a two (2) year period from the date of sale, in exchange for total proceeds of $10,000 in conjunction with the sale of 20,000 shares of common stock. The relative fair value of the 20,000 common stock warrants using the Black-Scholes option-pricing model was $8,946, or $0.44730 per share, based on a volatility rate of 209%, a risk-free interest rate of 1.28% and an expected term of 2.0 years. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On May 31, 2017, the Company sold warrants to purchase 300,000 shares of common stock at $3.00 per share over a two (2) year period from the date of sale, in exchange for total proceeds of $150,000 in conjunction with the sale of 300,000 shares of common stock. The relative fair value of the 300,000 common stock warrants using the Black-Scholes option-pricing model was $134,190, or $0.44730 per share, based on a volatility rate of 209%, a risk-free interest rate of 1.28% and an expected term of 2.0 years. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On May 25, 2017, the Company sold warrants to purchase 20,000 shares of common stock at $3.00 per share over a two (2) year period from the date of sale, in exchange for total proceeds of $10,000 in conjunction with the sale of 20,000 shares of common stock. The relative fair value of the 20,000 common stock warrants using the Black-Scholes option-pricing model was $5,887, or $0.29434 per share, based on a volatility rate of 205%, a risk-free interest rate of 1.30% and an expected term of 2.0 years. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On May 25, 2017, the Company sold warrants to purchase 100,000 shares of common stock at $3.00 per share over a two (2) year period from the date of sale, in exchange for total proceeds of $50,000 in conjunction with the sale of 100,000 shares of common stock. The relative fair value of the 100,000 common stock warrants using the Black-Scholes option-pricing model was $29,434, or $0.29434 per share, based on a volatility rate of 205%, a risk-free interest rate of 1.30% and an expected term of 2.0 years. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

On April 20, 2017, the Company sold warrants to purchase 500,000 shares of common stock at $3.00 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $500,000 in conjunction with the sale of 500,000 shares of common stock. The relative fair value of the 500,000 common stock warrants using the Black-Scholes option-pricing model was $626,641, or $1.25328 per share, based on a volatility rate of 202%, a risk-free interest rate of 1.01% and an expected term of 1.0 year. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

Warrants Exercised

On January 7, 2017, a warrant holder exercised warrants to purchase 2,666 shares of common stock at a strike price of $1.50 in exchange for proceeds of $3,999.

F-47

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

Common Stock Warrants Expired or Cancelled

No warrants were expired or cancelled during the six months ended June 30, 2017.

Note 12 – Income Taxes

For the six months ended June 30, 2017 and the year ended December 31, 2016, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At June 30, 2017 and December 31, 2016, the Company had approximately $10,548,000 and $ 10,212,000 of federal net operating losses, respectively. The net operating loss carry forwards, if not utilized, will begin to expire in 2031.

The components of the Company’s deferred tax asset are as follows:

	June 30,	December 31,
	2017	2016
Deferred tax assets:
Net operating loss carry forwards	$ 3,691,800	$ 3,574,200

Net deferred tax assets before valuation allowance	$ 3,691,800	$ 3,574,200
Less: Valuation allowance	(3,691,800 )	(3,574,200 )
Net deferred tax assets	$ -	$ -

A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and State statutory income tax rate to pre-tax loss is as follows:

	June 30,	December 31,
	2017	2016

Federal and state statutory rate	35%	35%
Change in valuation allowance on deferred tax assets	(35%)	(35%)

In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Note 13 – Subsequent Events

Property Purchase

On July 26, 2017, the Company closed on the purchase of property, consisting of a home, recreational facility and RV park located at 5535 State Highway 12 in La Veta, Colorado to be developed into a bioscience center. The home has 4 Bedrooms and 2 Baths, and the recreational facility has showers, laundry, and reception area with an additional equipment barn attached, in addition to another facility with 9,500 square feet. The RV Park has 24 sites with full hook-ups including water, sewer, and electric, which the Company plans to convert into a series of small research pods. The total purchase price of $975,000 was paid with $500,000 of cash and the seller carrying the remaining debt of $475,000 with a promissory note bearing interest at 5% per annum to be paid in four consecutive semi-annual installments in the amount of $118,750 plus accrued interest commencing on January 26, 2018 and continuing on the 26th day of July and the 26th day of January each year until the debt is repaid on July 26, 2019. The note carries a late fee of $5,937.50 in the event any installment payment is more than 30 days late, and upon default the interest rate shall increase to 12% per annum. In addition, 25,000 shares of the Company’s common stock were paid as a good faith deposit to the seller on July 18, 2017, which were valued at $30,000 based on the closing price of the Company’s common stock on the date of grant. The Company will need to raise additional funds in order to pay the remainder of the purchase price, as well as to complete the planned renovations.

F-48

WEED, INC.

(Formerly United Mines, Inc.)

Notes to Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

Common Stock Sales

On July 7, 2017, the Company sold 200,000 units at $0.50 per unit, consisting of 200,000 shares of common stock and warrants to purchase 200,000 shares of common stock at an exercise price of $3.00 per share, exercisable until July 7, 2019, in exchange for total proceeds of $100,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis.

Common Stock Cancellations

On July 24, 2017, the Company cancelled a total of 500,000 shares of common stock previously granted to a consultant for non-performance of services.

F-49

To the Board of Directors and

Stockholders of Sangre AT, LLC.

We have audited the accompanying balance sheet of Sangre AT, LLC. as of December 31, 2016, and the related statements of income, comprehensive income, stockholders’ equity, and cash flows from inception through December 31, 2016. Sangre AT, LLC.’s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Sangre AT, LLC as of December 31, 2016, and the results of its operations and its cash from inception through the period ended December 31, 2016, in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company had no revenues or assets as of December 31, 2016 which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ M&K CPAS, PLLC

Houston, Texas

November 16, 2017

F-50

SANGRE AT, LLC
BALANCE SHEET


	December 31,
	2016
ASSETS

Current assets:
Cash	$ -
Total current assets	-

Total assets	$ -


LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable	$ -
Total current liabilities	-

Stockholders' equity:
Members' equity	-
Total stockholders' equity	-

Total liabilities and stockholders' equity	$ -

The accompanying notes are an integral part of these financial statements.

F-51

SANGRE AT, LLC
STATEMENT OF OPERATIONS


	August 26, 2016
	(inception) to
	December 31, 2016

Revenue	$ -

Operating expenses:
General and administrative	-
Depreciation	-
Total operating expenses	-

Net operating loss	-

Other expense:	-

Net loss	$ -

The accompanying notes are an integral part of these financial statements.

F-52

SANGRE AT, LL C
STATEMENT OF STOCKHOLDERS' EQUITY


		Total
	Members'	Stockholders'
	Equity	Equity

Balance, August 26, 2016 (inception)	$ -	$ -

Net loss for the period from August 26, 2016 (inception) to December 31, 2016	-	-

Balance, December 31, 2016	$ -	$ -

T he accompanying notes are an integral part of these financial statements.

F-53

SANGRE AT, LLC
STATEMENT OF CASH FLOWS


	August 26, 2016
	(inception) to
	December 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income	$ -
Decrease (increase) in assets:
Prepaid expenses	-
Increase (decrease) in liabilities:
Accounts payable	-
Net cash provided by operating activities	-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the sale of members' interests	-
Net cash provided by financing activities	-

NET CHANGE IN CASH	-
CASH AT BEGINNING OF PERIOD	-

CASH AT END OF PERIOD	$ -

SUPPLEMENTAL INFORMATION:
Interest paid	$ -
Income taxes paid	$ -

The accompanying notes are an integral part of these financial statements.

F-54

Sangre AT, LLC

Notes to Financial Statements

For the Year Ended December 31, 2016

Note 1 – Nature of Business and Significant Accounting Policies

Nature of Business

Sangre AT, LLC (the “Company”, “Sangre AgroTech”), was incorporated under the laws of the State of Wyoming on August 26, 2016 (“Inception Date”) to conduct Cannabis research. The Company’s plan is to perform genome sequencing of numerous strains of Cannabis sativa, Cannabis indica, and hybrids in order to discover and describe compounds and/or classes of compounds which can be used effectively in the treatment of human disease. As in the case of the human genome, the cannabis genome is the blueprint of the plant that contains all the biological and chemical instructions for the growth, development, and synthesis of the plants’ constituent molecules. Through the process of whole genome sequencing, Sangre AgroTech can read and evaluate the potential of any one strain for its ability to produce native compounds which can be utilized for the treatment of human disease.

The Company has a calendar year end for reporting purposes.

Use of Estimates

Cash and Cash Equivalents

Fair Value of Financial Instruments

Property and Equipment

Software	3 years
Furniture and fixtures	5 years
Equipment	5-7 years

F-55

Sangre AT, LLC

Notes to Financial Statements

For the Year Ended December 31, 2016

Impairment of Long-Lived Assets

Revenue Recognition

Income Taxes

Uncertain Tax Positions

The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.

Recently Issued Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350) . ASU 2017-04 simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company intends to early adopt the ASU in 2017.

F-56

Sangre AT, LLC

Notes to Financial Statements

For the Year Ended December 31, 2016

No other new accounting pronouncements, issued or effective during the period from August 26, 2016 (inception) to December 31, 2016, have had or are expected to have a significant impact on the Company’s financial statements.

Note 2 – Going Concern

As shown in the accompanying financial statements, the Company had no revenues or assets at December 31, 2016. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing research services to begin generating revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern.

Note 3 – Subsequent Events

Commencement of Research Activities

The Company commenced research activities in March of 2017, consisting of a cannabis genomic study to complete a global genomic classification of the cannabis plant genus with the intent to discover native compounds in cannabis strains that can be utilized for the treatment of human disease.

Business Combination

On April 20, 2017, the Company closed on a Share Exchange Agreement (“SEA”) with WEED, Inc., an Arizona company that plans to become a true “Seed-to-Sale” company providing infrastructure, financial solutions and real estate options in the emerging cannabis market. Pursuant to the SEA, WEED, Inc. purchased all of the outstanding membership interests of Sangre AgroTech in consideration for an a total of 500,000 shares of common to seven individuals, valued at $1,003,850 based on the closing price of WEED Inc.’s common stock on the date of grant.

In connection with the SEA, two members of Sangre entered into Consulting Agreements, pursuant to which the members of Sangre agreed to provide consulting services to the Company for a period of one year following closing, with the option to extend for a two year period in annual increments, upon mutual written agreement by both parties. Pursuant to the agreement, the members were each awarded 50,000 shares of common stock with the issuances deferred until January 1, 2018.

F-57

SELECTED FINANCIAL DATA

As a smaller reporting company we are not required to provide this information.

MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

Disclaimer Regarding Forward Looking Statements

Our Management’s Discussion and Analysis or Plan of Operations contains not only statements that are historical facts, but also statements that are forward-looking. Forward-looking statements are, by their very nature, uncertain and risky. These risks and uncertainties include international, national and local general economic and market conditions; demographic changes; our ability to sustain, manage, or forecast growth; our ability to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other risks that might be detailed from time to time in our filings with the Securities and Exchange Commission.

Although the forward-looking statements in this Registration Statement reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

Overview

We are an early stage holding company currently focused on the development and application of cannabis-derived compounds for the treatment of human disease. Our wholly-owned subsidiary, Sangre AT, LLC (“Sangre”), has begun a planned five-year Cannabis Genomic Study to complete a genetic blueprint of the Cannabis plant genus, by creating a global genomic classification of the entire plant. By targeting cannabis-derived molecules that stimulate the endocannabinoid system, Sangre’s research team plans to develop scientifically-valid and evidence-based cannabis strains for the production of disease-specific medicines. The goal of the research is to identify, collect, patent, and archive a collection of highly-active medicinal strains. We plan to conduct this study only in states wherecannabis has been legalized for medicinal purposes.

Using annotated genomic data and newly generated phenotypic data, Sangre plans to identify and isolate regions of the plant genome which are related to growth, synthesis of desired molecules, and drought and pest resistance. This complex data set would then be utilized in a breeding program to generate and establish new hybrid cultivars which exemplify the traits that are desired by the medical and patient community. This breeding program would produce new seed stocks and clones, which we plan on patenting. If successful this intellectual property should generate immense value for the Company. After developing a comprehensive understanding of the annotated genome of a variety of cannabis strains, and obtaining intellectual property protection over the most promising strains, we plan move forward either independently or with strategic partners to develop medicinal products for the treatment of a multitude of human diseases.

In furtherance of our current, short terms goals, Sangre initiated the cannabis genome project in April 2017, by extracting DNA from seven cannabis strains in Tucson, Arizona. Sangre followed the initial extraction with a second round of extractions in July 2017. The extracted DNA is currently being sequenced by the Sangre team using a binary sequencing approach based on the use of two distinct sequencing technologies and a proprietary bioinformatics database. Following the generation of genomic data, the sequences will be annotated (compared) against over 300,000 plant genes to elucidate specific de novo pathways responsible for the synthesis of specific compounds and classes of compounds.

Under the genome project directives, additional strains are slated for sequencing and annotation as part of the overall expansion of this research project. An integral part of this expansion is the acquisition of additional DNA extraction, amplification, and sequencing technologies. The expansion also includes the installation of high-level IT networks for data acquisition, analysis, and storage.

On July 26, 2017, we acquired property located in La Veta, Colorado in order to Sangre to complete its 5-Year, $15+ million Cannabis Genomic Study. The site includes a 10,000+ sq. ft. building that will house Sangre’s genomic research facility, a 4,000+ square foot building for plant product analytics and plant product extraction, a 3,500 sq. ft. corporate office center, and 25 RV slots with full water and electric, which we plan to convert into a series of small research pods. Under the terms of the purchase agreement, we paid $525,000 down, along with 25,000 shares of our common stock, and Sangre took immediate possession of the property. We are obligated to pay an additional $400,000 in cash and issue an additional 75,000 shares of our common stock over the next two yearsin order to pay the entire purchase price. We estimate it will take approximately $675,000 in order to convert the existing buildings into the facilities necessary for Sangre AgroTech to conduct its research, plus an additional $1,000,000 for security & ground buildout, and an additional $1 million for scientific equipment, ordered for plant production and product extraction. We plan to complete the initial property renovations by Q1 of 2018. The equipment is scheduled to be delivered in Q2 2018. We will need to raise additional funds in order to pay the remainder of the purchase price, as well as to complete the planned renovations.

WEED Inc. acquired the property in La Veta, Colorado in order to facilitate the expansion of the genomic studies and the development of new hybrid strains. The facility is currently under re-design and renovation to convert the existing structures into a world-class genetics research center.

A gene-based breeding program will allow us to root out inferior cultivars and replace them with fully-validated and patentable cultivars which produce consistent plant products for the medicinal markets. The gene-based breeding program will improve cultivars and introduce integrity, stability, and quality to the market in the following ways:

●

accelerated and optimized growth rates; modern genomic resources will enhance traditional breeding methods

●

generate new cultivars, accelerating and perfecting the art of selective breeding

●

provide the ability to assay for specific genes within the crop, establish strain tracking, and promote market quality assurance

●

improved disease, pest, and drought resistance of the Cannabis plant

We believe the gene-based breeding program will facilitate and accelerate:

●

improved therapeutic properties, i.e., increased THC/CBD concentration and the production of specific classes of oils and terpenes

●

new therapies for migraines, epilepsy, cancer, PTSD, chronic head injury, and others

●

enhanced opportunities for new drug discovery

●

accelerated breeding of super-cultivars: drought, pest, and mold resistant, increased %THC

●

revenue generation through our unique ability to breed and genetically fingerprint new, super-cultivars; establish strong patent protection; and provide these cultivars to the market on a favorable cost and royalty basis.

Our goal with this program is to develop a translational breeding program to establish a new collection of Cannabis cultivars for the Colorado, national, and international markets. Through the use of genetic screening technology, cultivars can be up-selected for specific traits and grown to address the needs of consumers in the medicinal market.

Corporate Overview

We were originally incorporated under the name Plae, Inc., in the State of Arizona on August 20, 1999. At the time we operated under the name Plae, Inc., no business was conducted. No books or records were maintained and no meetings were held. In essence, nothing was done after incorporation until Glenn E. Martin took possession of Plae, Inc. in January 2005. On February 18, 2005, the corporate name was changed to King Mines, Inc. and then subsequently changed to its current name, United Mines, Inc., on March 30, 2005. No shares were issued until the Company became United Mines, Inc. From 2005 until 2015, we were an exploration stage mineral exploration company that owned a number of unpatented mining claims and Arizona State Land Department claims.

This discussion and analysis should be read in conjunction with our financial statements included as part of this Registration Statement.

Results of Operations for the Three Months ended June 30, 2017 compared to the Three Months ended June 30, 2016

Summary of Results of Operations

	Three Months Ended June 30,
	2017	2016
Revenue	$ -	$ -

Operating expenses:

General and administrative	84,313	23,615
Professional fees	476,311	195
Depreciation and amortization	5,422	32
Total operating expenses	566,046	23,842

Net operating loss	(566,046 )	(23,842 )

Goodwill impairment	(1,015,910 )	-
Loss on extinguishment of debt	(67,983 )	-
Interest expense	(834 )	(1,348 )

Net loss	$ (1,650,773 )	$ (25,190 )

Operating Loss; Net Loss

Our net loss increased by $1,625,583, from ($25,190) to ($1,650,773), from the three months ended June 30, 2017 compared to the three months ended June 30, 2016. Our operating loss increased by $542,204, from ($23,842) to ($566,046) for the same period. The increase in our net loss was primarily the result of increases in our operating expenses as well as a significant goodwill impairment expense related to our acquisition of Sangre. Our operating loss compared to the prior year period is primarily a result of a significant increase in professional fees and a slight increase in general and administrative expenses. These changes are detailed below.

Revenue

We have not had any revenues since our inception. Prior to October 1, 2014, we were an exploration stage mineral exploration company that owned a number of unpatented mining claims and Arizona State Land Department claims. In late 2014, we changed our short-term and long-term business focus to the medical cannabis sector. In the short-term we plan to conduct Sangre’s Cannabis Genomic Study over the next 5 years and process those result, and in the long-term is to be a company focused on purchasing land and building commercial grade “Cultivation Centers” to consult, assist, manage & lease to licensed dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana (Cannabis) sector. Our long-term plan is to become a True “Seed-to-Sale” company providing infrastructure, financial solutions and real estate options in this new emerging market, worldwide. We plan to make our brand global and therefore we will look for opportunities to conduct future research, marketing, import and exporting, and manufacturing of any proprietary products on an international level.

General and Administrative Expenses

General and administrative expenses increased by $60,698, from $23,615 for the three months ended June 30, 2016 to $84,313 for the three months ended June 30, 2017, primarily due to increased consulting and administrative costs incurred as we changed our business focus from mining to one involved in the cannabis research industry.

Professional Fees

Our professional fees increased during the three months ended June 30, 2017 compared to the three months ended June 30, 2016. Our professional fees were $476,311 for the three months ended June 30, 2017 and $195 for the three months ended June 30, 2016. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors, and increased significantly primarily as a result of increased stock-based compensation awards. We expect these fees to continue to grow steadily as our business expands. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.

Goodwill Impairment

During the three months ended June 30, 2017, we incurred a goodwill impairment expense of $1,015,910, compared to $0 for the three months ended June 30, 2016. The goodwill impairment expense for the three months ended June 30, 2017, relates entirely to our acquisition of Sangre AT, LLC, which closed on April 20, 2017. In connection with the acquisition we acquired all of the outstanding membership interests of Sangre in exchange for a total of 500,000 shares of our common stock issued to seven individuals. Those shares were valued at $1,003,850 based on the closing price of our common stock on the date of grant. A goodwill impairment loss is recognized when the carrying amount of goodwill exceeds its implied fair value. The goodwill impairment expense we recognized during the three months ended June 30, 2017, is the difference between the value of the shares of our common stock we granted, plus the value of the liabilities we assumed, and the fair value of the identifiable assets we acquired when we closed the acquisition of Sangre.

Loss on Extinguishment of Debt

During the three months ended June 30, 2017, we incurred a loss on extinguishment of debt of $67,983, compared to $0 for the three months ended June 30, 2016. The loss on extinguishment of debt for the three months ended June 30, 2017, relates entirely to the fact that on June 16, 2017, we issued 70,000 shares of our common stock in exchange for the extinguishment of an outstanding promissory note, consisting of $35,000 of principal and $33,250 of interest.

Interest Income/Expense; Net

Interest expense decreased from $1,348 to $834 for the three months ended June 30, 2016 compared to the same period in 2017. Our interest expense primarily relates to interest on a convertible note and short term loans.

Results of Operations for the Six Months ended June 30, 2017 compared to the Six Months ended June 30, 2016

Summary of Results of Operations

	Six Months Ended June 30,
	2017	2016
Revenue	$ -	$ -

Operating expenses:

General and administrative	152,447	48,335
Professional fees	1,057,297	120,543
Depreciation and amortization	9,660	65
Total operating expenses	1,219,404	168,943

Net operating loss	(1,219,404 )	(168,943 )

Goodwill impairment	(1,015,910 )	-
Loss on extinguishment of debt	(67,983 )	-
Interest expense	(2,218 )	(2,575 )

Net loss	$ (2,305,515 )	$ (171,518 )

Operating Loss; Net Loss

Our net loss increased by $2,305,997, from ($171,518) to ($2,305,515), from the six months ended June 30, 2017 compared to the six months ended June 30, 2016. Our operating loss increased by $1,050,461, from ($168,943) to ($1,219,404) for the same period. The increase in our net loss was primarily the result of increases in our operating expenses as well as a significant goodwill impairment expense related to our acquisition of Sangre. Our operating loss compared to the prior year period is primarily a result of a significant increase in professional fees and a slight increase in general and administrative expenses. These changes are detailed below.

Revenue

General and Administrative Expenses

General and administrative expenses increased by $104,112, from $48,335 for the six months ended June 30, 2016 to $152,447 for the six months ended June 30, 2017, primarily due to increased consulting and administrative costs incurred as we changed our business focus from mining to one involved in the cannabis research industry.

Professional Fees

Our professional fees increased during the six months ended June 30, 2017 compared to the six months ended June 30, 2016. Our professional fees were $1,057,297 for the six months ended June 30, 2017 and $120,543 for the six months ended June 30, 2016. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors, and increased significantly primarily as a result of increased stock-based compensation awards. We expect these fees to continue to grow steadily as our business expands. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.

Goodwill Impairment

During the six months ended June 30, 2017, we incurred a goodwill impairment expense of $1,015,910, compared to $-0- for the six months ended June 30, 2016. The goodwill impairment expense for the six months ended June 30, 2017, relates entirely to our acquisition of Sangre AT, LLC, which closed on April 20, 2017. In connection with the acquisition we acquired all of the outstanding membership interests of Sangre in exchange for a total of 500,000 shares of our common stock issued to seven individuals. Those shares were valued at $1,003,850 based on the closing price of our common stock on the date of grant. A goodwill impairment loss is recognized when the carrying amount of goodwill exceeds its implied fair value. The goodwill impairment expense we recognized during the six months ended June 30, 2017, is the difference between the value of the shares of our common stock we granted, plus the value of the liabilities we assumed, and the fair value of the identifiable assets we acquired when we closed the acquisition of Sangre.

Loss on Extinguishment of Debt

During the six months ended June 30, 2017, we incurred a loss on extinguishment of debt of $67,983, compared to $0 for the six months ended June 30, 2016. The loss on extinguishment of debt for the six months ended June 30, 2017, relates entirely to the fact that on June 16, 2017, we issued 70,000 shares of our common stock in exchange for the extinguishment of an outstanding promissory note, consisting of $35,000 of principal and $33,250 of interest.

Interest Income/Expense; Net

Interest expense decreased from $1,348 to $834 for the Six Months ended June 30, 2016 compared to the same period in 2017. Our interest expense primarily relates to interest on a convertible note and short term loans.

Liquidity and Capital Resources for Six Months ended June 30, 2017 compared to Six Months ended June 30, 2016

Introduction

During the six months ended June 30, 2017 and 2016, because of our operating, we did not generate positive operating cash flows. Our cash on hand as of June 30, 2017 was $473,234 and our monthly cash flow burn rate is approximately $45,000. Our short term cash needs have been satisfied through proceeds from the sales of our securities. We currently do not believe we will be able to satisfy our cash needs from our revenues for many years to come.

Our cash, current assets, total assets, current liabilities, and total liabilities as of June 30, 2017 and December 31, 2016, respectively, are as follows:

	June 30, 2017	December 31, 2016	Change

Cash	$ 473,234	$ 231	$ 473,003
Total Current Assets	545,057	5,284	539,773
Total Assets	659,458	5,548	653,910
Total Current Liabilities	236,315	281,226	(44,911 )
Total Liabilities	$ 236,315	$ 281,226	$ (44,911 )

Our current assets increased by $539,773 as of June 30, 2017 as compared to December 31, 2016, due to a significant increase in cash and prepaid expenses as of June 30, 2017. The increase in our total assets between the two periods was primarily attributed to the increase in our cash on hand of $473,234, which was primarily due to the cash we had from the sales of our securities as of June 30, 2017, as well as a significant increase in our property and equipment, net, which was primarily due to the addition of two vehicles acquired in January of 2017.

Our current liabilities and total liabilities decreased by $44,911, as of June 30, 2017 as compared to December 31, 2016. A primary cause of this decrease was the fact we extinguished an outstanding promissory note with the issuance of shares of our commons stock, partially offset by an approximate $15,000 increase in our accrued officer compensation and an approximate increase of $7,000 in our accounts payable between the two periods.

In order to repay our obligations in full or in part when due, we will be required to raise capital from other sources. There is no assurance, however, that we will be successful in these efforts.

Cash Requirements

We had cash available as of June 30, 2017 of $473,234 and $231 on December 31, 2016. Based on our lack of revenues and our current monthly burn rate, around $45,000, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund our future planned operations.

Sources and Uses of Cash

Operations

We had net cash used by operating activities of $300,726 for the six months ended June 30, 2017, as compared to $6,770 for the six months ended June 30, 2016. For the period in 2017, the net cash used in operating activities consisted primarily of our net loss of ($2,305,515), offset by goodwill impairment of $1,015,910, loss on extinguishment of debt of $67,983, shares issued for services of $980,801, depreciation of $9,660, and adjusted by an increase in prepaid expenses of $66,770, accrued compensation of $14,000, accrued interest of $1,897, and a decrease in accounts payable of $19,013. For the same period in 2016, the net cash provided by operating activities consisted primarily of our net loss of ($171,518), partially offset by shares issued for services of $119,312 and adjusted by a decrease in prepaid expenses of $1,550, and increases in accounts payable of $2,246, accrued compensation of $39,000, and accrued interest of $2,316.

Investments

We had net cash used by investing activities of $4,796 for the six months ended June 30, 2017, as compared to $0 for the six months ended June 30, 2016. For the period in 2017, the net cash used in investing activities consisted of purchases of property and equipment of $4,850, partially offset by cash received in acquisition of $54.

Financing

Our net cash provided by financing activities for the six months ended June 30, 2017 was $778,525, compared to $6,900 for the six months ended June 30, 2016. For the period in 2017, our financing activities related to proceeds from the sale of common stock of $777,999 and proceeds from notes payable, related parties of $9,000, offset by repayments on notes payable, related parties of ($8,474). For the period in 2016, our financing activities consisted of proceeds from notes payable, related parties of $12,900, offset by repayments on notes payable, related parties of ($6,000).

Results of Operations for Three Months ended March 31, 2017 compared to Three Months ended March 31, 2016

Summary of Results of Operations

	Three Months Ended March 31,
	2017	2016
Revenue	$ -	$ -

Operating expenses:

General and administrative	68,134	24,720
Professional fees	580,986	120,348
Depreciation and amortization	4,238	33
Total operating expenses	653,358	145,101

Net operating loss	(653,358 )	(145,101 )

Interest expense	(1,384 )	(1,227 )

Net loss	$ (654,742 )	$ (146,328 )

Operating Loss; Net Loss

Our net loss increased by $508,414, from ($146,328) to ($654,742), from the three months ended March 31, 2017 compared to the three months ended March 31, 2016. Our operating loss increased by $508,257, from ($145,101) to ($653,358) for the same period. The increase in operating loss and net loss compared to the prior year period is primarily a result of a significant increase in professional fees and a slight increase in general and administrative expenses. These changes are detailed below.

Revenue

We have not had any revenues since our inception. Prior to October 1, 2014, we were an exploration stage mineral exploration company that owned a number of unpatented mining claims and Arizona State Land Department claims. In late 2014, we changed our short-term and long-term business focus on the medical cannabis sector. In the short-term we plan to conduct Sangre’s Cannabis Genomic Study over the next 5 years and process those result, and in the long-term is to be a company focused on purchasing land and building commercial grade “Cultivation Centers” to consult, assist, manage & lease to licensed dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana (Cannabis) sector. Our long-term plan is to become a True “Seed-to-Sale” company providing infrastructure, financial solutions and real estate options in this new emerging market, worldwide. We plan to make our brand global and therefore we will look for opportunities to conduct future research, marketing, import and exporting, and manufacturing of any proprietary products on an international level.

General and Administrative Expenses

General and administrative expenses increased by $43,414, from $24,720 for the three months ended March 31, 2016 to $68,134 for the three months ended March 31, 2017, primarily due to increased consulting and administrative costs incurred as we changed our business focus from mining to one involved in the cannabis research industry.

Professional Fees

Our professional fees increased during the three months ended March 31, 2017 compared to the three months ended March 31, 2016. Our professional fees were $580,986 for the three months ended March 31, 2017 and $120,348 for the three months ended March 31, 2016. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors, and increased significantly primarily as a result of increased stock-based compensation awards. We expect these fees to continue to grow steadily as our business expands. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.

Interest Income/Expense; Net

Interest expense increased from $1,227 to $1,384 for the three months ended March 31, 2016 compared to the same period in 2017. Our interest expense primarily relates to interest on a convertible note and short term loans.

Liquidity and Capital Resources for Three Months ended March 31, 2017 compared to Three Months ended March 31, 2016

Introduction

During the three months ended March 31, 2017 and 2016, because of our operating, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2017 was $167,015 and our monthly cash flow burn rate is approximately $45,000. Our short term cash needs have been satisfied through proceeds from the sales of our securities. We currently do not believe we will be able to satisfy our cash needs from our revenues for many years to come.

Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2017 and December 31, 2016, respectively, are as follows:

	March 31, 2017	December 31, 2016	Change

Cash	$ 167,015	$ 231	$ 166,784
Total Current Assets	207,523	5,284	202,239
Total Assets	308,681	5,548	303,133
Total Current Liabilities	293,681	281,226	12,455
Total Liabilities	$ 293,681	$ 281,226	$ 12,455

Our current assets increased by $202,239 as of March 31, 2017 as compared to December 31, 2016, due to a significant increase in cash and prepaid expenses as of March 31, 2017. The increase in our total assets between the two periods was primarily attributed to the increase in our cash on hand of $166,784, which was primarily due to the cash we had from the sales of our securities as of March 31, 2017, as well as a significant increase in our property and equipment, net, which was primarily due to the addition of two vehicles acquired in January of 2017.

Our current liabilities and total liabilities increased by $12,455, as of March 31, 2017 as compared to December 31, 2016. A primary cause of this increase was an increase of $19,500 in our accrued officer compensation and an increase of approximately $5,000 in short term loans, partially offset by an approximate $13,000 decrease in our accounts payable between the two periods.

In order to repay our obligations in full or in part when due, we will be required to raise capital from other sources. There is no assurance, however, that we will be successful in these efforts.

Cash Requirements

We had cash available as of March 31, 2017 of $167,015 and $231 on December 31, 2016. Based on our lack of revenues and our current monthly burn rate, around $45,000, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund our future planned operations.

Sources and Uses of Cash

Operations

We had net cash used by operating activities of $131,041 for the three months ended March 31, 2017, as compared to $3,937 for the three months ended March 31, 2016. For the period in 2017, the net cash used in operating activities consisted primarily of our net loss of ($654,742), offset by shares issued for services of $547,138, depreciation of $4,238, and adjusted by an increase in prepaid expenses of $35,455, accrued compensation of $19,500, accrued interest of $1,233, and a decrease in accounts payable of $13,104. For the same period in 2016, the net cash provided by operating activities consisted primarily of our net loss of ($146,328), partially offset by shares issued for services of $119,312 and adjusted by a decrease in prepaid expenses of $775, and increases in accounts payable of $1,544, accrued compensation of $19,500, and accrued interest of $1,158.

Investments

We did not have any net cash provided (used) by investing activities for the three months ended March 31, 2017 or March 31, 2016.

Financing

Our net cash provided by financing activities for the three months ended March 31, 2017 was $297,825, compared to $4,000 for the three months ended March 31, 2016. For the period in 2017, our financing activities related to proceeds from the sale of common stock of $292,999 and proceeds from notes payable, related parties of $9,000, offset by repayments on notes payable, related parties of ($4,174). For the period in 2016, our financing activities consisted of proceeds from notes payable, related parties of $10,000, offset by repayments on notes payable, related parties of ($6,000).

Year Ended December 31, 2016 compared to Year Ended December 31, 2015

Results of Operations

Summary of Results of Operations

	Year Ended December 31,
	2016	2015
Revenue	$ -	$ -

Operating expenses:

General and administrative	2,211,787	594,446
Professional fees	1,933,733	639,149
Depreciation and amortization	130	130
Total operating expenses	4,145,650	1,233,725

Net operating loss	(4,145,650 )	(1,233,725 )

Interest expense	(5,321 )	(4,824 )

Net loss	$ (4,150,971 )	$ (1,238,549 )

Operating Loss; Net Loss

Our net loss increased by $2,912,422, from ($1,238,549) to ($4,150,971), from the year ended 2015 compared to 2016. Our operating loss increased by $2,911,925, from ($1,233,725) to ($4,145,650) for the same period. The increase in operating loss and net loss compared to the prior year is primarily a result of our increase in general and administrative expenses, as well as our increase in professional fees. These changes are detailed below.

Revenue

General and Administrative Expenses

General and administrative expenses increased by $1,617,341, from $594,446 for the year ended December 31, 2015 to $2,211,787 for the year ended December 31, 2016, primarily due to an increase in our stock-based compensation awarded to our executives.

Professional Fees

Our professional fees increased during the year ended December 31, 2016 compared to the year ended December 31, 2015. Our professional fees were $1,933,733 for the year ended December 31, 2016 and $639,149 for the year ended December 31, 2015. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors, and increased significantly primarily as a result of increased stock-based compensation awards. We expect these fees to continue grow steadily as our business expands. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.

Interest Income/Expense; Net

Interest expense increased from $4,824 to $5,321 for the year ended December 31, 2015 compared to the same period in 2016. Our interest expense primarily relates to interest on a convertible note and short term loans.

Liquidity and Capital Resources

Introduction

During the years ended December 31, 2016 and 2015, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of December 31, 2016 was $231 and our monthly cash flow burn rate was approximately $6,000. As a result, we had significant short term cash needs. These needs were satisfied through proceeds from the sales of our securities. We currently do not believe we will be able to satisfy our cash needs from our revenues for many years to come.

Our cash, current assets, total assets, current liabilities, and total liabilities as of December 31, 2016 and 2015, respectively, are as follows:

	December 31,2016	December 31, 2015	Change

Cash	$ 231	$ 7	$ 224
Total Current Assets	5,284	2,074	3,210
Total Assets	5,548	2,468	3,080
Total Current Liabilities	281,226	218,070	63,156
Total Liabilities	$ 281,226	$ 218,070	$ 63,156

Our current assets increased by $3,210 as of December 31, 2016 as compared to December 31, 2015. The increase in our total assets between the two periods was primarily attributed to an increase in prepaid expenses as of December 31, 2016.

Our current liabilities and total liabilities increased by $63,156, as of December 31, 2016 as compared to December 31, 2015. A large portion of this increase was due to higher accrued officer compensation.

In order to repay our obligations in full or in part when due, we will be required to raise significant capital from other sources. There is no assurance, however, that we will be successful in these efforts.

Cash Requirements

We had cash available as of December 31, 2016 of $231 and $7 on December 31, 2015. Based on our revenues, cash on hand and current monthly burn rate of approximately $45,000, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund operations.

Sources and Uses of Cash

Operations

We had net cash used in operating activities of $72,776 for the year ended December 31, 2016, as compared to $25,800 for the year ended December 31, 2015. In 2016, the net cash used in operating activities consisted primarily of our net loss of ($4,150,971), offset by shares issued for services, related parties of $3,600,000, shares issued for services of $377,812, and shares issued for down payment on land purchase of $42,500, adjusted by an increase in prepaid expenses of $2,986, accrued compensation of $71,505, accrued interest of $4,738, and a decrease in accounts payable of $16,087. For the same period in 2016, the net cash provided by operating activities consisted primarily of our net loss of ($1,238,549), offset by shares issued for services, related parties of $840,000 and shares issued for services of $266,640, adjusted by an increase in accounts payable of $19,199, accrued compensation of $74,000, accrued interest of $4,624, and a decrease in prepaid expenses of $7,956.

Investments

We did not have any net cash provided (used) by investing activities for the years ended December 31, 2016 or December 31, 2015.

Financing

Our net cash provided by financing activities for the year ended December 31, 2016 was $73,000, compared to $20,185 for the year ended December 31, 2015. For the period in 2016, our financing activities related to proceeds from the sale of common stock of $70,000 and proceeds from notes payable, related parties of $16,005, offset by repayments on notes payable, related parties of ($13,005). For the period in 2015, our financing activities consisted of proceeds from the sale of common stock of $24,000 and proceeds from notes payable, related parties of $1,300, offset by repayments on notes payable, related parties of ($5,115).

Contractual Obligations

December 31, 2016:

	2017	2018	2019	2020	2021	Total

Debt obligations	$ 51,300	$ -	$ -	$ -	$ -	$ 51,300
Operating leases	9,000	12,000	12,000	12,000	12,000	57,000
	$ 60,300	$ 12,000	$ 12,000	$ 12,000	$ 12,000	$ 108,300

Off Balance Sheet Arrangements

We have no off balance sheet arrangements.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

We have no information required to be disclosed under this Item.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risks, which include interest rate changes in United States of America and commodity prices. We do not engage in financial transactions for trading or speculative purposes.

Interest Rate Risk . There may be interest charged on our accounts payable, as well as interest we charge on our accounts receivable, depending on their age. Typically these interest rates are fixed are not affected by changes in market interest rates. However, from time to time we may enter into debt transactions that have a variable interest rate which would leave us subject to interest rate fluctuations.

Commodity Prices. If we get operational, we will be exposed to fluctuation in market prices for the raw materials necessary to manufacture our products. To mitigate risk associated with increases in market prices and commodity availability, we will attempt to negotiate contracts with favorable terms directly with vendors. We do not believe we will enter into forward contracts or other market instruments as a means of achieving our objectives or minimizing our risk exposures on these materials.

DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS, AND CONTROL PERSONS

The following table sets forth the names and ages of the current directors and executive officers of the Company, the principal offices and positions with the Company held by each person and the date such person became a director or executive officer of the Company. The executive officers of the Company are elected annually by the Board of Directors. The directors serve one-year terms until their successors are elected. The executive officers serve terms of one year or until their death, resignation or removal by the Board of Directors. Unless described below, there are no family relationships among any of the directors and officers.

Name	Age	Position(s)

Glenn E. Martin	63	President, Chief Executive Officer, Chief Financial Officer and a Director

Nicole M. Breen	41	Secretary, Treasurer and a Director

Glenn E. Martin was appointed as our President, Chief Executive Officer and Chief Financial Officer on September 30, 2014. Mr. Martin has been a Director since January 1, 2005. Mr. Martin was our President from 2005 until 2012. Prior to joining United Mines, Mr. Martin has served in an executive capacity with several different companies. From 1988 through the fall of 1992, Mr. Martin was Executive Director of World Trade Center, Tucson, a subsidiary of the former Twin Towers in New York City. In this position he oversaw the day to day operation, including projects, programs, and seminars for the U.S. Dept. of Commerce associate office in the W.T.C., Tucson promoting D.O.C. programs, servicing clients for both the D.O.C. and Small Business administration. During his tenure with World Trade Center he served as speaker for international trade seminars and the AIESEC (U.S) National Leadership Seminars. Member; Hong Kong Trade Association 1988 to present. Member; Society of Mining, Metallurgy & Exploration (2008). Guest speaker at Inaugural HKBAH Annual Event in May 2010 & member of Hong Kong Business Association of Hawaii (2010)

During our fiscal years ended December 31, 2016 and December 31, 2015, Mr. Martin received $7,995 and $4,000, respectively, in cash compensation for his services in addition to a total of 28,000,000 shares of our common stock as compensation for the years ended December 31, 2015 and December 31, 2016. As of December 31, 2016, Mr. Martin owns or controls an aggregate of 55,841,078 shares of our common stock.

Nicole M. Breen , was appointed as our Secretary and Treasurer on September 30, 2014. Ms. Breen has been a Director since January 1, 2005. Ms. Breen was our Secretary and Treasurer from 2005 until 2012. From June 2000 to 2012 she served as the Managing Associate of GEM Management Group, LLC specializing in acquiring mineral rights and mining properties, along with servicing administration requirements for the company. All Ms. Breen’s current work in the Cannabis industry is done on our behalf. In this position, she oversees as corporate secretary, recording secretary and the day-to-day treasury operations of the company. Ms. Breen received her Bachelor of Science in Physical Education in Education, with a minor in Elementary Education, from the University of Arizona.

During our fiscal years ended December 31, 2016 and December 31, 2015, Ms. Breen did not receive cash compensation for her services but she did receive a total of 16,000,000 shares of our common stock as compensation for the years ended December 31, 2015 and December 31, 2016. As of December 31, 2016, Ms. Breen owned 19,947,520 shares of our common stock.

Nicole Breen is Glenn Martin’s daughter.

EXECUTIVE COMPENSATION

The Summary Compensation Table shows certain compensation information for services rendered in all capacities for the fiscal years ended December 31, 2016 and 2015. Other than as set forth herein, no executive officer’s salary and bonus exceeded $100,000 in any of the applicable years. The following information includes the dollar value of base salaries, bonus awards, the number of stock options granted and certain other compensation, if any, whether paid or deferred.

SUMMARY COMPENSATION TABLE
Name and Principal Position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation ($)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)
Glenn E. Martin President, CEO and CFO	2016 2015	7,995 4,000	-0- -0-	2,100,000 490,000	-0- -0-	-0- -0-	-0- -0-	-0- -0-	2,107,995 494,000
Nicole M. Breen Secretary and Treasurer	2016 2015	-0- -0-	-0- -0-	1,200,000 280,000	-0- -0-	-0- -0-	-0- -0-	-0- -0-	1,200,000 280,000

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END

	Option Awards					Stock Awards
Name	Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)	Option Exercise Price ($)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested ($)	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)

Glenn E. Martin	-0-	-0-	-0-	N/A	N/A	-0-	-0-	-0-	-0-

Nicole M. Breen	-0-	-0-	-0-	N/A	N/A	-0-	-0-	-0-	-0-

In 2014 and 2016 we entered into employment agreements with Glenn E. Martin, our Chief Executive Officer and Chief Financial Officer, Nicole Breen, our Secretary and Treasurer and Ryan Breen, our Vice President and Social Media Officer.

Under the terms of our agreement with Mr. Martin dated October 1, 2016, he serves as our President and Chief Executive Officer. The agreement is for a two-year term and Mr. Martin received Seven Million (7,000,000) shares of our common stock, restricted in accordance with Rule 144, and is to receive Seven Million (7,000,000) additional shares as his annual salary for agreeing to serve as our President and Chief Executive Officer. Additionally, Mr. Martin is entitled to One Million (1,000,000) shares of a yet-to-be-created class of Series B Preferred Stock if we regain “fully-reporting” status with the Securities and Exchange Commission. We are obligated to maintain and pay the premiums for “key man” life insurance in the amount of $1,000,000. Our agreement with Mr. Martin also contains various provisions related to his termination without cause and in the event we undergo a change of control transaction. To date, no “key man” insurance has been obtained.

Under the terms of our agreement with Mrs. Breen dated October 1, 2016, she serves as our Secretary and Treasurer. The agreement is for a two-year term and Ms. Breen received Four Million (4,000,000) shares of our common stock, restricted in accordance with Rule 144, and is to receive Four Million (4,000,000) additional shares as her annual salary for agreeing to serve as our Secretary and Treasurer. Additionally, Ms. Breen is entitled to One Hundred Thousand (100,000) shares of a yet-to-be-created class of Series B Preferred Stock if we regain “fully-reporting” status with the Securities and Exchange Commission. Our agreement with Ms. Breen also contains various provisions related to her termination without cause and in the event we undergo a change of control transaction.

Under the terms of our agreement with Mr. Ryan Breen dated October 1, 2016, he serves as our Vice President and Social Media Officer. The agreement is for a two-year term and Mr. Breen received One Million (1,000,000) shares of our common stock, restricted in accordance with Rule 144, and is to receive One Million (1,000,000) additional shares as his annual salary for agreeing to serve as our Vice President and Social Media Officer. Additionally, Mr. Breen is entitled to One Hundred Thousand (100,000) shares of a yet-to-be-created class of Series B Preferred Stock if we regain “fully-reporting” status with the Securities and Exchange Commission. Our agreement with Mr. Breen also contains various provisions related to his termination without cause and in the event we undergo a change of control transaction.

When our Board of Directors approved the employments agreements they resolved to create a new series of preferred stock to be entitled “Series B Convertible Preferred Stock” with the following rights and preferences: (i) no dividend rights; (ii) no liquidation preference over the Company’s common stock; (iii) conversion rights into shares of common stock at a ratio of 20 shares of common stock for each share of Series V Convertible Preferred Stock; (iv) no redemption rights; (v) no call rights by the Company; and (vi) voting rights on an “as converted” basis on all matters properly brought before our common stockholders for a vote.

Long-Term Incentive Plans. We do not provide its officers or employees with pension, stock appreciation rights, long-term incentive or other plans and has no intention of implementing any of these plans for the foreseeable future.

Employee Pension, Profit Sharing or other Retirement Plans. We do not have a defined benefit, pension plan, profit sharing or other retirement plan, although it may adopt one or more of such plans in the future.

Compensation of Directors

Our directors did not receive any compensation for their services as directors during the fiscal year ended December 31, 2016 or 2015.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth, as of June 30, 2017, certain information with respect to our equity securities owned of record or beneficially by (i) each Officer and Director of the Company; (ii) each person who owns beneficially more than 5% of each class of the Company’s outstanding equity securities; and (iii) all Directors and Executive Officers as a group.

Common Stock
Title of Class	Name and Address of Beneficial Owner (1)	Amount and Nature of Beneficial Ownership	Percent of Class (2)
Common Stock	Glenn E. Martin (3)(4)	55,841,078	55.80 %
Common Stock	Nicole M. Breen (3)(5)	19,947,520	19.89 %
Common Stock	Ryan Breen (6)	5,047,766 (7)	5.05 %
Common Stock	All Directors and Officers As a Group (2 persons)	75,788,598	75.49 %

(1)

Unless otherwise indicated, based on 99,991,020 shares of common stock issued and outstanding. Shares of common stock subject to options or warrants currently exercisable, or exercisable within 60 days, are deemed outstanding for purposes of computing the percentage of the person holding such options or warrants, but are not deemed outstanding for the purposes of computing the percentage of any other person.

(2)

Indicates one of our officers or directors.

(3)

Unless indicated otherwise, the address of the shareholder is WEED, Inc., at 4920 N. Post Trail, Tucson, AZ 85750.

(4)

Includes 80,666 shares of common stock held in the name of Tanque Verde Valley Missionary Society, an entity controlled by Mr. Martin.

(5)

Includes 305,505 shares of common stock held in the name of GEM Management Group, LLC, an entity controlled by Ms. Breen, and an aggregate of 15,927 shares of common stock held in the name of Ms. Breen’s children.

(6)

Ryan Breen is the spouse of Nicole M. Breen.

(7)

Includes 37,151 shares owned in the name of Daniel J. Breen & Ryan Breen.

The issuer is not aware of any person who owns of record, or is known to own beneficially, ten percent or more of the outstanding securities of any class of the issuer, other than as set forth above. The issuer is not aware of any person who controls the issuer as specified in Section 2(a)(1) of the 1940 Act. There are no classes of stock other than common stock issued or outstanding. The Company does not have an investment advisor.

There are no current arrangements which will result in a change in control.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Employment Agreements

Under the terms of our agreement with Mr. Martin dated October 1, 2016, he serves as our President and Chief Executive Officer. The agreement is for a two-year term and Mr. Martin received Seven Million (7,000,000) shares of our common stock, restricted in accordance with Rule144, and is to receive Seven Million (7,000,000) additional shares as his annual salary for agreeing to serve as our President and Chief Executive Officer. Additionally, Mr. Martin is entitled to One Million (1,000,000) shares of a yet-to-be-created class of Series B Preferred Stock if we regain “fully-reporting” status with the Securities and Exchange Commission. We are obligated to maintain and pay the premiums for “key man” life insurance in the amount of $1,000,000. Our agreement with Mr. Martin also contains various provisions related to his termination without cause and in the event we undergo a change of control transaction. To date, no “key man” insurance has been obtained.

Share Issuances

On October 1, 2016, we granted 7,000,000 shares of common stock to Glenn E. Martin, our Chief Executive Officer, as a bonus for services to be performed from January 1, 2017 to December 31, 2018, as our primary executive officer, pursuant to an amended employment agreement. The total fair value of the common stock was $700,000 based on the closing price of our common stock on the date of grant.

In addition, on October 1, 2016, we granted a total of 14,000,000 shares of common stock to Glenn E. Martin, our Chief Executive Officer, for services performed from January 1, 2015 to December 31, 2016, as our primary executive officer, pursuant to his previous employment agreement. The total fair value of the common stock was $1,400,000 based on the closing price of our common stock on the date of grant.

On October 1, 2016, we granted 4,000,000 shares of common stock to Nicole Breen, our Secretary and Treasurer, for services to be performed from January 1, 2017 to December 31, 2018, in those capacities, pursuant to an amended employment agreement. The total fair value of the common stock was $400,000 based on the closing price of our common stock on the date of grant.

In addition, on October 1, 2016, we granted a total of 8,000,000 shares of common stock to Nicole, our Secretary and Treasurer, for services performed from January 1, 2015 to December 31, 2016, in those capacities, pursuant to their previous employment agreement. The total fair value of the common stock was $800,000 based on the closing price of our common stock on the date of grant.

On October 1, 2016, we granted 1,000,000 shares of common stock to Ryan Breen, our Vice President and Social Media Officer, for services to be performed from January 1, 2017 to December 31, 2018, in those capacities, pursuant to an amended employment agreement. The total fair value of the common stock was $100,000 based on the closing price of our common stock on the date of grant.

On October 1, 2016, we granted a total of 2,000,000 shares of common stock to Ryan, our Vice President and Social Media Officer, for services performed from January 1, 2015 to December 31, 2016, in those capacities, pursuant to a previous employment agreement. The total fair value of the common stock was $200,000 based on the closing price of our common stock on the date of grant.

On January 1, 2015, we granted 7,000,000 shares of common stock to our Glenn E. Martin, our Chief Executive Officer, as a bonus for services performed from January 1, 2015 to December 31, 2016, as our primary executive officer. The total fair value of the common stock was $490,000 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on June 29, 2015.

On January 1, 2015, we granted 4,000,000 shares of common stock to Nicole Breen, our Secretary and Treasurer, as a bonus for services performed from January 1, 2015 to December 31, 2016, in those capacities. The total fair value of the common stock was $280,000 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on June 29, 2015.

On January 1, 2015, we granted 1,000,000 shares of common stock to Ryan Breen, our Vice President and Social Media Officer, as a bonus for services performed from January 1, 2015 to December 31, 2016. The total fair value of the common stock was $70,000 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on June 29, 2015.

On or about December 5, 2014, we issued 18,000,000 shares to Glenn Martin, our Chief Executive Officer, at $0.05 per share, in exchange for services rendered to the company from January 1, 2012 until December 31, 2014.

On or about September 30, 2014, we issued: (i) an aggregate of 9,600,000 shares to Glenn Martin, Nicole Breen and Ryan Breen, affiliates of the company, at $0.05 per share, in exchange for services rendered to the company from July 2012 to September 30, 2014.

Notes Payable

On various dates, we received advances from our Chief Executive Officer, Glenn Martin. Mr. Martin owns approximately 56% of our common stock. The unsecured non-interest bearing loans are due on demand. The largest aggregate amount outstanding was $9,000 and $10,000 during the periods ended June 30, 2017 and December 31, 2016, respectively.

Lease of Real Property

We lease our executive offices our Glenn E. Martin, our President, on a month-to-month basis at a monthly rent of $1,000, which began on April 1, 2017.

DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

Section 15 of our Articles of Incorporation provides that, to the fullest extent permitted by law, no director or officer shall be personally liable to the corporation or its shareholders for damages for breach of any duty owed to the corporation or its shareholders.

Section 16 of our Articles of Incorporation provides that, to the fullest extent permitted by the General Corporation Law of the State of Nevada we will indemnify our officers and directors from and against any and all expenses, liabilities, or other matters.

Article IX of our Bylaws further addresses indemnification of our directors and officers and allows us to indemnify our directors in the event they meet certain criteria in terms of acting in good faith and in an official capacity within the scope of their duties, when such conduct leads them to be involved in a legal action.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 (the “Act”) may be permitted to directors, officers and controlling persons of the small business issuer pursuant to the foregoing provisions, or otherwise, the small business issuer has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.

AVAILABLE INFORMATION

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the resale of shares of our common stock by the Selling Shareholders. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits filed therewith. For further information about us, our common stock and the Selling Shareholders, reference is made to the registration statement and the exhibits filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and in each instance we refer you to the copy of such contract or other document filed as an exhibit to the registration statement. A copy of the registration statement and the exhibits filed therewith may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street, NE, Washington, DC 20549, and copies of all or any part of the registration statement may be obtained from that office upon the payment of the fees prescribed by the SEC. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the website is www.sec.gov .

Upon effectiveness of this registration statement, we will become subject to the information and periodic reporting requirements of the Exchange Act and, in accordance therewith, we will file periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information will be available for inspection and copying at the public reference room and website of the SEC referred to above.

EXPERTS

The financial statements of WEED, Inc. as of December 31, 2016 and December 31, 2015 and for the years ended December 31, 2016 and December 31, 2015, and the balance sheets of WEED, Inc. as of December 31, 2016 and December 31, 2015 have been included herein in reliance upon the reports of M&K CPAS, PLLC., independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.

PART II – INFORMATION NOT REQUIRED IN PROSPECTUS

OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

We will pay all expenses in connection with the registration and sale of the common stock by the Selling Shareholders, who may be deemed to be underwriters in connection with their offering of shares. The estimated expenses of issuance and distribution are set forth below:

Registration Fees	Approximately	$ 1,094
Transfer Agent Fees	Approximately	2,000
Costs of Printing and Engraving	Approximately	1,000
Legal Fees	Approximately	40,000
Accounting and Audit Fees	Approximately	51,000
Total		$ 95,094

INDEMNIFICATION OF DIRECTORS AND OFFICERS

RECENT SALES OF UNREGISTERED SECURITIES

In the last three fiscal years and subsequent interim periods, we issued the following shares of common stock and preferred stock. The following issuances were made in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended. For common stock sales, we relied on the representations of the purchaser contained in the securities purchase agreement signed by the purchaser that indicated the purchaser was knowledgeable about our management and our operations, was a sophisticated investor, and understood the purchase was part of a private placement, in order to rely on the exemption from registration contained in Section 4(a)(2) of the Securities Act. For the common stock issued for services, we relied on the representations of the purchaser contained in the consulting agreement signed by the purchaser and the fact the consultant did work for the company and was familiar with the company, its operations and its management, in order to rely on the exemption from registration contained in Section 4(a)(2) of the Securities Act. For the common stock issued to our management and directors for services rendered, we relied also on the facts that our current management and directors are current shareholders of our company and are familiar with our company and its operations by virtue of being a member of our management team and/or a member of our Board of Directors.

During the three months ended June 30, 2017, we issued, or agreed to issue, the following:

Common Stock Sales

(i) On May 31, 2017, we sold 20,000 units at $0.50 per unit, consisting of 20,000 shares of common stock and warrants to purchase 20,000 shares of common stock at an exercise price of $3.00 per share, exercisable until May 31, 2019, in exchange for total proceeds of $10,000.

I-1

(ii) On May 31, 2017, we sold 300,000 units at $0.50 per unit, consisting of 300,000 shares of common stock and warrants to purchase 150,000 shares of common stock at an exercise price of $3.00 per share, exercisable until May 31, 2019, in exchange for total proceeds of $150,000.

(iii) On May 25, 2017, we sold 20,000 units at $0.50 per unit, consisting of 20,000 shares of common stock and warrants to purchase 20,000 shares of common stock at an exercise price of $3.00 per share, exercisable until May 25, 2019, in exchange for total proceeds of $10,000.

(iv) On May 25, 2017, we sold 20,000 units at $0.50 per unit, consisting of 100,000 shares of common stock and warrants to purchase 100,000 shares of common stock at an exercise price of $3.00 per share, exercisable until May 25, 2019, in exchange for total proceeds of $50,000.

(v) On April 20, 2017, we sold 500,000 units at $1.00 per unit, consisting of 500,000 shares of common stock and warrants to purchase 500,000 shares of common stock at an exercise price of $3.00 per share, exercisable until April 20, 2018, in exchange for total proceeds of $500,000.

Common Stock Issued for Acquisition

On April 20, 2017, we issued a total of 500,000 shares of common to seven individuals pursuant to the closing of an acquisition of Sangre AT, LLC, a Wyoming limited liability company (“Sangre”) in exchange for 100% of the interests in Sangre. The total fair value of the common stock was $1,003,850 based on the closing price of our common stock on the date of grant.

Common Stock and warrants Issued for Settlement of Convertible Debt

On June 16, 2017, a convertible note previously issued by us, consisting of $35,000 of principal and $33,250 of unpaid interest, was assigned to a third party and the debt was exchanged for a unit offering, consisting of 70,000 shares of common stock and warrants to purchase 70,000 shares of common stock at an exercise price of $3.00 per share, exercisable until June 16, 2018. The stock was valued at $86,800 based on the closing price of our common stock on the date of exchange and the warrants were valued at $49,433.

Common Stock Issued for Services

On April 20, 2017, we granted an aggregate of 116,000 shares of common stock to eleven consultants for services performed. The aggregate fair value of the common stock was $232,893 based on the closing price of our common stock on the date of grant.

Common Stock Subscribed for Services

On April 20, 2017, we granted 50,000 shares of common stock to each of two consultants for services performed. The issuance of the shares has been deferred until January 1, 2018. The aggregate fair value of the common stock was $200,770 based on the closing price of our common stock on the date of grant.

I-2

Common Stock Cancellations

On April 25, 2017, a total of 4,820,953 shares of our common stock were cancelled and returned to treasury in compliance with the September 30, 2014 approval by the majority of shareholders to the terms of a Settlement Agreement dated December 11, 2013 and signed on August 19, 2014 pursuant to Case No. C20125545 in the Superior Court of the State of Arizona, whereby among other provisions, the Plaintiffs, consisting of United Mines, Inc. (“UMI”) and its then principals, agreed to the cancellation of a total of 4,820,953 shares of common stock and to transfer control of the company in exchange for (i) sixty five (65) of the unpatented Bureau of Land Management (“BLM”) mining claims, the mill site, buildings and equipment, (ii) the four (4) Arizona State Land Department Exploration Permits registered to the Company, and (iii) any permits, financial and reclamation guaranties, bonds and licenses connected with the foregoing assets. In addition, thirty-three (33) unpatented BLM mining claims remained in UMI’s possession, along with any associated permits, financial and reclamation guaranties, bonds, licenses, and the rights to the corporation, the corporation’s name, stock symbol, or any other asset of UMI, which remained the property of UMI under the management of Glenn E. Martin.

During the three months ended March 31, 2017, we issued, or agreed to issue, the following:

Common Stock Sales

(i) On March 15, 2017 and March 31, 2017, we received an aggregate $235,000 of advances on the subsequent sale on April 20, 2017 of 375,000 units at $1.00 per unit, consisting of 375,000 shares of common stock and warrants to purchase 375,000 shares of common stock at an exercise price of $3.00 per share, exercisable until April 20, 2019, in exchange for total proceeds of $375,000.

(ii) On January 23, 2017, we sold 2,000 units at $2.00 per unit, consisting of 2,000 shares of common stock and warrants to purchase 2,000 shares of common stock at an exercise price of $3.00 per share, exercisable until January 23, 2018, in exchange for total proceeds of $4,000.

(iii) On January 9, 2017, we sold 50,000 units at $1.00 per unit, consisting of 50,000 shares of common stock and warrants to purchase 50,000 shares of common stock at an exercise price of $3.00 per share, exercisable until January 9, 2018, in exchange for total proceeds of $50,000.

Warrants Exercised

(i) On January 7, 2017, a warrant holder exercised warrants to purchase 2,666 shares of common stock at a strike price of $1.50 in exchange for proceeds of $3,999.

Common Stock Issued for Bartered Assets

(i) On January 18, 2017, we exchanged 66,000 units, consisting of 66,000 shares of common stock and warrants to purchase 66,000 shares of common stock at an exercise price of $3.00 per share, exercisable until January 18, 2018, in exchange for a 2017 Audi Q7 and a 2017 Audi A4.

Common Stock Issued for Services

(i) On March 2, 2017, we granted 50,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $142,500 based on the closing price of our common stock on the date of grant.

(ii) On March 2, 2017, we granted 12,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $34,200 based on the closing price of our common stock on the date of grant.

(iii) On January 7, 2017, we granted 50,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $210,250 based on the closing price of our common stock on the date of grant.

I-3

During the three months ended December 31, 2016, we issued, or agreed to issue, the following :

(i) On October 31, 2016, we sold 50,000 units at $0.10 per unit, consisting of 50,000 shares of common stock and warrants to purchase 50,000 shares of common stock at an exercise price of $1.50 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $5,000.

(ii) On October 25, 2016, we sold 150,000 units at $0.3333 per unit, consisting of 150,000 shares of common stock and warrants to purchase 150,000 shares of common stock at an exercise price of $1.50 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $50,000.

(iii) On October 19, 2016, we sold 25,000 units at $0.20 per unit, consisting of 25,000 shares of common stock and warrants to purchase 25,000 shares of common stock at an exercise price of $1.50 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $5,000.

(iv) On October 19, 2016, we sold 100,000 units at $0.10 per unit, consisting of 100,000 shares of common stock and warrants to purchase 100,000 shares of common stock at an exercise price of $1.50 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $10,000.

(v) On November 8, 2016, we granted 50,000 shares of common stock as a good faith deposit on a potential land purchase agreement that has not yet closed, as we do not currently have sufficient resources. The total fair value of the common stock was $42,500 based on the closing price of our common stock on the date of grant.

(vi) On October 1, 2016, we granted 7,000,000 shares of common stock to our CEO, Glenn E. Martin, as a bonus for services performed pursuant to an amended employment agreement. The total fair value of the common stock was $700,000 based on the closing price of our common stock on the date of grant.

(vii) In addition, on October 1, 2016, we granted a total of 14,000,000 shares of common stock to Mr. Martin for services performed pursuant to his previous employment agreement. The total fair value of the common stock was $1,400,000 based on the closing price of our common stock on the date of grant.

(viii) On October 1, 2016, we granted 4,000,000 shares of common stock to Nicole Breen as a bonus for services performed pursuant to an amended employment agreement. The total fair value of the common stock was $400,000 based on the closing price of our common stock on the date of grant.

(ix) In addition, on October 1, 2016, we granted a total of 8,000,000 shares of common stock to Nicole Breen for services performed pursuant to their previous employment agreement. The total fair value of the common stock was $800,000 based on the closing price of our common stock on the date of grant.

(x) On October 1, 2016, we granted 1,000,000 shares of common stock to Ryan Breen as a bonus for services performed pursuant to an amended employment agreement. The total fair value of the common stock was $100,000 based on the closing price of our common stock on the date of grant.

(xi) On October 1, 2016, we granted a total of 2,000,000 shares of common stock to Ryan Breen for services performed pursuant to their previous employment agreement. The total fair value of the common stock was $200,000 based on the closing price of our common stock on the date of grant.

(xii) On October 19, 2016, we granted 10,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $8,500 based on the closing price of our common stock on the date of grant.

Common stock warrants granted during the three months ended December 31, 2016:

(i) On October 31, 2016, we sold warrants to purchase 50,000 shares of common stock at $1.50 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $5,000 in conjunction with the sale of 50,000 shares of common stock.

(ii) On October 25, 2016, we sold warrants to purchase 150,000 shares of common stock at $1.50 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $50,000 in conjunction with the sale of 150,000 shares of common stock.

I-4

(iii) On October 19, 2016, we sold warrants to purchase 25,000 shares of common stock at $1.50 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $5,000 in conjunction with the sale of 25,000 shares of common stock.

(iv) On October 19, 2016, we sold warrants to purchase 100,000 shares of common stock at $1.50 per share over a one (1) year period from the date of sale, in exchange for total proceeds of $10,000 in conjunction with the sale of 100,000 shares of common stock.

During the three months ended September 30, 2016, we issued, or agreed to issue, the following :

(i) On September 28, 2016, we granted 600,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $60,000 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on November 23, 2016.

(ii) On September 28, 2016, we granted 600,000 shares of common stock to a different consultant for services performed. The total fair value of the common stock was $60,000 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on November 23, 2016.

(iii) On September 28, 2016, we granted 600,000 shares of common stock to a third consultant for services performed. The total fair value of the common stock was $60,000 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on November 23, 2016.

During the three months ended June 30, 2016, we did not issue any of our securities .

During the three months ended March 31, 2016, we issued, or agreed to issue, the following :

(i) On March 18, 2016, we granted 60,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $5,820 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

(ii) On March 18, 2016, we granted 500,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $48,500 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

(iii) On March 18, 2016, we granted 120,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $11,640 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

(iv) On February 12, 2016, we granted 120,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $5,832 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

(v) On February 1, 2016, we granted 500,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $22,000 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

(vi) On February 1, 2016, we granted 500,000 shares of common stock to another consultant for services performed. The total fair value of the common stock was $22,000 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

(vii) On February 1, 2016, we granted 20,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $880 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

I-5

(viii) On February 1, 2016, we granted 60,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $2,640 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on October 27, 2016.

During the three months ended December 31, 2015, we did not issue any of our securities .

During the three months ended September 30, 2015, we issued, or agreed to issue, the following :

(i) On August 17, 2015, we sold 90,000 units at $0.10 per unit, consisting of 90,000 shares of common stock and warrants to purchase 90,000 shares of common stock at an exercise price of $0.50 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $9,000. We did not issue these shares until the quarter ended December 31, 2016.

During the six months ended June 30, 2015, we issued the following :

(i) During the six months ended June 30, 2015, we issued a total of 2,775,000 shares of common stock in satisfaction of common stock granted during the year ended December 31, 2014, in the aggregate value of $156,100

(ii) On January 1, 2015, we granted 120,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $8,400 based on the closing price of our common stock on the date of grant.

(iii) On January 1, 2015, we granted 7,000,000 shares of common stock to our CEO, Glenn E. Martin, for services performed. The total fair value of the common stock was $490,000 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on June 29, 2015.

(iv) On January 1, 2015, we granted 4,000,000 shares of common stock to Nicole Breenfor services performed. The total fair value of the common stock was $280,000 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on June 29, 2015.

(v) On January 1, 2015, we granted 1,000,000 shares of common stock to Ryan Breen for services performed. The total fair value of the common stock was $70,000 based on the closing price of our common stock on the date of grant. The shares were subsequently issued on June 29, 2015.

(vi) On January 30, 2015, we sold 50,000 units, consisting of 50,000 shares of common stock and warrants to purchase 50,000 shares of common stock at an exercise price of $0.10 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $5,000.

(vii) On February 12, 2015, we granted 60,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $8,850 based on the closing price of our common stock on the date of grant.

(viii) On February 20, 2015, we granted 240,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $21,600 based on the closing price of our common stock on the date of grant.

(ix) On February 20, 2015, we sold another 40,000 units, consisting of 50,000 shares of common stock and warrants to purchase 50,000 shares of common stock at an exercise price of $0.25 per share over a one (1) year period from the date of purchase in exchange for total proceeds of $10,000.

(x) On March 16, 2015, we granted 50,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $4,000 based on the closing price of our common stock on the date of grant.

(xi) On March 16, 2015, we granted 60,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $4,800 based on the closing price of our common stock on the date of grant.

(xii) On March 16, 2015, we granted 120,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $9,600 based on the closing price of our common stock on the date of grant.

I-6

(xiii) On March 16, 2015, we granted 40,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $3,200 based on the closing price of our common stock on the date of grant.

(xiv) On March 16, 2015, we granted 40,000 shares of common stock to another consultant for services performed. The total fair value of the common stock was $3,200 based on the closing price of our common stock on the date of grant.

(xv) On April 1, 2015, we granted 600,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $40,000 based on the closing price of our common stock on the date of grant.

(xvi) On April 1, 2015, we granted 500,000 shares of common stock to a consultant for services performed. The total fair value of the common stock was $48,000 based on the closing price of our common stock on the date of grant.

On or about December 5, 2014, we issued the following :

(i) 18,000,000 shares to Glenn Martin, our Chief Executive Officer, at $0.05 per share.

(ii) 989,000 shares to two non-affiliates, at an average price of $0.20 per share.

On or about September 30, 2014, we issued the following :

(i) An aggregate of 9,600,000 shares to Glenn Martin, Nicole Breen and Ryan Breen, affiliates of we, at $0.05 per share.

(ii) 1,500,000 shares to two non-affiliates, valued at $0.05 per share.

I-7

EXHIBITS

3.1 (1)	Articles of Incorporation of WEED, Inc.

3.2 (1)	Bylaws of WEED, Inc.

5.1**	Legal Opinion of Legal Counsel

10.1 (1)	Employment Agreement with Glenn E. Martin dated October 1, 2016

10.2 (1)	Employment Agreement with Nicole Breen dated October 1, 2016

10.3 (1)	Employment Agreement with Ryan Breen dated October 1, 2016

10.4 (1)	Share Exchange Agreement by and between WEED, Inc. and Sangre AT, LLC dated April 20, 2017

10.5 (1)	Promissory Note dated July 26, 2017 issued to A.R. Miller for acquisition of La Veta, CO Property

10.6 (1)	Deed of Trust dated July 26, 2017 related to acquisition of La Veta, CO Property

10.7*	Form of Securities Purchase Agreement

10.8*	Form of Warrant Agreement

10.9*	Purchase and Sale Agreement by and between WEED, Inc. and Greg DiPaolo’s Pro Am Golf, LLC dated October 24, 2017

23.1	Consent of M&K CPAS, PLLC.

23.2**	Consent of Legal Counsel (included in Exhibit 5.1)

Included herewith.

To be included in subsequent filing.

(1) Incorporated by reference from our Registration Statement on Form S-1 filed with the Commission on August 11, 2017.

I-8

Undertakings

A. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by our director, officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

B. The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(a) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(b) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) (Section 230.424(b) of Regulation S-K) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

(c) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of the securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

I-9

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, in the City of Tucson, State of Arizona.

	WEED, Inc.




Dated: November 16, 2017	/s/ Glenn E. Martin
	By: Glenn E. Martin
	Its: President, Chief Executive Officer (Principal Executive Officer), Chief Financial Officer (Principal Accounting Officer)

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates stated.

Dated: November 16 , 2017	/s/ Glenn E. Martin
	By: Glenn E. Martin, Director and President, Chief Executive Officer (Principal Executive Officer), Chief Financial Officer (Principal Accounting Officer)



Dated: November 16, 2017	/s/ Nicole M. Breen
	By: Nicole M. Breen, Director, Secretary and Treasurer

I-10

Exhibit 10.7

WEED Inc.

____________________________

SECURITIES PURCHASE AGREEMENT

__________________________

Page 1 of 8

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is made and entered into effective as of the X h . Day of XXXXXX, 2017 (the “Effective Date”) by and between WEED Inc., a Nevada corporation (the “Company”), formerly United Mines Inc. and XXXXX XXXXXXX, an individual (the “Purchaser”). The Company and Purchaser shall each be referred to as a “Party” and collectively as the “Parties.”

1. PURCHASE OF SHARES: On the Closing Date (as hereinafter defined), subject to the terms and conditions set forth in this Agreement, the Purchaser hereby agrees to purchase, and the Company hereby agrees to sell, (a) (XX,XXX) shares of common stock of the Company, par value $0.001 (the “Shares”), and (b) Warrants to purchase XXXX XXXXXX (XX,XXX) shares of common stock of the Company (the “Warrants”), in form and substance substantially as set forth in Exhibit A attached hereto, for a total purchase price of XXXXXX XXXXXX Dollars ($XX,XXX.XX) (the “Purchase Price”). The Shares and the Warrants shall collectively be referred to herein as the “Securities.”

2. CLOSING AND DELIVERY:

a) Upon the terms and subject to the conditions set forth herein, the consummation of the purchase and sale of the Securities (the “Closing”) shall take place as follows: (a) Purchaser will pay $XXXXXX, as the full Purchase Price, on or before XXXXXXXX X th . 2017, and will be issued XXXXX XXXXXXXXX (XX,XXX) Shares, and all XX,XXX of the Warrants at the exercise price of $3.00, valid for 2 years from date of this Agreement. All shares and warrants due shall be delivered within ten (10) business days of delivery of payment. The Closing shall take place at the offices of counsel for the Company or by the exchange of documents and instruments by mail, courier, facsimile, email or wire transfer to the extent mutually acceptable to the Parties hereto. The $XX,XXX has been acknowledged and received.

(i) The Company shall deliver to the Purchaser (A) a certificate representing the applicable number of Shares, free from restrictions on transfer except as set forth in this Agreement, and (B) on the Closing Date, the Warrants.

(ii) The Purchaser shall deliver to the Company the applicable portion of the Purchase Price.

3. REPRESENTATIONS, WARRANTIES AND AGREEMENTS BY PURCHASER: The Purchaser hereby represents, warrants and agrees as follows:

a) Purchase for Own Account. Purchaser represents that he is acquiring the Securities solely for his own account and beneficial interest for investment and not for sale or with a view to distribution of the Securities or any part thereof, has no present intention of selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the same, and does not presently have reason to anticipate a change in such intention.

b) Ability to Bear Economic Risk. Purchaser acknowledges that an investment in the Securities involves a high degree of risk, and represents that he is able, without materially impairing his financial condition, to hold the Securities for an indefinite period of time and to suffer a complete loss of his investment.

c) Access to Information. The Purchaser acknowledges that the Purchaser has been furnished with such financial and other information concerning the Company, the directors and officers of the Company, and the business and proposed business of the Company as the Purchaser considers necessary in connection with the Purchaser’s investment in the Securities. Purchaser has also had an opportunity to review the Company’s filings with the Securities and Exchange Commission. As a result, the Purchaser is thoroughly familiar with the proposed business, operations, properties and financial condition of the Company and has discussed with officers of the Company any questions the Purchaser may have had with respect thereto.

Page 2 of 8

The Purchaser understands:

(i) The risks involved in this investment, including the speculative nature of the investment;

(ii) The financial hazards involved in this investment, including the risk of losing the Purchaser’s entire investment;

(iii) The lack of liquidity and restrictions on transfer of the Securities; and

(iv) The tax consequences of this investment.

The Purchaser has consulted with the Purchaser’s own legal, accounting, tax, investment and other advisers with respect to the tax treatment of an investment by the Purchaser in the Securities and the merits and risks of an investment in the Securities.

d) Securities Part of Private Placement. The Purchaser has been advised that the Securities have not been registered under the Securities Act of 1933, as amended (the “Act”), or qualified under the securities law of any state, on the ground, among others, that no distribution or public offering of the Securities is to be effected and the Securities will be issued by the Company in connection with a transaction that does not involve any public offering within the meaning of section 4(2) of the Act and/or Regulation D as promulgated by the Securities and Exchange Commission under the Act, and under any applicable state blue sky authority. The Purchaser understands that the Company is relying in part on the Purchaser’s representations as set forth herein for purposes of claiming such exemptions and that the basis for such exemptions may not be present if, notwithstanding the Purchaser’s representations, the Purchaser has in mind merely acquiring the Securities for resale on the occurrence or nonoccurrence of some predetermined event. The Purchaser has no such present intention.

e) Purchaser Not Affiliated with Company. The Purchaser, either alone or with the Purchaser’s professional advisers (i) are unaffiliated with, have no equity interest in, and are not compensated by, the Company or any affiliate or selling agent of the Company, directly or indirectly, (ii) has such knowledge and experience in financial and business matters that the Purchaser is capable of evaluating the merits and risks of an investment in the Securities; and (iii) has the capacity to protect the Purchaser’s own interests in connection with the Purchaser’s proposed investment in the Securities.

f) Further Limitations on Disposition. Purchaser further acknowledges that the Securities are restricted securities under Rule 144 of the Act, and, therefore any certificates reflecting the ownership interest in the Shares or the Warrants will contain a restrictive legend substantially similar to the following:

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (ii) TO THE EXTENT APPLICABLE, RULE 144 UNDER THE ACT (OR ANY SIMILAR RULE UNDER THE ACT RELATING TO THE DISPOSITION OF SECURITIES), OR (iii) AN OPINION OF COUNSEL, IF SUCH OPINION SHALL BE REASONABLY SATISFACTORY TO COUNSEL TO THE ISSUER, THAT AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND APPLICABLE STATE LAW IS AVAILABLE.

Without in any way limiting the representations set forth above, Purchaser further agrees not to make any disposition of all or any portion of the Securities unless and until:

(i) There is then in effect a Registration Statement under the Act covering such proposed disposition and such disposition is made in accordance with such Registration Statement; or

Page 3 of 8

(ii) Purchaser shall have obtained the consent of the Company and notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, Purchaser shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration under the Act or any applicable state securities laws.

Notwithstanding the provisions of subparagraphs (i) and (ii) above, no such registration statement or opinion of counsel shall be necessary for a transfer by such Purchaser to a partner (or retired partner) of Purchaser, or transfers by gift, will or intestate succession to any spouse or lineal descendants or ancestors, if all transferees agree in writing to be subject to the terms hereof to the same extent as if they were Purchasers hereunder as long as the consent of the Company is obtained.

g) Accredited Investor Status. Purchaser is an “accredited investor” as such term is defined in Rule 501 under the Act because Purchaser either:

(i) has a net worth of at least $1,000,000 (including home and personal property), or

(ii) had an individual income of more than $200,000 in each of the two most recent calendar years, and reasonably expects to have an individual income in excess of $200,000 in the current calendar year; or along with Purchaser’s spouse had joint income in excess of $300,000 in each of the two most recent calendar years, and reasonably expects to have a joint income in excess of $300,000 in the current calendar year.

For purposes of this Agreement, “individual income” means “adjusted gross income” as reported for Federal income tax purposes, exclusive of any income attributable to a spouse or to property owned by a spouse: (i) the amount of any interest income received which is tax-exempt under Section 103 of the Internal Revenue Code of 1986, as amended, (the “Code”), (ii) the amount of losses claimed as a limited partner in a limited partnership (as reported on Schedule E of form 1040), (iii) any deduction claimed for depletion under Section 611 et seq. of the Code and (iv) any amount by which income from long-term capital gains has been reduced in arriving at adjusted gross income pursuant to the provisions of Sections 1202 of the Internal Revenue Code as it was in effect prior to enactment of the Tax Reform Act of 1986.

For purposes of this Agreement, “joint income” means, “adjusted gross income,” as reported for Federal income tax purposes, including any income attributable to a spouse or to property owned by a spouse, and increased by the following amounts: (i) the amount of any interest income received which is tax-exempt under Section 103 of the Internal Revenue Code of 1986, as amended (the “Code”), (ii) the amount of losses claimed as a limited partner in a limited partnership (as reported on Schedule E of Form 1040), (iii) any deduction claimed for depletion under Section 611 et seq. of the Code and (iv) any amount by which income from long-term capital gains has been reduced in arriving at adjusted gross income pursuant to the provisions of Section 1202 of the Internal Revenue Code as it was in effect prior to enactment of the Tax Reform Act of 1986.

For the purposes of this Agreement, “net worth” means (except as otherwise specifically defined) the excess of total assets at fair market value, including home and personal property, over total liabilities, including mortgages and income taxes on unrealized appreciation of assets.

h) No Backup Withholding. The Social Security Number shown in this Agreement is correct, and the Purchaser is not subject to backup withholding because (i) the Purchaser has not been notified that he or she is subject to backup withholding as a result of a failure to report all interest and dividends or (ii) the Internal Revenue Service has notified the Purchaser that he or she is no longer subject to backup withholding.

Page 4 of 8

j) Purchase Price Arbitrarily Determined. The Purchaser acknowledges that the Purchase Price of the Shares and the exercise price of the Warrants being offered hereby was determined by management and bears no relationship to the Company’s current assets, book value, net worth or operations, or stock market price, and may not be indicative of our actual value. Although the Company’s common stock trades on the OTC Markets Pink Sheets, volume has been light since inception and thus no indication as to the market value of the Shares.

4. REPRESENTATIONS, WARRANTIES AND AGREEMENTS BY COMPANY: The Company hereby represents, warrants and agrees as follows:

a) Authority of Company. The Company has all requisite authority to execute and deliver this Agreement and to carry out and perform its obligations under the terms of this Agreement.

b) Authorization. All actions on the part of the Company necessary for the authorization, execution, delivery and performance of this Agreement by the Company and the performance of the Company’s obligations hereunder has been taken or will be taken prior to the issuance of the Securities. This Agreement, when executed and delivered by the Company, shall constitute valid and binding obligations of the Company enforceable in accordance with their terms, subject to laws of general application relating to bankruptcy, insolvency, the relief of debtors and, with respect to rights to indemnity, subject to federal and state securities laws.

Upon their issuance the Securities will be validly issued, fully paid and nonassessable, will not violate any preemptive rights, rights of first refusal, or any other rights granted by the Company, will be issued in compliance with all applicable federal and state securities laws, and will be free of any liens or encumbrances, other than any liens or encumbrances created by or imposed upon the Purchaser through no action of the Company; provided, however, that the Securities may be subject to restrictions on transfer under state and/or federal securities laws as set forth herein or as otherwise required by such laws at the time the transfer is proposed.

c) Governmental Consents. All consents, approvals, orders, or authorizations of, or registrations, qualifications, designations, declarations, or filings with, any governmental authority required on the part of the Company in connection with the valid execution and delivery of this Agreement, the offer, sale or issuance of the Securities, or the consummation of any other transaction contemplated hereby shall have been obtained, except for notices required or permitted to be filed with certain state and federal securities commissions, which notices will be filed on a timely basis.

d) Use of Proceeds. The Company intends to use the proceeds from this offering for general working capital purposes at the discretion of the Company’s management.

5. INDEMNIFICATION: The Purchaser hereby agrees to indemnify and defend the Company and its officers and directors and hold them harmless from and against any and all liability, damage, cost or expense incurred on account of or arising out of:

(a) Any breach of or inaccuracy in the Purchaser’s representations, warranties or agreements herein;

(b) Any disposition of any Securities contrary to any of the Purchaser’s representations, warranties or agreements herein;

(c) Any action, suit or proceeding based on (i) a claim that any of said representations, warranties or agreements were inaccurate or misleading or otherwise cause for obtaining damages or redress from the Company or any director or officer of the Company under the Act, or (ii) any disposition of any Securities.

Page 5 of 8

6. MISCELLANEOUS:

a) Binding Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the Parties. Nothing in this Agreement, expressed or implied, is intended to confer upon any third party any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

b) Governing Law; Venue. This Agreement shall be governed by and construed under the laws of the State of Arizona as applied to agreements among Arizona residents, made and to be performed entirely within the State of Arizona. The Parties agree that any action brought to enforce the terms of this Agreement will be brought in the appropriate federal or state court having jurisdiction over Pima County, Arizona, United States of America.

c) Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

d) Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

e) Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the Party to be notified, (b) when sent by confirmed facsimile if sent during normal business hours of the recipient, if not, then on the next business day, or (c) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent as follows:

If to the Company: WEED, Inc. 4920 N. Post Trail, Tucson, AZ 85750

Telephone (520) 818-8582 Attn: Glenn E. Martin

If to Purchaser: XXXXXX XXXXXX XXXXXXX. XXXXX,XX 00000

Telephone: (XXX) XXX-XXXX email: XXXXXX@XXXXXXX.com

or at such other address as the Company or Purchaser may designate by ten (10) days advance written notice to the other Party hereto.

f) Modification; Waiver. No modification or waiver of any provision of this Agreement or consent to departure therefrom shall be effective unless in writing and approved by the Company and the Purchaser.

g) Entire Agreement; Successors. This Agreement and the Exhibits hereto constitute the full and entire understanding and agreement between the Parties with regard to the subjects hereof and no Party shall be liable or bound to the other Party in any manner by any representations, warranties, covenants and agreements except as specifically set forth herein. The representations, warranties and agreements contained in this Agreement shall be binding on the Purchaser’s successors, assigns, heirs and legal representatives and shall inure to the benefit of the respective successors and assigns of the Company and its directors and officers.

h) Expenses. Each Party shall pay their own expenses in connection with this Agreement. In addition, should either Party commence any action, suit or proceeding to enforce this Agreement or any term or provision hereof, then in addition to any other damages or awards that may be granted to the prevailing Party, the prevailing Party shall be entitled to have and recover from the other Party such prevailing Party’s reasonable attorneys’ fees and costs incurred in connection therewith.

i) Currency. All currency is expressed in U.S. dollars.

Page 6 of 8

IN WITNESS WHEREOF, the Parties have executed this Securities Purchase Agreement as of the date first written above.

“Company”		“Purchaser”

WEED Inc., a Nevada corporation By: Glenn E. Martin Its: Chief Executive Officer		By: XXXXX XXXXXXXX, an indiviDUAL

Page 7 of 8

A-1

Exhibit A

Form of Warrant sent separately

Page 8 of 8

Exhibit 10.8

WEED INC.

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (ii) TO THE EXTENT APPLICABLE, RULE 144 UNDER THE ACT (OR ANY SIMILAR RULE UNDER THE ACT RELATING TO THE DISPOSITION OF SECURITIES), OR (iii) AN OPINION OF COUNSEL, IF SUCH OPINION SHALL BE REASONABLY SATISFACTORY TO COUNSEL TO THE ISSUER, THAT AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND APPLICABLE STATE LAW IS AVAILABLE.

WEED No. XXXX

STOCK PURCHASE WARRANT

THIS IS TO CERTIFY that, for value received, XXXXXX., a Arizona corporation and/or assigns (the “Holder”) is entitled, subject to the terms and conditions set forth herein, to purchase from WEED Inc., a Nevada corporation (the “Company”) up to XXXXXXXXXXXXXXXX (XXX,XXX) fully paid and nonassessable shares of common stock of the Company (the “Warrant Securities”) at the initial price of $3.00 (Three Dollars) per share but subject to adjustment as provided in Section 3 below, (the “Exercise Price”), upon payment by cashier’s check or wire transfer of the Exercise Price for such shares of the Common Stock to the Company at the Company’s offices.

1. Exercisability . This Warrant may be exercised in whole or in part at any time, or from time to time, between the date hereof and 5:00 p.m. Pacific Standard Time on XXXXXXX., 2019, by presentation and surrender hereof to the Company of a notice of election to purchase duly executed and accompanied by payment by check or wire transfer of the Exercise Price.

2. Manner of Exercise . In case of the purchase of less than all the Warrant Securities, the Company shall cancel this Warrant upon the surrender hereof and shall execute and deliver a new warrant of like tenor for the balance of the Warrant Securities. Upon the exercise of this Warrant, the issuance of certificates for securities, properties or rights underlying this Warrant shall be made forthwith (and in any event within three (3) business days thereafter) without charge to the Holder including, without limitation, any tax that may be payable in respect of the issuance thereof: provided, however, that the Company shall not be required to pay any tax in respect of income or capital gain of the Holder.

Page 1 of 6

If and to the extent this Warrant is exercised, in whole or in part, the Holder shall be entitled to receive a certificate or certificates representing the Warrant Securities so purchased, upon presentation and surrender to the Company of the form of election to purchase attached hereto duly executed, and accompanied by payment of the purchase price.

3. Adjustment in Number of Shares .

(A) Adjustment for Reclassifications . In case at any time or from time to time after the issue date the holders of the Common Stock of the Company (or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received, or, on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to receive, without payment therefore, other or additional stock or other securities or property (including cash) by way of stock split, spin-off, reclassification, combination of shares or similar corporate rearrangement (exclusive of any stock dividend of its or any subsidiary’s capital stock), then and in each such case the Holder of this Warrant, upon the exercise hereof as provided in Section 1, shall be entitled to receive the amount of stock and other securities and property which such Holder would hold on the date of such exercise if on the issue date he had been the holder of record of the number of shares of Common Stock of the Company called for on the face of this Warrant and had thereafter, during the period from the issue date, to and including the date of such exercise, retained such shares and/or all other or additional stock and other securities and property receivable by him as aforesaid during such period, giving effect to all adjustments called for during such period. In the event of any such adjustment, the Exercise Price shall be adjusted proportionally.

(B) Adjustment for Reorganization, Consolidation, Merger . In case of any reorganization of the Company (or any other corporation the stock or other securities of which are at the time receivable on the exercise of this Warrant) after the issue date, or in case, after such date, the Company (or any such other corporation) shall consolidate with or merge into another corporation or convey all or substantially all of its assets to another corporation, then and in each such case the Holder of this Warrant, upon the exercise hereof as provided in Section 1 at any time after the consummation of such reorganization, consolidation, merger or conveyance, shall be entitled to receive, in lieu of the stock or other securities or property to which such Holder would be entitled had the Holder exercised this Warrant immediately prior thereto, all subject to further adjustment as provided herein; in each such case, the terms of this Warrant shall be applicable to the shares of stock or other securities or property receivable upon the exercise of this Warrant after such consummation.

4. No Requirement to Exercise .

Nothing contained in this Warrant shall be construed as requiring the Holder to exercise this Warrant prior to or in connection with the effectiveness of a registration statement.

Page 2 of 6

5. No Stockholder Rights . Unless and until this Warrant is exercised, this Warrant shall not entitle the Holder hereof to any voting rights or other rights as a stockholder of the Company, or to any other rights whatsoever except the rights herein expressed, and, no dividends shall be payable or accrue in respect of this Warrant.

6. Registration Rights . If the Company at any time proposes to register any of its securities under the Act, including under an S-1 Registration Statement or otherwise, it will each such time give written notice to all holders of outstanding warrants of its intention so to do. Upon the written request of a holder or holders of any such warrants given within 30 days after receipt of any such notice, the Company will use its best efforts to cause all shares underlying the exercise of such warrants to be registered under the Act (with the securities which the Company at the time propose to register); provided, however, that the Company may, as a condition precedent to its effective such registration, require each Holder to agree with the Company and the managing underwriter or underwriters of the offering to be made by the Company in connection with such registration that such Holder will not sell any securities of the same class or convertible into the same class as those registered by the Company (including any class into which the securities registered by the Company are convertible) for such reasonable period after such registration becomes effective (not exceeding 90 days) as shall then be specified in writing by such underwriter or underwriters if in the opinion of such underwriter or underwriters the Company's offering would be materially adversely affected in the absence of such an agreement. All expenses incurred by the Company in complying with this Section, including without limitation all registration and filing fees, listing fees, printing expenses, fees and disbursements of all independent accountants, or counsel for the Company and the expense of any special audits incident to or required by any such registration and the expenses of complying with the securities or blue sky laws of any jurisdiction shall be paid by the Company.

7. Exchange . This Warrant is exchangeable upon the surrender hereof by the Holder to the Company for new warrants of like tenor representing in the aggregate the right to purchase the number of Warrant Securities purchasable hereunder, each of such new warrants to represent the right to purchase such number of Warrant Securities as shall be designated by the Holder at the time of such surrender.

Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and, in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it and reimbursement to the company of all reasonable expenses incidental thereto, and upon surrender and cancellation hereof, if mutilated, the Company will make and deliver a new warrant of like tenor and amount, in lieu hereof.

8. Elimination of Fractional Interests . The Company shall not be required to issue certificates representing fractions of securities upon the exercise of this Warrant, nor shall it be required to issue scrip or pay cash in lieu of fractional interests. All fractional interests shall be eliminated by rounding any fraction up to the nearest whole number of securities, properties or rights receivable upon exercise of this Warrant.

Page 3 of 6

9. Reservation of Securities . The Company shall at all times reserve and keep available out of its authorized shares of Common Stock or other securities, solely for the purpose of issuance upon the exercise of this Warrant, such number of shares of Common Stock or other securities, properties or rights as shall be issuable upon the exercise hereof. The Company covenants and agrees that, upon exercise of this Warrant and payment of the Principal Value, all shares of Common Stock and other securities issuable upon such exercise shall be duly and validly issued, fully paid, non-assessable and not subject to the preemptive rights of any stockholder.

10. Notices to Holder . If at any time prior to the expiration of this Warrant or its exercise, any of the following events shall occur:

(a) the Company shall take a record of the holders of any class of its securities for the purpose of entitling them to receive a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of current or retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company; or

(b) the Company shall offer to all the holders of a class of its securities any additional shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company, or any option or warrant to subscribe therefor; or

(c) a dissolution, liquidation or winding up of the Company (other than in connection with a consolidation or merger) or a sale of all or substantially all of its property, assets and business as an entirety shall be proposed.

then, in any one or more said events, the Company shall give written notice of such event to the Holder at least fifteen (15) days prior to the date fixed as a record date or the date of closing the transfer books for the determination of the stockholder entitled to such dividend, distribution, convertible or exchangeable securities or subscription rights, or entitled to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of closing the transfer books, as the case may be.

11. Transferability . This Warrant may not be transferred or assigned by the Holder without prior written approval by the Company.

12. Informational Requirements . The Company will transmit to the Holder such information, documents and reports as are generally distributed to stockholders of the Company concurrently with the distribution thereof to such stockholders.

Page 4 of 6

13. Notice . Notices to be given to the Company or the Holder shall be deemed to have been sufficiently given if delivered personally or sent by overnight courier or messenger, or by facsimile transmission. Notices shall be deemed to have been received on the date of personal delivery or facsimile transmission. The address of the Company and of the Holder shall be as set forth in the Company’s books and records.

14. Consent to Jurisdiction and Service . The Company consents to the jurisdiction of any court of the State of Arizona, and of any federal court located in Arizona, in any action or proceeding arising out of or in connection with this Warrant. The Company waives personal service of any summons, complaint or other process in connection with any such action or proceeding and agrees that service thereof may be made at the location provided in Section 13 hereof, or, in the alternative, in any other form or manner permitted by law. Pima County, Arizona shall be proper venue.

15. Successors . All the covenants and provisions of this Warrant shall be binding upon and inure to the benefit of the Company, the Holder and their respective legal representatives, successors and assigns.

16. Attorneys Fees . In the event the Investors or any holder hereof shall refer this Warrant to an attorney to enforce the terms hereof, the Company agrees to pay all the costs and expenses incurred in attempting or effecting collection hereunder, including reasonable attorney's fees, whether or not suit is instituted.

17 . Governing Law . THIS WARRANT SHALL BE GOVERNED, CONSTRUED AND INTERPRETED UNDER THE LAWS OF THE STATE OF ARIZONA, WITHOUT GIVING EFFECT TO THE RULES GOVERNING CONFLICTS OF LAW.

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by the signature of its President and to be delivered in Tucson, Arizona.

Dated: XXXXXXXXXX 2017		WEED Inc. A Nevada corporation

		By: Glenn E. Martin I ts: Chief Executive Officer & President

Page 5 of 6

[FORM OF ELECTION TO PURCHASE]

The undersigned, the holder of the attached Warrant, hereby irrevocably elects to exercise the purchase right represented by this Warrant Certificate for, and to purchase securities of WEED, Inc. and herewith makes payment of $__________ therefor, and requests that the certificates for such securities be issued in the name of, and delivered to ___________________, whose address is ______________________________.

Dated:

____________________, 20___


	By:

	Its:
	(Signature must conform in all respects to name of holder as specified on the face of the Warrant Certificate)


	(Insert Social Security or Other Identifying Number of Holder)

Page 6 of 6

Exhibit 10.9

PURCHASE AND SALE AGREEMENT

AGREEMENT made as of this _____ day of October 2017 by and between Greg DiPaolo’s Pro Am Golf, LLC, having an address at 7060 East Lake Rd.- Route 5, Westfield, NY 14787, email: dumptruck1@fairpoint.net (the “Seller”) and WEED, Inc., a Nevada corporation, having an address at 4920 N. Post Trail, Tucson, AZ 85750, email: gemartin21@aol.com, as agent for a limited liability entity to be formed (the “Purchaser”).

RECITALS:

WHEREAS Seller is the owner of that certain improved real property located at 7060 East Lake Rd., Westfield, New York known as Sugar Hill Golf Course.

WHEREAS Purchaser desires to purchase, and Seller desires to sell, such real property on the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Purchaser and Seller agree as follows:

Description . Seller hereby agrees to sell and convey, and Purchaser agrees to purchase from Seller, on the terms and conditions set forth herein, the following:

1.1

Premises . That certain real estate located at 7060 East Lake Rd., Westfield, County of Chautauqua, State of New York, with approximately 44.8 acres and tax map numbers 160.00-2-06, 160.00-2-07 and 160.00-2-46, along with all improvements situated thereon and all fixtures, machinery and equipment attached or appurtenant to the land or building used in connection with it (the “Premises”); together with all right, title and interest of Seller, if any, in and to the land lying in the bed of any street, highway, waterway and the lake adjoining the Premises and to any taking by condemnation or any damage to the Premises by reason of a change of grade of any street or highway, and all of the estate and rights of Seller in and to the Premises. The parties may, prior to Closing, enter into an agreement for the purchase and sale of personal property used in the operation of the golf course located at the Premises.

Purchase Price . The total consideration for the Premises shall be the sum of $800,000 (the “Purchase Price”) and payable in the following manner:

2.1

Earnest Money Deposit . Upon execution of this Agreement by all parties, Purchaser shall pay to Gleichenhaus, Marchese & Weishaar, P.C. (the “Escrow Agent”), to be held in a non-interest bearing escrow account, subject to the terms of Section 16 of this Agreement, the sum of $10,000 (the “Deposit”). The Deposit is non-refundable, except as set forth in Sections 2.3 and 4.1.

2.2

Balance of Purchase Price . On the Closing Date (as hereinafter defined), Purchaser shall pay the Purchase Price, plus or minus prorations and adjustments in accordance with this Agreement, to Seller in cash, bank wire, bank check or certified check, less the Deposit.

2.3

Default. If Seller is unable or unwilling to perform or transfer its rights, title and interest to Purchaser in accordance with the terms of this Agreement, or willfully defaults under this Agreement, Purchaser shall have the following remedies: (a) receive a refund of the Deposit, (b) bring an action for specific performance, and (c) sue for damages. If Purchaser shall fail to perform any of its obligations hereunder and Seller is not in default hereunder, Seller's sole remedy shall be to retain the Deposit as liquidated damages, and thereupon Purchaser and Seller shall each be released from all liability under this Agreement.

Initial Due Diligence Material . Within 10 days after the date of this Agreement is executed by the Seller, Seller shall deliver to Purchaser copies of the following:

3.1

The original abstract of title and/or any title insurance policy in Seller’s possession.

3.2

An original of the survey for the Premises dated January 2, 2007.

3.3

All correspondence, reports, evaluations, assessments, audits and other materials in Seller’s possession that relate to environmental, soil conditions and engineering reports, and related matters at the Premises.

Title Documents . Purchaser may obtain the following items at its expense, but Purchaser shall receive a credit at closing for any such out of pocket expenses: (i) a full land/title abstract covering the Premises (minimum 80 year search) together with a current title “date down” dated subsequent to the date of this Agreement (“Abstract”), (ii) complete tax search for the Premises dated after the date of this Agreement (“Tax Search”), (iii) legible recorded copies of all encumbrances for the Premises (“Recorded Documents”), (iv) a survey according to Chautauqua County Bar Association standards for the Premises prepared by a land surveyor licensed in New York State which shall be certified to the Purchaser and then redated within thirty (30) days of the Closing Date (“Survey”) and (v) State and County UCC searches for the Seller and previous owners of the Premises for the five (5) years prior to the date of this Agreement (“UCC Search”) (the Abstract, Tax Search, Recorded Documents, Survey and UCC Searches are collectively referred to as the “Title Documents”). Purchaser may, in its sole and absolute discretion, disapprove any title exceptions or survey matters set forth on the Title Documents and shall notify Seller of any such disapproved title exceptions (“Disapproved Encumbrances”). If within ten (10) days after receipt of notice of the Disapproved Encumbrances, Seller is unable to cure, cause the removal of, or obtain title insurance (at Seller’s sole cost and expense) against the Disapproved Encumbrances, then Purchaser will have the option to either (i) waive the Disapproved Encumbrances and proceed to Closing (as hereinafter defined), or (ii) terminate this Agreement by notice to Seller in which event the Deposit and out of pocket expenses to third parties will be immediately refunded to the Purchaser.

Contingencies . The following contingencies shall apply to the Purchaser’s obligation to purchase the Premises.

5.1

Inspection Contingency . Purchaser shall have a period of 45 days from the date the Deposit is delivered to the Escrow Agent (the “Inspection Period”) to determine to its satisfaction whether the Premises is acceptable to Purchaser in Purchaser’s sole and absolute discretion. In the event Purchaser determines that the Premises is not suitable then Purchaser may, at its sole and absolute election (a) terminate this Agreement by giving Seller written notice of its election to terminate during the Inspection Period, or (b) waive this inspection contingency and proceed to Closing. If Purchaser shall not have notified Seller of the release of this inspection contingency in writing during the Inspection Period, then the Inspection Period shall be extended until the fifth business day following Purchaser’s receipt of Seller’s written notice which shall require Purchaser to waive this inspection contingency and proceed to Closing or terminate this Agreement at which time the inspection contingency shall be deemed to have not been satisfied and thereupon this Agreement will be considered to have been terminated and Purchaser and Seller shall each be released from all liability under this Agreement.

5.2

Financing Contingency . Purchaser shall have a period of 90 days from the date the Deposit is delivered to the Escrow Agent (the “Financing Period”) to obtain a written commitment from a lender, in the usual form of such lender, to make a secured loan to pay the Purchase Price upon terms acceptable to Purchaser (the “Commitment Letter”). Purchaser shall pay all fees, costs and expenses of procuring such commitment and loan. If a Commitment Letter is not issued within the Financing Period, this agreement shall continue in full force and effect (but no longer subject to the contingency provided in this Section 5.2) unless: (1) Purchaser delivers to Seller's attorney, within three business days after the expiration of the Financing Period, a written notice that Purchaser was unable to procure such commitment and therefor elects to terminate this agreement; or (2) Purchaser obtains Seller's written consent to an extension of said Financing Period. If this agreement is terminated as provided above, Purchaser shall retain the Deposit, whereupon Seller and Purchaser shall have no further rights against each other hereunder.

Purchaser Right to Enter Premises and Conduct Testing . During the Inspection Period, Purchaser shall have the right to conduct due diligence on and inspect the Premises and all buildings and improvements located on the Premises on reasonable notice to the Seller. In connection therewith, Purchaser or its engineers, architects, building consultants, environmental investigators or other representatives or agents shall have the right to do all environmental, surveying, engineering, seismographic, soil borings and other tests with respect to the Premises and the buildings and improvements located on the Premises for the purpose of satisfying purchaser, in its sole and absolute discretion, that the Premises is suitable for Purchaser’s purposes and that the Premises meets or exceeds all underwriting, legal and regulatory standards and requirements of Purchaser. Purchaser shall restore the Premises, improvements and buildings on the Premises to substantially the same condition as it was immediately prior to Purchaser's inspection. Purchaser shall defend, indemnify and hold Seller, its affiliates, subsidiaries, officers, directors and agents harmless from and against any injuries, loss, cost, expense or damage of any kind or nature suffered or incurred by Seller or its employees or agents as a result of such entry and inspection.

Seller’s Representations and Warranties . Seller represents and warrants to the Purchaser that the following matters are true and correct as of the date hereof and as of the Closing Date. These provisions shall survive the Closing, or if the Closing does not occur, the termination of this Agreement:

7.1

Authorization . Seller has the requisite power and authority to enter into this Agreement and to carry out the transactions contemplated hereby, and to execute this Agreement, the Deed, assignments and other instruments or documents reasonably necessary to effect the transactions contemplated by this Agreement.

7.2

Ownership. Seller is the sole and lawful owner of the Premises and there is no option to purchase, right of first refusal to purchase, contract of sale, mortgage, life estate or other limited estate, lease or tenancy affecting any portion of the Premises, except for this Agreement and any interest that will be terminated as of or before the Closing.

7.3

No Conflict . Neither the execution or delivery nor the performance of Seller of this Agreement or any of the other transaction documents to which Seller is a party will conflict with, or will result in a breach of, or will constitute a default under, (i) any judgment, statute, rule, order, decree, writ, injunction or regulation of any court or other governmental authority, or (ii) any agreement or instrument by which Seller may be bound. The parties confirm that the Agreement between them dated November 8, 2016 is terminated.

7.4

[Reserved] .

7.5

Consents . No permit, approval, or authorization of, or designation, declaration or filing with, any governmental authority or any other person or entity on the part of Seller is required in connection with the execution or delivery by Seller of this Agreement or the consummation of the transactions contemplated hereby, except with regard to M&T Bank and the US Bankruptcy Court.

7.6

Litigation, etc. Except for Seller’s bankruptcy filing and any judgments listed therein, to the best of Seller’s knowledge after due inquiry, there is no suit, action or litigation, administrative hearing, arbitration, labor controversy or negotiation, or other proceeding or governmental inquiry or investigation known to Seller, affecting Seller or Seller’s properties (including, but not limited to, environmental or land use proceedings) pending or, to the best of Seller’s knowledge after due inquiry, threatened against the Seller which, if resolved adversely, would have a material adverse effect on the Premises or on the ability of Seller to consummate the transactions contemplated hereby. There are no known judgments, consent decrees or injunctions against, affecting or binding upon Seller. Seller has received no notice of any violations of any governmental law, ordinance, requirement, order or regulation the violation of which would have a material adverse effect on the Premises or on the ability of Seller to consummate the transactions contemplated hereby, and to Seller’s best knowledge after due inquiry Seller has received no notice of any claimed default with respect to any of the foregoing.

7.7

Condemnation . No condemnation action has been filed or threatened against the Premises.

7.8

Zoning . The Premises are zoned as follows: R-3 for tax parcels 160.00-2-6 and 160.00-2-7 and CR for tax parcel 160.00-2-46. The use being made of the Premises at present is in conformity with the special use permits issued by the Town of Portland and NYS DEC permits (SPDES Permit (Permit ID: 9-0660-0035/00001, NY 006816) and Lake Erie Freshwater Withdrawal permit (Permit ID: 9-0660-00163/00001)) issued for the Premises (the “Permits”); all required certificates and permits of that type have been issued, are in full force and effect; and the Premises comply with all applicable building, fire, zoning and other ordinances and regulations. No permits or licenses or certificates of occupancy pertaining to the ownership or operation of the Premises, other than the Permits, are required by any governmental agency having jurisdiction over the Premises or its operation.

7.9

No Violations, Proceedings or Restrictions . There is no action or proceeding (zoning or otherwise) or governmental investigation pending, or, to the knowledge of the Seller, threatened against or relating to the Seller, the Premises or the transaction contemplated by this Agreement, nor, to the knowledge of the Seller, is there any basis for such an action. The Premises and their present use and condition do not violate any applicable deed restrictions or other covenants, restrictions or agreements, site plan approvals, zoning or subdivision regulations or urban redevelopment plans applicable to the Premises, as modified by any duly issued variances. No notes or notices of violation of law or municipal ordinances or of federal, state, county or municipal or other governmental agency regulation, orders or requirements relating to the Premises have been entered or received by the Seller, and the Seller has no reason to believe that any note or notice may or will be entered.

7.10

Roads . The Seller has no knowledge of any federal, state or local plans to change the highway or road system in the vicinity of the Premises or to restrict or change access from any highway or road to the Premises or of any pending or threatened condemnation of the Premises or of any plans for improvements which might result in a special assessment against the Premises. All roads bounding the Premises are public roads and the deed is the only instrument necessary to convey to the Purchaser full access to and the right to the roads freely as well as all rights appurtenant to the Premises in the roads.

7.11

Utilities . Water is supplied to the Premises by private well. Natural gas is supplied by private gas well subject to the terms and conditions of a gas purchase agreement. There are electricity, data and telephone utilities serving the Premises.

7.12

Environmental Compliance . Seller and, to the best of its knowledge after due inquiry, any tenants who have occupied the Premises, are in compliance with all applicable federal, state and local laws and regulations relating to pollution control and environmental contamination including, without limitation, all laws and regulations governing the generation, use, collection, treatment, storage transportation, recovery, removal, discharge or disposal of hazardous materials (as defined below) and all laws and regulations with regard to record keeping, notification and reporting requirements respecting hazardous materials (as defined below). The Seller has not (i) received any notice of, or (ii) been subject to any administrative or judicial proceedings pursuant to such laws or regulations either now or at any time. There are no present facts or circumstances that could form the basis for the assertion of any claim against the Seller or to the best of its knowledge after due inquiry, any tenant relating to environmental matters including, without limitation, any claim arising from past or present environmental practices asserted under the comprehensive Environmental Response, Compensation and Liability Act of 1980 (“CERCLA”), at the Resource Conservation and Recovery Act (“RCRA”) or any other federal, state or local environmental statute. No part of the Premises contains any offensive toxic contaminated, hazardous materials or any other substances which constitutes a health, safety or environmental risk to any person or property. For purposes of this paragraph, the term “hazardous materials” means materials defined as “hazardous substances”, “hazardous wastes” or “solid wastes” in CERCLA, RCRA and in any similar federal, state or local environmental statute.

7.13

No Flood Plain . The Premises is not located in a regulatory flood plain area (inclusive of flood way area) as defined by the most recent FEMA mapping for the community in which the Premises is located.

7.14

Leases . There are no leases or licenses affecting the Premises.

7.15

No Other Contracts . There are no unrecorded contracts or contracts which will affect the Premises and/or Purchaser from and after the Closing.

7.16

No Rollback Taxes . The Premises is not subject to any rollback taxes, any increase in taxes which are due to change in the ownership or use of the Premises.

7.17

No Encumbrances . There are no easements, rights of way, gas, timber, or mineral rights except as set forth in the Search and Seller warrants that it will not encumber the Premises without the Purchaser’s prior written consent.

7.18

Mechanic’s Liens . The Seller represents and warrants that no services, material or work have been supplied to the Seller’s contractors, subcontractors or materialmen with respect to the Premises for which payment has not been made in full. If, subsequent to the Closing Date, any mechanic’s or other lien, charge or order for the payment of money shall be filed against the Premises or against the Purchaser or the Purchaser’s assigns, based upon any act or omission, or alleged act or omission before or after the Closing Date, of the Seller, its agents, servants or employees, or any contractor, subcontractor or materialmen connected with the construction and completion by the Seller of improvements at the Premises, or repairs made to the Premises by or on behalf of the Seller (whether or not the lien, charge or order shall be valid or enforceable as such), within ten (10) days after notice to the Seller of the filing of notice, the Seller shall take action, by bonding, deposit, payment or otherwise, as will remove or satisfy the lien of record against the Premises.

7.19

Absence of Untrue Statements . No representation or warranty contained herein by or on behalf of the Seller, nor any statement or certificate furnished hereunder or in connection herewith, contains or will contain an untrue statement of a material fact or omits or will omit to state a material fact necessary to make the statements contained therein not misleading.

Covenants of Seller . Seller hereby covenants with Purchaser, as follows:

8.1

Transfers and Encumbrances. Between the date hereof and the Closing Date or the Purchaser’s earlier termination of this Agreement, as the case may be, Seller may market the Premises for sale. In the event Seller receives an acceptable bona fide offer from a third party (an “Offeror”) to purchase the Premises or any portion thereof, Seller shall give Purchaser written notice of such bona fide offer, together with a copy of the proposed contract of sale executed by the Offeror (the “Proposed Contract”). Within fifteen (15) days of receipt of such notice and Proposed Contract, Purchaser shall either exercise or waive its right of first refusal. If Purchaser elects to exercise its right of first refusal, it shall, within said fifteen (15) day period deliver to Seller a written purchase offer executed by the Purchaser containing the same terms and conditions stated in the Proposed Contract. If Purchaser fails to deliver such executed purchase offer to Seller within said fifteen (15) day period, Purchaser shall be deemed to have waived its right of first refusal. If Seller shall receive such an offer which is not consummated by delivery of a deed to the Offeror (or its respective heirs, successors and assigns), Purchaser’s right of first refusal shall remain applicable to subsequent acceptable bona fide offers. If the offer in question does not include all of the Premises, such right of first refusal shall remain in effect with respect to the remaining portion of the Premises. If such an offer is consummated by delivery of a deed to the Offeror, then Purchaser shall receive a refund of the Deposit.

8.2

Contracts . Seller shall not, without the prior written consent of the Purchaser, which shall not be unreasonably withheld, enter into any contract with respect to the Premises that shall survive the Closing or will otherwise affect the use, operation, enjoyment or development of the Premises after Closing.

8.3

Operation Pending Closing. During the period commencing on the date hereof and ending on the Closing Date (as hereinafter defined), Seller shall, at Seller’s sole cost and expense, (i) maintain and operate the Premises in compliance with all laws, ordinances and other requirements of any governmental authority having jurisdiction and substantially in the same manner in which it maintained and operated the Premises immediately before entering into this Agreement, as though Seller were retaining the Premises and (ii) maintain and keep Seller’s insurance in full force and effect.

8.4

Violations. All notices of violations of law, ordinances, orders or other governmental requirements against or affecting the Premises (“Violations”) on the Closing Date (as hereinafter defined) issued by a governmental authority shall be complied with by Seller and the Premises shall be conveyed free of same. Seller shall furnish to Purchaser an authorization to make the necessary searches therefore. If Seller shall receive any notice of Violation during the term of this Agreement, it shall furnish a true copy of same to Purchaser promptly after receipt by Seller. If any such Violation shall, in Purchaser’s reasonably exercised opinion or in the opinion of Purchaser’s counsel, constitute an impediment to Purchaser’s application for the Required Approvals (as hereinafter defined), Seller shall, after written request by Purchaser, promptly perform all such work as shall be required to cure and shall cause the Violation to be removed. In the event such Violation cannot be removed then Purchaser shall have the right to terminate this Agreement and the Deposit with all interest accrued thereon shall be returned to the Purchaser and Seller shall immediately thereafter refund to Purchaser all payments made by Purchaser to Seller in connection with the Agreement.

Seller’s Closing Documents . The Premises shall be conveyed and transferred by Seller to Purchaser on the Closing Date by the following instruments; the parties shall agree upon the instrument no later than 5 days prior to the Closing Date:

9.1

Premises . A warranty deed with lien covenants in proper statutory form for recording, duly executed by Seller and acknowledged (the “Deed”) so as to convey the Purchaser good and marketable title in fee simple to the Premises, free and clear of all claims, liabilities, obligations, security interest, liens, judgments and encumbrances except as specifically provided otherwise herein and such other documents as may be appropriate or necessary to convey the real property interest intended to be conveyed.

9.2

Termination of Lease . Seller will deliver at Closing a termination the Lease executed by Seller and its tenant.

9.3

FIRPTA . An affidavit required by Section 1445 of the Internal Revenue Code of 1986, as amended (the “Code”), and the Regulations pursuant thereto, and acceptable to the Purchaser (the “FIRPTA Affidavit”).

9.4

Closing Statement . A Closing Statement showing all closing costs and expenses of each party, all credits, debits and all pro-rations and showing the net amount due from Purchaser at Closing.

9.5

Seller’s Closing Certificate. A certificate, dated as of the Closing Date, duly executed by Seller, stating that the representations and warranties of Seller contained in this Agreement are true and correct in all material respects on the Closing Date (with appropriate modifications of those representations and warranties made in Section 7 hereof to reflect any changes therein or identifying any representation or warranty which is not, or is no longer, true and correct in all material respects and explaining the state of facts giving rise to the change).

10.

Prorations and Adjustments . The following shall be prorated and adjusted between Seller and Purchaser as of midnight on the day preceding the Closing, except as otherwise specified:

10.1

Real Estate Taxes and Assessments, etc. All rent, real estate taxes and assessments (including water and sewer assessments) with respect to the Premises and such other items as are customarily adjusted in transactions of this nature shall be prorated and adjusted as of midnight on the day preceding the Closing Date. All adjustments shall survive Closing.

11.

Closing . The Purchaser and the Seller agree that the purchase and sale contemplated by this Agreement will be consummated as follows:

11.1

Title Transfer . The Seller agrees to convey all of Seller’s right, title and interest in the title to the Premises to the Purchaser by the Deed and such other appropriate or necessary transfer instruments by 10:00 A.M. on the Closing Date and, effective on the delivery of the Deed and other transfer instruments by the Seller to the Purchaser. At the Closing, the Purchaser will not be required to assume or to pay or discharge any liabilities of the Seller.

11.2

Closing Date . The closing (the “Closing”) of this transaction will take place at the offices of the Chautauqua County Clerk, or at such other location as shall be agreed to by the parties hereto, on February 1, 2018 and after the satisfaction of all contingencies contained in this Agreement (the “Closing Date”). Either party may, after the above date, declare time is of the essence and set a specific time for Closing on a business day at least seven (7) business days after receipt of written notice that time is of the essence has been declared.

12.

Closing Costs . The expenses of Closing shall be paid in the following manner:

12.1

Seller’s Costs . In connection with the consummation of this transaction, Seller shall pay (i) any and all prorations or adjustments required by this Agreement in favor of Purchaser or according to local custom; (ii) any and all transfer taxes, and conveyance fees; and (iii) the cost associated with any title insurance policy obtained for Purchaser as required in Section 4.

12.2

Purchaser’s Costs . In connection with the consummation of this transaction, Purchaser shall pay (i) all fees in connection with the recording of the Deed, (ii) any and all prorations or adjustments required by this Agreement in favor of Seller or according to local custom; and (iii) the cost of Title Documents, but Purchaser shall receive a credit at Closing for such documented costs.

13.

Eminent Domain . If, prior to the Closing Date, eminent domain proceedings materially affecting the Premises shall be threatened or commenced by any competent public authority against the Premises or any portion thereof which would materially and adversely affect Purchaser’s ability to use the Premises, Purchaser shall have the option to (i) proceed with this transaction and pay the Purchase Price at the Closing and receive an assignment from Seller of all of Seller’s right, title and interest in and to such condemnation proceeding, in which event any compensation paid or payable as a result of such eminent domain proceedings shall be and become the sole property of Purchaser or (ii) terminate this Agreement in which event Seller shall retain such award, and the Deposit plus interest accrued thereon shall be returned to Purchaser, and all documents furnished or delivered pursuant to the terms of this Agreement shall be returned to the party who furnished them and thereafter both parties shall be released from any further liability hereunder. Seller agrees that it shall give to Purchaser written notice of any such threatened or actual eminent domain proceedings within five (5) days after Seller first becomes aware thereof. If the eminent domain proceedings do not materially affect the Premises, Purchaser shall have no right to terminate this Agreement, but shall receive a credit or an assignment, at Closing, of any compensation paid or payable as a result of such eminent domain proceedings. In the event of any such non-material taking, Seller shall not compromise, settle or adjust any claims to such award without Purchaser’s prior written consent (which will not be unreasonably withheld), it being understood and agreed that Purchaser has an interest in all such proceeds.

14.

Broker’s Commissions . Purchaser represents and warrants that Purchaser has not entered into any agreement which might result in the obligation to pay any brokerage commission, finder’s fee or other compensation with respect to the transaction contemplated hereby. Purchaser agrees to indemnify Seller and hold Seller harmless from and against any losses, liabilities, damages, costs and expenses (including attorneys’ fees) incurred by Seller by reason of any breach or inaccuracy of the representation and warranty contained in this Section 14. Seller represents and warrants that Seller has not entered into any agreement which might result in the obligation to pay any brokerage commission, finder’s fee or other compensation with respect to the transaction contemplated hereby. Seller agrees to indemnify Purchaser and hold Purchaser harmless from and against any losses, liabilities, damages, costs and expenses (including attorney’s fees) incurred by Purchaser by reason of any breach or inaccuracy of the representation and warranty contained in this Section 14. The provisions of this Section 14 shall survive the Closing, or if the Closing does not occur, the termination of this Agreement.

15.

Miscellaneous .

15.1

Capacity . Each individual and entity executing this Agreement hereby individually represents and warrants that he and/or it has the capacity set forth on the signature pages hereof with full power and authority to bind the party on whose behalf he and/or it is executing this Agreement to the terms hereof.

15.2

Entire Agreement . This Agreement constitutes the entire Agreement between the Purchaser and the Seller relating to this sale and supersedes all other prior agreements and representations in connection with said sale. There are no agreements, understandings, warranties or representations between the Purchaser and the Seller except as set forth herein.

15.3

No Amendment or Waiver . This Agreement shall not be altered, amended, changed, waived, terminated or otherwise modified in any respect or particular unless the same shall be in writing and signed by the parties hereto. No waiver by any party of any breach hereunder shall be deemed a waiver of any other or subsequent breach.

15.4

Counterparts and Facsimile Documents. This Agreement may be executed in any number of counterparts, each of which will be considered to be an original, but all of which when taken together shall constitute one and the same instrument. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart so that all signature pages are physically attached to the same instrument. The signature page of any counterpart may be detached therefrom without impairing the legal effect of the signature(s) thereon provided such signature page is attached to any other counterpart identical thereto except having additional signature pages executed by other parties to this Agreement attached thereto.

15.5

Notice . Any notice, demand, request or communication of any kind required or permitted hereunder shall be sufficiently given if sent by (i) hand delivery, (ii) reputable overnight carrier, (iii) United States registered or certified mail, postage prepaid, return receipt requested or (iv) or email (with confirmation of receipt thereof) to the parties at their address set forth above or at such other address each may designate from time to time. A copy of any such notice, demand, request or communication sent to Purchaser shall be sent to the attention of Robert A. Biltekoff, Esq., Biltekoff Law Office, LLC, 43 Court St., Suite 930, Buffalo, NY 14202. A copy of any such notice, demand, request or communication sent to Seller shall be sent to the attention of Robert B. Gleichenhaus, Esq., Gleichenhaus, Marchese & Weishaar, PC, 43 Court St., Suite 930, Buffalo, NY 14202. Any such notice, demand, request or communication shall be deemed to have been duly given or served on the date shown on the return receipt or other evidence of delivery, if mailed, or on the date shown on the confirmation receipt, if telecopied or emailed.

15.6

Governing Law . This Agreement shall be interpreted and enforced in accordance with the laws of the State of New York. If any provisions of this Agreement shall be unenforceable or invalid, the same shall not affect the remaining provisions of this Agreement.

15.7

Parties . Except as otherwise provided in this Agreement, this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and to their respective heirs, executors, administrators, successors and assigns.

15.8

No Assignment . Neither party shall have the right to assign this Agreement without the prior written consent of the other party.

15.9

Headings . Section headings of this Agreement have been inserted for convenience of reference only and will in no way modify or restrict any provisions hereof or be used to construe any such provision.

15.10

Exhibits . All Exhibits attached hereto are incorporated herein by reference and made a part hereof.

15.11

Additional Acts . Each party hereto shall from time to time perform such additional acts as the other party may reasonably request to effectuate the intent of this Agreement.

15.12

Interpretation and Enforcement . If suit or action is filed to interpret or enforce this Agreement, the prevailing party shall be entitled to be awarded its reasonable attorneys’ fees and disbursements through all appeals in addition to other costs and disbursements allowed by law, including those incurred on appeal.

16.

Escrow Conditions . Upon execution of this Agreement by all parties, Purchaser shall deliver to Gleichenhaus, Marchese & Weishaar, PC, having a mailing address at 43 Court St., Suite 930, Buffalo, NY 14202 ("Escrow Agent"), Purchaser's check in the amount of $10,000 being the amount to be paid by Purchaser upon the execution of this agreement (the "Deposit").

Escrow Agent shall hold the Deposit in accordance with this agreement, or a joint instruction signed by Seller and Purchaser, or separate instructions of like tenor signed by Seller and Purchaser, or a final judgment of a court of competent jurisdiction. If Escrow Agent shall receive an instruction from Seller or Purchaser, Escrow Agent may act in accordance with such instruction if the other party shall fail to notify Escrow Agent not to act in accordance with such instruction within ten days after delivery of such instruction by Escrow Agent to said other party. Escrow Agent at any time may deposit the Deposit with a court of competent jurisdiction, and upon notice to Seller and Purchaser of such deposit Escrow Agent shall have no further responsibility or liability hereunder. Escrow Agent hereby is authorized and directed to deliver the Deposit to Seller if, as and when title closes.

Seller and Purchaser acknowledge that Escrow Agent is merely a stakeholder, and that Escrow Agent shall not be liable for any act or omission unless taken or suffered in bad faith, in willful disregard of this agreement or involving gross negligence.

Without limiting the generality of the foregoing, Escrow Agent shall have no responsibility to protect, demand payment of, collect, or enforce any obligation with respect to the Deposit, or for any diminution of the value, or the failure to earn income, of the Deposit for any cause. Escrow Agent shall not be required to invest the Deposit in an interest bearing account or other income producing investment.

All instructions or notices given pursuant to this Section 16 shall be in writing and delivered in accordance with the requirements for notices pursuant to this agreement. For purposes of this Section 16, such instructions and notices shall be deemed delivered on the date of delivery, if by hand, or on the date of mailing, if mailed, except that no instruction or notice to Escrow Agent shall be deemed effectively delivered to Escrow Agent until actual receipt thereof by Escrow Agent.

17. Termination . This Agreement shall terminate and be null and void if not executed by Seller and returned to Purchaser on or before 5:00 P.M. on the 27 th day of October, 2017.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

SELLER:		PURCHASER:
Greg DiPaolo’s Pro Am Golf, LLC		WEED, Inc.


By:	By:
Gregory DiPaolo, its Managing Member	Glenn E. Martin, its President


By:
Patti Ann Brown, its Managing Member


ESCROW AGENT:
Gleichenhaus, Marchese & Weishaar, PC


By:
Name:
Title:


Seller’s Attorney		Purchaser’s Attorney

Robert B. Gleichenhaus, Esq. Gleichenhaus, Marchese & Weishaar, PC 43 Court St, Ste 930 Buffalo, NY 14202 (716) 845-6446 gleich4@yahoo.com		Robert A. Biltekoff, Esq. Biltekoff Law Office, LLC 43 Court St, Ste 930 Buffalo, NY 14202 (716) 748-7314 rob@biltekoffllc.com

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the inclusion in this Registration Statement on Form S-1 of our report dated August 11, 2017, of WEED, Inc. relating to the audit of the financial statements for the periods ending December 31, 2016 and 2015 and the reference to our firm under the caption “Experts” in the Registration Statement.

/s/ M&K CPAS, PLLC

www.mkacpas.com

Houston, Texas

November 16, 2017

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the inclusion in this Registration Statement on Form S-1 of our report dated November 16, 2017, of Sangre AT, LLC relating to the audit of the financial statements for the period from inception through December 31, 2016 and the reference to our firm under the caption “Experts” in the Registration Statement.

/s/ M&K CPAS, PLLC

www.mkacpas.com

Houston, Texas

November 16, 2017